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Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and
their associated genes (cas) encode an adaptive, small-RNA-based immune
system that protects prokaryotes from infectious phages and plasmids. CRISPRCas systems can be classified into three types based on their cas gene content.
My thesis work focused on two parts. First, I investigated the mechanism and
function of RNA cleavage in type III CRISPR-Cas immunity. Secondly, I
developed a tool to manipulate prokaryotic genomes and gene expression by
using an engineered type II CRISPR-Cas system.
To date, all three types of CRISPR-Cas systems target DNA. Type III
CRISPR-Cas immunity displays an elaborate targeting mechanism and
distinguishes itself from type I and type II systems in at least two ways. My
previous work in collaboration with other members of the lab helped to discover
that the system cleaves both DNA and RNA molecules, and that active
transcription across the target is necessary for targeting. Whereas DNA cleavage
is required for phage DNA clearance and essential for immunity against infection,
the function of RNA cleavage is unknown. It is well established that gene
expression of many phages is temporally regulated. Using a type III-A CRISPRCas system of Staphylococcus epidermidis as a model, I first identified a new
CRISPR-associated RNase, Csm6. The transcriptional requirement for DNA

cleavage created a challenge for host bacteria. When the target was located in a
late-expressed phage gene, the phage infection cycle can proceed unchecked
until the target was transcribed, resulting in a sharp increase of viral genomes in
host cells. In this targeting condition, genetic inactivation of the type III-A RNases
Csm3 and Csm6 led to the accumulation of the target phage mRNA and
abrogated immunity. Csm6 was also required to provide defense in the presence
of mutated phage targets, when DNA cleavage efficiency was reduced. My
results showed that the degradation of phage transcripts by CRISPR-associated
RNases ensures robust immunity in situations that lead to a slow clearance of
the target DNA.
Recent work on the type II CRISPR-Cas adaptive immune systems has led to
the discovery of Cas9, a dsDNA nuclease whose sequence specificity is
programmed by small CRSPR RNAs (crRNAs). In collaboration with Dr. David
Bikard, a former colleague, we found when reprogrammed to target the genomes
of host bacteria, CRISPR can target and kill the cells. The lethal consequence
upon targeting made CRISPR-Cas a novel tool for sequence-specific counterselection. When combined with editing templates, we demonstrated fast and
efficient genome editing in Streptococcus pneumoniae, Escherichia coli (when
used in combination with λ-Red recombination) and Staphylococcus aureus.
Later, we inactivated the nuclease domains of Cas9, creating a catalytically dead
Cas9 (dCas9) which retained DNA binding activity. We demonstrated that dCas9,
when programmed with appropriate crRNAs, acted as a transcription repressor
by preventing the binding of the RNA polymerase (RNAP) to promoter

sequences or as a transcription terminator by blocking the elongating RNAP. In
addition, a fusion between the ω subunit of the RNA polymerase and dCas9
allowed for programmable transcription activation. The easy programmability and
high specificity of crRNA-guided Cas9 and dCas9 greatly facilitates both genome
editing and modulation of gene expression, and is likely to substantially advance
our capability to decipher gene function in prokaryotes and manipulate them for
biotechnological purposes.

ACKNOWLEDGEMENTS
First and foremost I would like to express my deepest gratitude to my Ph.D.
advisor, Dr. Luciano Marraffini. I joined Dr. Marraffini’s lab in January 2011 as his
first graduate student. Dr. Marraffini is intelligent, hardworking, open-minded and
inspirational. Throughout the years, his careful and patient mentorship has been
instrumental to my Ph.D. training. In his lab, I am very grateful to have the
opportunity to both study basic biology and extract the knowledge there for new
technological development. In both cases, Dr. Marraffini always asks me to test
hypotheses with rigorous scientific methods and actively inspires me to explore
new frontiers. Dr. Marraffini supports me in many different levels. In addition to
his mentorship in the lab, he generously supports me to go to conferences on a
yearly basis; he gives due advice, support and respect to all of my proposals,
ideas and issues. I am truly indebted to him for accepting me as a student and
mentoring me along the way, as I learned a great deal about science,
collaboration, perseverance as well as family, friendship and things that will
impact my life for the many years to come.
I would like to give much credit to my thesis committee – Drs. Vincent
Fischetti, Cori Bargmann and Hermann Steller for contributing their expertise to
my thesis work. They constantly challenged and encouraged me, which helped
me to foster a rigorous and agile scientific mind. I also thank them for patiently
listening to me and giving me frank career advice.

iii

I would like to thank Dr. Martin Jinek from University of Zurich for serving as
my external examiner. Dr. Jinek’s previous works include biochemical
characterization of Cas9 and Csm6, the two CRISPR-associated proteins that
are the core of my thesis project.
Next I would like to thank all current and previous members of the Marraffini
lab for being wonderful colleagues and friends. In particular, I want to mention
the people who trained and collaborated with me on my thesis work. Dr. David
Bikard is a former post-doc who trained me and introduced me to the fascinating
world of synthetic biology. He is always sharp, insightful and resourceful and I
constantly learn new facts and ideas from him. Importantly, our collaboration led
to the development of the type II CRISPR-Cas as a genome editing and gene
regulation tool in bacteria. Dr. Poulami Samai, a former post-doc, is a skillful
biochemist who trained me on many techniques including protein purification,
Southern blot, and various in vitro DNA/RNA cleavage assays. In the lab, we
were studying similar projects with regard to the targeting stage of type III
CRISPR-Cas immunity and often shared data and gave mutual encouragement.
She helped me set up a few important in vitro assays that allowed me to
interrogate my thesis question. Gregory Goldberg is a graduate student who
collaborated with me on various projects. I thank him for always being critical and
rigorous toward my work and gave me many useful suggestions for my thesis
project. I want to thank Dr. Joshua Modell, a methodical and inspirational postdoc who is currently collaborating with me on multiple new projects. I want to
thank Dr. Asma Hatoum-Aslan, a former post-doc for teaching me the primer
iv

extension assay and Inbal Maniv, our former lab manager for collaborating on a
CRISPR “escaper” project.
Kudos to the David Rockefeller graduate program and the Deans’ Office
(current members: Drs. Sidney Strickland, Emily Harms and Andrea Morris,
Kristen Cullen, Marta Delgado, Cristian Rosario and Stephanie Fernandez) for
supporting me both financially and academically. My graduate school experience
would not have been so smooth without help and input from them.
I would like to thank my former mentors at Rockefeller, Drs. Seth Darst and
Robert Darnell. In 2009 through the Rockefeller Summer Undergraduate
Research Fellowship program, I worked in Dr. Darst’s lab where I learned a great
deal about protein purification. In 2010, I rotated in Dr. Darnell’s lab and learned
about antibody internalization and the HITS-CLIP technique. These learning
experiences are important parts of my Ph.D. training, and I thank members from
both labs for helping me then and afterwards.
I would like to thank Dr. Connie Zhao, Bin Zhang and Sophie Huang from the
genomics, Drs. Henrik Molina, Milica Tešić Mark from the proteomics and Drs.
Alison North and Kaye Thomas from the imaging resource centers at Rockefeller
for helping me with various of my projects. I would like to thank all my past and
current collaborators outside Rockefeller University for contributing their
expertise and reagents. They are Dr. Bruce Levin from Emory University, Dr.
Feng Zhang from the Broad Institute and MIT, Dr. Donald Court from National
Cancer Institute and Dr. Ann Hochschild from Harvard Medical School.
v

Last but not least, I would like to extend my gratitude to my parents, Chao
Jiang and Yinhong Lou for their unconditional love and support; for coming to the
U.S. together with me and giving me the freedom to pursue what I love. Equally I
want to thank all my friends here at Rockefeller, Weil Cornell and Sloan-Kettering
for spending their times with me and making my graduate school career an
unforgettable experience.

vi

TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION ............................................................................. 1
1.1

Bacteriophages and their life cycles ........................................................ 1

1.2 CRISPR-Cas is a small-RNA-based adaptive immune system in
prokaryotes ....................................................................................................... 6
1.2.1

Type I CRISPR-Cas systems .......................................................... 10

1.2.2

Type II CRISPR-Cas systems ......................................................... 11

1.2.3

Type III CRISPR-Cas systems ........................................................ 13

CHAPTER 2 APPLICATION OF TYPE II CRISPR-CAS SYSTEM IN BACTERIAL
GENOME EDITING AND GENE REGULATION ................................................ 16
2.1

Existing genome editing technology in bacteria ..................................... 17

2.1.1

Allelic replacement .......................................................................... 17

2.1.2

λ-Red recombination ....................................................................... 22

2.2

Existing gene modulation tools in bacteria ............................................ 26

2.2.1

Small-RNA-mediated gene repression in bacteria .......................... 26

2.2.2

Transcription activation in bacteria.................................................. 30

2.3

CRISPR-Cas-mediated counter-selection and genome editing ............. 31

2.3.1

CRISPR-Cas as a sequence-specific counter-selection tool .......... 33

2.3.2

Analysis of targeting requirement by Cas9 complex ....................... 40

2.3.3 General scheme for the Cas9-complex-mediated counter-selection
for genome editing .......................................................................................... 49
2.3.4

Genome editing in Streptococcus pneumoniae .............................. 51

2.3.5

Genome editing in E.coli ................................................................. 59

2.3.6

Genome editing in Staphylococcus aureus ..................................... 64

2.3.7

Cas9-complex-mediated cleavage actively induces recombination 70

2.3.8

Discussion ...................................................................................... 72

2.3.8.1 CRISPR may be a universal counter-selection tool ..................... 72
2.3.8.2 The mutation frequency of CRISPR-Cas in the targeting construct
and its effect on counter-selection ............................................................ 73
2.3.8.3 Off-target effect ............................................................................ 74
2.4 Dead Cas9 (dCas9) mediates sequence-specific genetic repression and
activation in bacteria........................................................................................ 75
vii

2.4.1

dCas9 mediates transcription repression ........................................ 77

2.4.2

dCas9 mediates transcription activation ......................................... 81

2.4.3

Discussion ...................................................................................... 87

CHAPTER 3 TYPE III CRISPR-CAS SYSTEM .................................................. 90
3.1

Functionality of type III-A CRISPR-Cas of Staphylococcus epidermidis 92

3.2

Type III CRISPR-Cas immunity requires transcription ......................... 100

3.3

Type III CRISPR-Cas targets both DNA and RNA .............................. 105

3.4 Discovery of Csm6 as a novel RNase associated with the type III-A
CRISPR-Cas system ..................................................................................... 110
3.5

A challenge for transcription-dependent targeting ............................... 115

3.6 Transcriptional requirement of type III-A CRISPR-Cas targeting leads to
accumulation of phage DNA .......................................................................... 120
3.7

The biological function of RNases in type III CRISPR immunity .......... 127

3.8 Requirement of Csm6 in providing immunity against phages with target
mutations....................................................................................................... 139
3.9

Discussion ........................................................................................... 147

CHAPTER 4 PERSPECTIVES ......................................................................... 153
CHAPTER 5 MATERIALS AND METHODS ..................................................... 158
5.1

Bacterial strains and growth conditions ............................................... 158

5.2

Bacterial strain construction ................................................................ 159

5.3

Plasmid Cloning .................................................................................. 159

5.3.1

Cloning in E.coli ............................................................................ 159

5.3.2

Cloning in S. pneumoniae ............................................................. 160

5.3.3

Cloning in S. aureus...................................................................... 160

5.4

Plasmid DNA preparation .................................................................... 161

5.5

Conjugation ......................................................................................... 161

5.6

Preparation of electrocompetent S. aureus cells ................................. 162

5.7

Preparation of competent E.coli cells .................................................. 162

5.8

E. coli λ-Red recombination ................................................................. 162

5.9

S. aureus transformation ..................................................................... 163

5.10 S. pneumoniae transformation ............................................................ 164
5.11 Preparation of S. pneumoniae genomic DNA ...................................... 164
viii

5.12 Analysis of targeting requirement (PAM and seed sequences) by Cas9
complex in S. pneumoniae ............................................................................ 165
5.13 Generation of targeting constructs and editing templates for genome
editing in S. pneumoniae ............................................................................... 166
5.14 β-galactosidase (Miller) assay ............................................................. 166
5.15 Fluorescence measurements for dCas9-mediated transcription
repression and activation .............................................................................. 166
5.16 Northern blot analysis .......................................................................... 167
5.17 Plasmid-curing assay .......................................................................... 167
5.18 Purification of Csm6 ............................................................................ 168
5.19 Csm6 RNA cleavage assay ................................................................. 169
5.20 Csm6 DNA cleavage assay ................................................................. 170
5.21 Co-transcriptional DNA cleavage assay .............................................. 170
5.22 Phage infections and plate reader growth curves ................................ 171
5.23 Measurement of average burst size .................................................... 172
5.24 Extraction of total RNA in S. aureus .................................................... 172
5.25 Extraction of total DNA in S. aureus .................................................... 173
5.26 qPCR ................................................................................................... 173
5.27 RNA sequencing ................................................................................. 174
5.28 Southern blot ....................................................................................... 174

ix

LIST OF FIGURES
Figure 1-1 Bacteriophage T4 ................................................................................ 1
Figure 1-2 Phages predate on bacteria ................................................................ 2
Figure 1-3 Lytic and lysogenic life cycles of phages ............................................. 4
Figure 1-4 Three stages of CRISPR-Cas immunity ............................................. 8
Figure 2-1 Genome editing through allelic replacement ..................................... 19
Figure 2-2 Genome editing through allelic replacement continued. .................... 21
Figure 2-3 Genome editing through λ-Red recombination .................................. 24
Figure 2-4 Small RNAs mediate gene repression............................................... 28
Figure 2-5 Transcription activation in bacteria .................................................... 31
Figure 2-6 CRISPR-Cas as a counter-selection tool: initial proof of principle in
Streptococcus pneumoniae ................................................................................ 36
Figure 2-7 CRISPR-Cas as a counter-selection tool in E.coli ............................. 39
Figure 2-8 Analysis of targeting requirement by Cas9 complex.......................... 42
Figure 2-9 PAM analysis .................................................................................... 46
Figure 2-10 Analysis of the protospacer sequences ........................................... 48
Figure 2-11 A general scheme for genome editing mediated by the Cas9
complex .............................................................................................................. 50
Figure 2-12 Methodology for genome editing in S. pneumoniae ........................ 51
Figure 2-13 Genome editing in S. pneumoniae .................................................. 54
Figure 2-14 Distribution of distances between PAMs ......................................... 55
Figure 2-15 Sequential introduction of mutations by CRISPR-mediated genome
editing in S. pneumoniae .................................................................................... 57
Figure 2-16 Multiplex editing in S. pneumoniae .................................................. 59
Figure 2-17 CRISPR-mediated genome editing in E.coli .................................... 61
Figure 2-18 Allelic replacement in S. aureus ...................................................... 65
Figure 2-19 CRISPR-mediated genome editing in S. aureus ............................. 68
Figure 2-20 CRISPR-Cas induces recombination .............................................. 71
Figure 2-21 A schematic for dCas9-mediated transcription repression .............. 76
Figure 2-22 dCas9 mediates transcription repression ........................................ 78
Figure 2-23 A schematic for dCas9-mediated transcription activation. ............... 81
x

Figure 2-24 dCas9-ω mediates transcription activation ...................................... 83
Figure 2-25 dCas9-ω mediates transcription activation (continued) ................... 85
Figure 3-1 The type III-A CRISPR-Cas locus of Staphylococcus epidermidis
RP62a ................................................................................................................ 92
Figure 3-2 Type III-A CRISPR-Cas has anti-plasmid activity .............................. 94
Figure 3-3 A plasmid-borne type III-A CRISPR-Cas system is functional in
Staphylococcus aureus ...................................................................................... 97
Figure 3-4 Transcription is required for the type III-A CRISPR-Cas to target
phage ............................................................................................................... 101
Figure 3-5 Transcription is required for the type III-A CRISPR-Cas to target
plasmids ........................................................................................................... 104
Figure 3-6 Co-transcriptional DNA cleavage by purified Cas10-Csm complex . 107
Figure 3-7 RNA cleavage by purified Cas10-Csm complex .............................. 109
Figure 3-8 RNase activity of Csm6 ................................................................... 111
Figure 3-9 Csm6 is not involved in DNA targeting ............................................ 113
Figure 3-10 Phage lytic cycle............................................................................ 116
Figure 3-11 Models for co-transcriptional type III CRISPR-Cas immunity when
targeting early- and late-expressed phage genes............................................. 118
Figure 3-12 Co-transcriptional type III CRISPR-Cas targeting leads to
accumulation of phage DNA ............................................................................. 122
Figure 3-13 Corroboration of phage DNA accumulation in vivo ........................ 124
Figure 3-14 Co-transcriptional DNA cleavage using different complex:target
ratios ................................................................................................................. 126
Figure 3-15 Csm3 and Csm6 are required for the degradation of phage
transcripts ......................................................................................................... 129
Figure 3-16 Csm6, and not Csm3, degrades phage transcripts in the vicinity of
the region targeted by the Cas10-Csm complex............................................... 131
Figure 3-17 Degradation of phage transcripts by Csm3 and Csm6 enables type
III CRISPR-Cas immunity targeting late-expressed genes ............................... 134
Figure 3-18 Degradation of phage transcripts by Csm6 enables type III CRISPRCas immunity against late-expressed genes .................................................... 138
xi

Figure 3-19 Csm6 is required to provide immunity against viruses with target
mutations .......................................................................................................... 142
Figure 3-20 Mismatches in crRNA:target leads to accumulation of target DNA 144
Figure 3-21 Csm6 is required to provide immunity against viruses with target
mutations (continued) ....................................................................................... 146
Figure 3-22 A model for co-transcriptional cleavage of target DNA and its
transcript during type III-A CRISPR-Cas immunity ........................................... 151

xii

LIST OF TABLES
Table 1 Spacers used in Chapter 3 .................................................................. 175
Table 2 Targeting constructs and editing templates used for genome editing in S.
pneumonaie ...................................................................................................... 176
Table 3 Spacers used for dCas9-mediated transcription repression and activation
......................................................................................................................... 177
Table 4 DNA oligonucleotides used in Chapter 2 ............................................. 178
Table 5 DNA oligonucleotides used in Chapter 3 ............................................. 181
Table 6 RNA oligonucleotides used in Chapter 3 ............................................. 182

xiii

CHAPTER 1
1.1

INTRODUCTION

Bacteriophages and their life cycles

Figure 1-1 Bacteriophage T4
(A) An electron micrograph of bacteriophage T4; adapted from (Miller et al. 2003).
(B) A phage (in this case T4) is composed of a proteinous head and tail structure.
The head encapsulates its DNA or RNA genome. The image is adapted from
“https://en.wikipedia.org/wiki/Bacteriophage” with modifications.
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and
their associated genes (cas) encode an adaptive, small-RNA-based immune
system that protects prokaryotes from infectious phages and plasmids. The
immunity pathway is divided into three stages: adaptation, CRISPR RNA (crRNA)
biogenesis and targeting. On the basis of cas gene conservation and operon
organization, CRISPR-Cas can be divided into three major types. In addition to
being an immune system, CRISPR-Cas has been repurposed as a versatile tool
for genome editing. A recent review (Jiang and Marraffini 2015) written by my
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advisor, Dr. Luciano Marraffini and me summarizes current understanding of
CRISPR-Cas biology in prokaryotes and its many applications in biotechnology.

Figure 1-2 Phages predate on bacteria
A transmission electron micrograph of a thin section of Escherichia coli K-12
infected with phage T4. Dark materials are phage DNA. Image courtesy of John
Wertz.
Bacteriophages (Figure 1-1), or phages for short, are viruses that infect and
replicate within bacteria (Figure 1-2). First discovered independently by Fredrick
Twort and Felix d’Herelle in 1915 (Twort 1915) and 1917 (d'Herelle 1917),
phages are probably the most abundant and genetically diverse entities known to
exist in biology. It is estimated there are 1031 phages on Earth (Hatfull 2008), and
they infect an estimated 1023 bacteria per second (Suttle 2007). Because their
massive predation on bacteria that live in the ocean, soil as well as the human
gut, phages play a tremendous role on global ecology (Wommack and Colwell
2000) and human health (Reyes et al. 2012). Historically, studies conducted on
phages between the years 1940 and 1970 laid much of the most fundamental
groundwork for modern molecular genetics. For instance, experiments with
2

phage T4 uncovered the existence of mRNA, the nature of the genetic code and
the function of ribosome (Karam 1994). In addition, basic research on phages
has led to the development of many useful tools such as phagemids, phageplasmid hybrids that can be used as an efficient delivery method of nucleic acids
into bacteria (Westwater et al. 2002). Phage display is another powerful
technique for the study of protein-protein and protein-DNA interactions (Smith
1985; Kehoe and Kay 2005). With this technique, large libraries of proteins can
be screened and amplified through in vitro selection, a process widely used in
drug discovery (Smith and Petrenko 1997). The infectious nature of phages is
also harnessed as antibacterial agents (Nobrega et al. 2015), which offer a
plausible solution to the rise of multi-drug resistant infectious bacteria caused by
conventional antibiotic treatment.

3

Figure 1-3 Lytic and lysogenic life cycles of phages
(A) In a lytic cycle, an infective phage immediately initiates reproduction and
lyses host cells to release its progeny. (B) In a lysogenic cycle, a phage inserts
its genome into the bacterial chromosome to become a prophage, which is
replicated along with the bacterial DNA. (C) Under certain conditions such as
DNA damage, the lysogenic cycle can convert to the lytic cycle as shown in (A).
This figure is adapted from Microbiology, 7/e © 2008 John Wiley & Sons.
Generally, a phage is composed of a protein capsid that encapsulates a DNA
or RNA genome (Figure 1-1B). In many cases, the capsid, also known as the
head, has a tail structure attached to it. The tail structure is a hollow tube made
of proteins that allows the phage to penetrate bacterial membrane and cell wall
and inject its genetic material into the cell. Upon infection, phages typically
sustain two distinct life cycles – lytic and lysogenic (Figure 1-3) (Herskowitz and
4

Hagen 1980). Lytic phages immediately enter a reproductive phase, in which
their genetic material is replicated and packaged into a few hundred of progeny
phage particles. The lytic cycle concludes with lysis of the host bacteria and
release of phage progeny. By contrast, temperate phages can adopt either of the
two life cycles, depending on their genetic circuits and environmental factors. If
the lysogenic cycle is chosen, a single copy of the phage genome integrates into
the bacterial chromosome to become a prophage, which is replicated together
with the host chromosome. A switch to the lytic cycle can initiate under certain
stress conditions such as DNA damage (Herskowitz and Hagen 1980). During
this, the once-dormant prophage excises from the bacterial genome and follows
the program similar to that of a lytic phage. The lysis-lysogeny decision has been
a paradigm for gene regulatory network, and has been extensively characterized
in the temperate phage λ (Oppenheim et al. 2005).
For many large double-stranded DNA phages such as T4 and λ, expression of
phage genes is temporally regulated (Miller et al. 2003; Oppenheim et al. 2005).
Immediately transcribed upon infection, most early genes encode enzymes
involved in DNA replication and phage-encoded RNA polymerases that turn on
late phage genes. These genes usually encode various phage parts such as the
head and tail structures, packaging machinery and lytic enzymes that degrade
bacterial cell walls. Temporal gene regulation is a “clever” way to ensure efficient
utilization of host resources, and to control the timing of cell lysis so that an
optimum number of phage progeny can be produced.
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1.2
CRISPR-Cas is a small-RNA-based adaptive immune system in
prokaryotes
Bacteria have evolved different ways to protect themselves against phage
infections. Some of the best-known types of phage defense mechanisms are
restriction-modification (Wilson 1991; Tock and Dryden 2005), abortive infection
(Chopin et al. 2005) and CRISPR-Cas.
CRISPR-Cas systems encode an adaptive, small-RNA-based immune system
that protects prokaryotes from infectious phages and plasmids (Deveau et al.
2010; Horvath and Barrangou 2010; Terns and Terns 2011; Wiedenheft et al.
2012; Barrangou and Marraffini 2014). A typical CRISPR-Cas locus in bacteria
and archaea is composed of the CRISPR array and CRISPR-associated genes
(cas) (Figure 1-4A).The CRISPR array is a cluster of short repetitive sequences
(30-40 bp long) separated by equally short “spacer” sequences. Many spacer
sequences match the genomes of phages and plasmids of bacteria and archaea
(Bolotin et al. 2005; Mojica et al. 2005; Pourcel et al. 2005). This observation led
to the hypothesis that CRISPR systems protect prokaryotes from infection by
these genetic elements (Bolotin et al. 2005; Mojica et al. 2005; Pourcel et al.
2005; Makarova et al. 2006). The bioinformatics predictions were first
demonstrated by two experimental studies showing that CRISPR loci prevent
viral (Barrangou et al. 2007) and plasmid (Marraffini and Sontheimer 2008)
infection.
CRISPR-Cas immunity is divided into three stages (Figure 1-4). In the first
stage, known as the adaptation phase, Cas proteins integrate short regions of
6

the invader’s genome into the CRISPR array as new spacers (Figure 1-4A).
Reviews about this phenomenon are published elsewhere (Heler et al. 2014). In
the second stage, the CRISPR array is transcribed and processed by Cas
proteins to generate small CRISPR RNAs (crRNAs) that contain a full or partial
spacer sequence (Figure 1-4B-D). During the third stage, or the targeting phase,
processed crRNAs associate with Cas nucleases to guide the ribonucleoprotein
complex to the target sequence (Figure 1-4B-D). Cleavage of the target
sequence, also known as protospacer, results in both the destruction of the
invader’s genome and immunity. On the basis of cas gene conservation and
operon organization, CRISPR prokaryotic immune systems can be divided into
three major types (Makarova et al. 2011), each of which presents variations of
the general immunity mechanism described above (Figure 1-4B-D).

7

Figure 1-4 Three stages of CRISPR-Cas immunity
(A) A typical CRISPR-Cas locus in bacteria and archaea is composed of a
CRISPR array and CRISPR-associated genes (cas). In the first stage, known as
the adaptation phase, Cas proteins acquire a short sequence of the genetic
material of viral and plasmid invaders, known as a “spacer”, and integrate it into
the first repeat of the CRISPR array, establishing a memory of infection. (B-D) In
the second stage, known as the crRNA biogenesis phase, the CRISPR array is
transcribed as a precursor crRNA (pre-crRNA), which is processed by Cas
proteins into a short crRNA (mature crRNA). In the third stage, known as the
targeting phase, the crRNA acts as a guide to specify the target of cleavage by
Cas nucleases. Based on the cas gene content, there are three different types of
CRISPR-Cas systems. They differ in the mechanisms of crRNA biogenesis and
targeting, but also possibly in the mechanisms of adaptation as well. Closed and
open arrowheads indicate RNA and DNA cleavage, respectively. Abbreviations:
crRNA,

CRISPR

RNA;

PAM,

protospacer-adjacent

polymerase; tracrRNA, trans-encoded crRNA.
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motif;

RNAP,

RNA
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1.2.1 Type I CRISPR-Cas systems
Type I CRISPR-Cas systems encode proteins that form CRISPR-associated
complex for antiviral defense (Cascade) and Cas3 (Figure 1-4B). The CRISPR
array is transcribed as a long precursor crRNA that is processed at the repeat
sequences to liberate short, mature crRNAs (Brouns et al. 2008). Cleavage is
achieved by the Cas6 endoribonuclease, a subunit of the Cascade complex with
repeat-specific activity. Cas6 cleaves the repeat sequence eight nucleotides
upstream of the spacer sequence, liberating a small crRNA containing a full
spacer flanked by partial repeats. The crRNA remains associated to Cascade
and guides the complex to its target.
Efficient immunity requires the interaction between the first eight nucleotides
of the target (a region known as the target “seed”) and the complementary
sequence of the crRNA guide (Semenova et al. 2011; Wiedenheft et al. 2011) at
the 5’ end of the DNA:RNA duplex. Viruses containing mutations in this region
can indeed escape type I CRISPR immunity in E. coli (Semenova et al. 2011).
Mutations in the sixth nucleotide of the seed are exceptions – they do not affect
CRISPR immunity. This is due to the noncanonical ribbon structure formed by a
guide crRNA and its cognate ssDNA target within the Cascade complex. This
conformation requires outward rotation of every sixth nucleotide in the
crRNA:ssDNA hybrid (Jackson et al. 2014; Mulepati et al. 2014; Zhao et al. 2014).
As such, the sixth nucleotide of the seed can remain unpaired without
compromising the unusual structure, and a mutation at this location does not
affect immunity.
10

A second requirement for type I immunity is the presence of a nucleotide motif
immediately upstream of the target sequence, the protospacer-adjacent motif
(PAM). For the type I-E system of E. coli the PAM is an AWG trinucleotide and it
is recognized by CasA, a member of the Cascade complex (Sashital et al. 2012).
It is believed that the PAM requirement for immunity allows “tolerance to self”: it
prevents the autoimmunity against the spacer DNA sequences, which are
complementary to the crRNAs they encode. Absence of a PAM in the 5’ end of
the target prevents spacer targeting. Similar to the alteration to the seed
sequence, mutations in the PAM promote the escape of bacteriophages from
CRISPR immunity (Semenova et al. 2011).
If both conditions are met, i.e. base-pairing within the seed and the presence
of a PAM, recruitment of the Cas3 ssDNA nuclease cleaves and degrades the
displaced DNA strand within the target sequence (Westra et al. 2012) and
degrades it with 3’-5’ processivity (Gong et al. 2014; Huo et al. 2014).
1.2.2 Type II CRISPR-Cas systems
Type II CRISPR-Cas systems are defined by the presence of the Cas9 RNAguided endonuclease and are the simplest of all CRISPR types (Figure 1-4C).
Processing of the precursor crRNA does not require a dedicated, repeat-specific
endoribonuclease. Instead, type II CRISPR loci produce a small trans-encoded
crRNA (tracrRNA) with a region of complementarity to the repeat sequence
(Deltcheva et al. 2011). The tracrRNA is bound by the Cas9 nuclease and forms
a dsRNA interaction with the repeat sequences of the precursor crRNA that is
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cleaved by RNase III. The result of this reaction is the generation of a Cas9
enzyme loaded with both the tracrRNA and the crRNA guide, a ribonucleoprotein
complex that is necessary and sufficient for CRISPR immunity (Sapranauskas et
al. 2011).
Similar to type I, type II CRISPR immunity requires six to eight nucleotides of
seed sequence (Deveau et al. 2008; Jiang et al. 2013a) as well as a PAM
(Deveau et al. 2008), which for the Streptococcus pyogenes SF370 type II-A
CRISPR-Cas system is NGG (Mojica et al. 2009; Jiang et al. 2013a). As opposed
to type I, however, the seed and PAM sequences are located at the 3’ end of the
target. As a consequence of these requirements, viruses can escape CRISPR
immunity by mutating any of these sequences (Barrangou et al. 2007; Deveau et
al. 2008). Upon infection, the tracrRNA/crRNA/Cas9 ribonucleoprotein complex
scans the viral genome for the presence of PAM sequences. Binding of Cas9 to
the PAM favors the unwinding of the target sequence immediately upstream of
the motif, allowing the crRNA to probe for the presence of a matching sequence
(Sternberg et al. 2014). A productive annealing results in the formation of a
crRNA:target R-loop that triggers cleavage by Cas9. The enzyme harbors two
nuclease domains (HNH and RuvC (Sapranauskas et al. 2011; Jinek et al. 2014;
Nishimasu et al. 2014)), each of which cuts one target DNA strand. The tracrRNA
is a co-factor of Cas9 and it is also required for DNA cleavage (Gasiunas et al.
2012; Jinek et al. 2012).
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1.2.3 Type III CRISPR-Cas systems
Type III CRISPR-Cas systems are possibly the most complex of all CRISPR
types. These loci are defined by the presence of genes encoding Cas10 and the
repeat-associated mysterious protein (RAMP) modules Csm or Cmr for type III-A
or III-B, respectively (Makarova et al. 2011), which together form the Cas10-Csm
or Cas10-Cmr complexes (Hale et al. 2009; Zhang et al. 2012; Hatoum-Aslan et
al. 2013). As in type I systems, crRNA precursor processing is achieved by the
Cas6 repeat-specific endoribonuclease (Carte et al. 2008) (Figure 1-4D). In
contrast to type I systems, however, Cas6 is not part of the Cas10 complex (Hale
et al. 2009; Zhang et al. 2012; Hatoum-Aslan et al. 2013), and recent
experiments suggested that repeat sequences are important to incorporate the
Cas6 products into the complex prior to targeting (Sokolowski et al. 2014). Also
in contrast to type I, the crRNAs generated by Cas6 cleavage are further trimmed
at the 3’ end in a process known as crRNA maturation. Type III crRNA
maturation eliminates the 3’-end repeat sequences that remain after Cas6
cleavage and generates a heterogeneous population of mature crRNA guides
which differ by increments of six nucleotides at the maturation end (Hale et al.
2008; Hatoum-Aslan et al. 2011).
As opposed to the other CRISPR types, a seed sequence has not been
identified. Moreover, multiple mutations within the target do not abrogate
immunity (Manica et al. 2013). No PAM requirements have been reported for
type III targeting either. Instead, the lack of base pairing between the target 5’
flanking sequences and the crRNA tag is essential for type III CRISPR immunity
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(Marraffini 2010). Since there is perfect homology between the upstream repeat
and the crRNA tag (this is transcribed from the repeat DNA), this property
enables the discrimination between bona fide targets and the CRISPR array itself
to avoid autoimmunity.
Two unique features of type III CRISPR-Cas systems are (i) that transcription
across the target is required for immunity (Deng et al. 2013; Goldberg et al.
2014), and (ii) both DNA (Marraffini and Sontheimer 2008; Manica et al. 2011;
Goldberg et al. 2014; Samai et al. 2015) and RNA (Hale et al. 2009; Zhang et al.
2012; Staals et al. 2014; Tamulaitis et al. 2014; Zebec et al. 2014; Samai et al.
2015) targets are cleaved. In addition, only crRNA guides complementary to the
coding, but not the template, DNA strand provide effective immunity (Goldberg et
al. 2014). Because these guides are also complementary to, and cleave, the
target transcript, type III CRISPR-Cas immunity leads to the co-transcriptional
destruction of both the target DNA and its transcripts (Peng et al. 2015; Samai et
al. 2015). Whereas DNA cleavage is essential for immunity, the function of RNA
targeting is unknown, and has been one of the focuses of my thesis.
The transcription requirement allows tolerance of foreign elements that can
silence the region targeted by type III CRISPR-Cas systems. For example, this
permits discrimination between the lytic and lysogenic cycles of temperate
phages. Temperate phages with targets for type III CRISPR immunity within the
lytic genes, which are expressed only during the lytic cycle but not during the
prophage stage, can be maintained as prophages inside the cell even if they
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contain a target that perfectly matches a crRNA (Goldberg et al. 2014). Induction
of the lytic cycle, however, re-initiates transcription and targeting, and thus type
III immunity can prevent the lethal reactivation of prophages.
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CHAPTER 2
APPLICATION OF TYPE II CRISPR-CAS SYSTEM
IN BACTERIAL GENOME EDITING AND GENE REGULATION
In this chapter, I will introduce existing genome editing and gene regulation
techniques in bacteria and some drawbacks associated with them. I will describe
the development of type II CRISPR-Cas as a novel sequence-specific counterselection tool, and its application in bacterial genome editing and gene regulation.
Most of this work (Bikard et al. 2013; Jiang et al. 2013a) was done in close
collaboration with Dr. David Bikard, a previous post-doc in our lab, who’s also a
great mentor and friend of mine.
Since our initial proof-of-principle demonstration of CRISPR-mediated
genome editing in E.coli and Streptococcus pneumoniae (Jiang et al. 2013a), the
approach has been successfully applied for genetic manipulation in many more
bacterial species, including Lactobacillus (Oh and van Pijkeren 2014),
Clostridium (Wang et al. 2015; Xu et al. 2015), Streptomyces (Cobb et al. 2015;
Huang et al. 2015), Actinomycetes (Tong et al. 2015), Staphylococcus (Chapter
2.3.6), Salmonella (in collaboration with Zhenrun J. Zhang, unpublished data) as
well as bacteriophages (Kiro et al. 2014; Martel and Moineau 2014). CRISPRmediated gene regulation has been demonstrated in E.coli (Bikard et al. 2013; Qi
et al. 2013), Mycobacterium (Choudhary et al. 2015), Bacteroides (Mimee et al.
2015) and Actinomycetes (Tong et al. 2015). The easy programmability of the
CRISPR-Cas system greatly facilitated genome editing and modulation of gene
expression, and is likely to substantially advance our capability to both decipher
gene function in prokaryotes and manipulate them for biotechnological purposes.
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2.1

Existing genome editing technology in bacteria
Reverse genetics is a powerful approach for identification and understanding

of gene function. The general methodology consists of first mutation of the gene
of interest and then analysis of the resulting phenotype. In bacteria, genome
modification is typically achieved by using allelic replacement (Hamilton et al.
1989) or λ-Red recombinase-mediated recombination (Court et al. 2002).
2.1.1 Allelic replacement
Allelic replacement (Figure 2-1) is a classical genetic engineering technique
(Hamilton et al. 1989), and has been extensively used to generate knock-out,
knock-in or point mutations in chromosomal genes. The method typically makes
use of temperature-sensitive plasmids, on which a replacing gene fragment with
homologous sequences flanking the chromosomal gene of interest is cloned.
Upon introduction to a host such as E.coli and selection of appropriate antibiotic,
the plasmid can replicate and be maintained at a permissive temperature (e.g.,
30°C). When shifted to a nonpermissive temperature (e.g., 43°C), the plasmid
can no longer be maintained episomally, and in the presence of the appropriate
selective antibiotic, homologous recombination between the plasmid-borne
homology arms and the chromosome results in plasmid integration (Figure 2-1B
and Figure 2-2A). Since the integrant harbors two sets of homology arms, a
second recombination event can happen. Because this is usually a lowfrequency event, the plasmid typically carries a counter-selection marker such as
the sacB gene derived from Bacillus subtilis. Expression of the gene in E.coli is
lethal in the presence of sucrose (Blomfield et al. 1991), and leads to plasmid
17

excision. Depending on where the second recombination event takes place, the
chromosome either undergoes a gene replacement or reverts back to the original
genotype at a roughly 1:1 ratio (Figure 2-1C).
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Figure 2-1 Genome editing through allelic replacement
(A) First, a temperature-sensitive plasmid harboring a desired mutation along
with two homology arms are constructed. The plasmid also carries an antibiotic
marker (e.g. kan) and a counter-selection marker (e.g. sacB). Upon introduction
in host cells such as E.coli and selection using kanamycin, the plasmid can be
maintained at a permissive temperature (e.g. 30°C). (B) When shifted to a
nonpermissive temperature (e.g., 43°C), the plasmid is forced to integrate into
the region of the host chromosome carrying the gene of interest (goi) through
homologous recombination. This low-frequency event can be selected using
kanamycin. (C) Using a counter-selection marker such as the sacB gene, a
second recombination event resulting in gene replacement or reversion can take
place at a roughly 1:1 ratio. Abbreviations: kan, kanamycin-resistant marker; goi,
gene of interest.
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Figure 2-2 Genome editing through allelic replacement continued.
Same as Figure 2-1 except that the initial plasmid integration step can also occur
through recombination of the right homology arm, as opposed to the left
homology arm shown in Figure 2-1B.
Allelic replacement suffers from some drawbacks. First, it is a two-step
method that requires cloning, which could be lengthy and labor-intensive. Second,
the success of the method depends crucially on counter-selection makers.
Although the sacB sucrose sensitivity system remains the most effective bacterial
counter-selection tool to date, expression of the gene is harmless in most grampositive bacteria and thus cannot support counter-selection in these species
(Reyrat et al. 1998).
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2.1.2 λ-Red recombination
Bacterial recombineering, first developed in E.coli by Kenan Murphy in 1998
(Murphy 1998), is a genetic engineering technique that uses phage-encoded
homologous recombination systems to recombine linear DNA fragments into
bacterial chromosomes (Court et al. 2002). In contrast to classical techniques
such as allelic replacement, recombineering is a single-step procedure that does
not require laborious construction of plasmids containing homology arms (Figure
2-1). Instead, all that is required is synthesis of standard oligonucleotides (oligos)
that provide the homology. These oligos can be used directly or for the making of
PCR products that are used for recombineering.
Recombination systems encoded by either redαβδ from phage λ (Murphy
1998; Yu et al. 2000) or recE/recT from Rac prophage (Zhang et al. 1998) can
mediate efficient recombination of linear DNA fragments. Now widely used in
E.coli, the λ-Red system is composed of three λ genes: exo, bet and gam, which
encode the Exo, Beta and Gam proteins, respectively (Figure 2-3A). When a
linear dsDNA fragment carrying short sequences of homology on each end is
introduced to host cells, λ Exo, an exonuclease, degrades the dsDNA in a 5’ to 3’
direction (Little 1967; Carter and Radding 1971). As Exo is highly processive
(Matsuura et al. 2001), the current model suggests that the protein binds one of
the two dsDNA strands and degrades that strand completely (Figure 2-3B)
(Mosberg et al. 2010; Pines et al. 2015). The ssDNA generated is then stably
bound by λ Beta (Figure 2-3D). The function of λ Beta is to protect the DNA from
single-strand nuclease attack and promote annealing of the exogenous DNA to
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the complementary ssDNA sequences in the chromosome (Kmiec and Holloman
1981; Muniyappa and Radding 1986; Karakousis et al. 1998). Specifically, the
recombination of the ssDNA intermediate preferentially occurs at the lagging
strand of the replication fork during DNA replication (Figure 2-3D) (Ellis et al.
2001). The third protein, λ Gam, confers the full recombination potential to the
system. Gam inhibits RecBCD (Karu et al. 1975; Murphy 1991), host nucleases
that would otherwise rapidly degrade cellular linear dsDNA (Figure 2-3B).
ssDNAs on the other hand, are not substrates for RecBCD. Therefore, ssDNA
fragments can be recombined to the host genome with the presence of only λ
Beta (Figure 2-3C) (Ellis et al. 2001). Recombineering with ssDNA is more
efficient than with dsDNA and is the method of choice to create point mutations.
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Figure 2-3 Genome editing through λ-Red recombination
(A) The λ-Red recombination system comprises of the Exo, Beta and Gam
proteins from phage λ. Both linear ssDNAs and dsDNAs can be used as
substrates for recombination. (B) When a linear dsDNA fragment is introduced to
host cells, λ Exo degrades the dsDNA in a 5’ to 3’ direction and generates a
ssDNA. In the meantime, λ Gam protects the dsDNA from degradation by
inhibiting host nucleases RecBCD. Red segments on DNAs denote new
sequences to be incorporated and gray segments denote short sequences
homologous to host chromosomes. (C) Recombination of ssDNA fragments does
not require λ Exo and Gam. (D) λ Beta binds the ssDNA fragments, protects
them from single-strand nuclease attack and promotes annealing of the DNA
preferentially to the lagging strand of the replication fork. (E) Among recombined
cells, another round of cellular replication is required to complete the synthesis of
the newly introduced modification on the opposite strand. This results in 50% of
the recombined cells inheriting the change. Abbreviations: dsDNA, doublestranded DNA; ssDNA, single-stranded DNA.
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The single-step λ-Red recombination system integrates linear DNA fragments
into the host chromosomes, which circumvents the need for the extensive in-vitro
cloning that conventional genetic engineering techniques entail. Although the
system substantially simplifies genome editing, currently it has only been shown
to work in a limited number of species. These species include E.coli (Datsenko
and Wanner 2000), Salmonella (Karlinsey 2007), Streptomyces (Gust et al. 2004)
and Mycobacterium (van Kessel and Hatfull 2008). Additionally, when the
intention is to create point mutations, the recombineering technique suffers from
a big downside – lack of selection. Typically recombinants are found in only 0.01%
of the treated cells if dsDNA is used or 0.1% if cells are treated with ssDNA
(http://redrecombineering.ncifcrf.gov/) (Yu et al. 2000; Ellis et al. 2001), and thus
screening of a large number of colonies is required.
2.2

Existing gene modulation tools in bacteria
Unlike eukaryotic cells that can be modulated by RNAi (Hannon and Rossi

2004), methods for gene regulation are limited in bacteria. Two existing tools for
gene repression and activation are small antisense RNAs (sRNAs) (Storz et al.
2011) and DNA-binding transcription activators (Ptashne and Gann 1997).
2.2.1 Small-RNA-mediated gene repression in bacteria
RNA elements are important regulators for gene expression in all domains of
life. In bacteria, one such regulator comprises riboswitches, which are ciselements that modulate the translation of the mRNAs harboring them (Waters
and Storz 2009). Another class of regulators naturally found in bacteria is small
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RNAs (sRNA). Typically 50-300 nucleotides long and often trans-encoded, these
sRNAs usually negatively control translation and stability of target mRNAs by
base-pairing (Waters and Storz 2009; Storz et al. 2011). Inhibition of translation
is achieved by base-pairing at or near ribosome binding sites (RBS) and
occlusion of ribosomes (Figure 2-4A). Base-pairing between the sRNAs and the
coding region of mRNA recruits RNase E that degrades the target mRNA,
leading to downregulation of the gene (Figure 2-4B). In many cases, the RNA
chaperone Hfq is required for the function and/or stability of the trans-encoded
sRNAs (Figure 2-4A, B and C) (Vogel and Luisi 2011).
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Figure 2-4 Small RNAs mediate gene repression
(A) Small RNA (sRNA) in association with the RNA chaperone, Hfq can repress
gene expression by base-pairing at or near ribosome binding sites (RBS) of its
target mRNA, which occludes ribosomes from binding and initiating translation.
(B) sRNA/Hfq complex base-pairs with the coding region of mRNA and recruits
RNase E, which degrades the target mRNA and leads to downregulation of the
gene. (C) Hfq may protect some sRNAs from degradation by ribonucleases such
as RNase E. This figure is adapted from (Vogel and Luisi 2011).
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Though the programmable nature of trans-encoded-sRNA offers a promising
possibility to repress gene expression at will, the efficacy of different sRNAs in
repression has been variable (Man et al. 2011; Sharma et al. 2012). Conceivably,
the efficacy can be influenced by factors such as the sequence of sRNAs, their
interaction with Hfq and thus stability in vivo, as well as sequence of target
mRNAs and their secondary structures. Since no robust design rule currently
exists, identification of functional sRNAs often requires screening of a library of
sRNAs (Man et al. 2011; Sharma et al. 2012). This process is laborious and
severely limits the application of sRNAs as a tool for gene repression.
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2.2.2 Transcription activation in bacteria
In both prokaryotes and eukaryotes, transcription activation is generally
achieved by DNA-binding activators (Ptashne and Gann 1997). Activators are
proteins composed of a DNA-binding domain that recognizes and binds specific
sites on DNA, and an activation domain that recruits transcriptional machinery to
the DNA (Figure 2-5A). Early work in yeast showed that fusing a DNA-binding
domain to a subunit of the RNA polymerase II holoenzyme activates transcription
from a promoter bearing sequences recognizable by the DNA-binding domain
(Barberis et al. 1995; Farrell et al. 1996; Gaudreau et al. 1997).
In E.coli, the RNAP core enzyme consists of subunits of α, β and β’ in the
stoichiometry α2ββ’ (Burgess 1969) and one of several alternative σ subunits that
direct the enzyme to specific promoters (Helmann and Chamberlin 1988). An
additional protein of unknown function, ω, has been categorized as a subunit of
RNAP based on its co-purification with RNAP (Burgess 1969). On the other hand,
the cI protein from phage λ is a DNA-binding protein that recognizes the operator
sequence located on λ DNA (Li et al. 1994). Early studies showed that by
tethering λcI to α or ω subunit of RNAP, the chimeric protein effectively mediates
transcription activation of genes bearing the λ operator (Figure 2-5B) (Dove et al.
1997; Dove and Hochschild 1998). However, one big downside of transcription
activation is that the recognition sequence on the DNA is determined by the
activator and fixed. Therefore it requires engineering of the promoter sequence of
the gene before it can be activated. Overall, this makes the method cumbersome
and time-consuming.
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Figure 2-5 Transcription activation in bacteria
(A) A transcription activator comprises of a DNA-binding domain that recognizes
and binds specific sites on DNA, and an activation domain, in many cases a
subunit of the RNA polymerase (RNAP) that recruits RNAP to the DNA. (B) In
E.coli, by tethering the cI protein of phage λ to the α subunit of RNAP, the
transcription activator can recruit RNAP to genes bearing the λ operator, thus
activating transcription.
2.3

CRISPR-Cas-mediated counter-selection and genome editing
As introduced in Chapter 2.1, current bacterial genome editing methods such

as allelic replacement and λ-Red recombination suffer from a common
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disadvantage – the limited utility or complete lack of counter-selection markers.
Therefore there is a need to develop new and easy counter-selection tools that
can function in a wide range of bacterial species.
To date, all three types of CRISPR-Cas systems are reported to cleave DNA.
Importantly, our lab discovered that when programmed to target the chromosome
of Streptococcus pneumoniae, CRISPR-Cas causes autoimmunity and kills the
cells (Bikard et al. 2012). The lethal consequence upon targeting, presumably
due to inability of the cellular machinery to repair the cleaved DNA, opened up a
possibility to adopt CRISPR-Cas as a sequence-specific counter-selection tool in
bacteria, and potentially facilitate genome editing when combined with existing
methods.
Not all types of CRISPR-Cas systems are suitable for repurposing as genetic
engineering tools. For example, the DNA cleavage activity of type I and type III
crRNA:Cas ribonucleoprotein complexes is not well characterized and the
biogenesis of crRNA guides requires a specialized Cas endoribonuclease, Cas6.
In addition, these complexes are composed of multiple protein subunits (Figure
1-4B and D), increasing the engineering required to make them work in
heterologous hosts. In contrast, type II CRISPR-Cas systems present a simpler
mechanism which relies on the crRNA-guided nuclease Cas9, its tracrRNA
cofactor, and the house-keeping RNase III (Chapter 1.2.2). To further simplify the
system, the crRNA and tracrRNA can be fused to form a single guide RNA
(sgRNA) (Jinek et al. 2012). Creation of sgRNA obviates the need for RNase III,
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which is required for canonical crRNA processing canonically (Deltcheva et al.
2011). In the work presented below, we used the canonical tripartite system
consisting of the Cas9 nuclease, its tracrRNA cofactor and its crRNA guide that
specify the target. In all studied bacterial species (including E.coli, Streptococcus
pneumoniae, Staphylococcus aureus and Salmonella) we worked with,
heterologous expression of the tripartite system had programmable DNA
targeting activity, suggesting that host RNase III or homologous enzymes in
those species can support crRNA processing and thus CRISPR functionality. It
remains possible that host RNase III in other species might not support crRNA
processing, in which case the sgRNA-mediated version of engineering would be
needed in those species.
2.3.1 CRISPR-Cas as a sequence-specific counter-selection tool
In order to test the feasibility of adapting the type II CRISPR-Cas as a
counter-selection tool, we chose to work with S. pneumoniae because the
organism is naturally competent for DNA uptake and the genome can be easily
modified by linear PCR products provided exogenously (Claverys et al. 2009).
Using the parental strain, R6, we first constructed strain crR6, in which the nonessential gene IS1167 is replaced by the CRISPR01 locus of Streptococcus
pyogenes SF370 along with a kanamycin-resistant marker, aphA-3 (Figure 2-6A).
This CRISPR-Cas locus encodes tracrRNA, Cas9 and a CRISPR array with six
spacers. The locus also contains cas1, cas2 and csn2, genes that are involved in
the adaptation phase (Heler et al. 2014) but are dispensable for targeting.
Notably, the SF370 Cas9 was later widely repurposed as a robust genome
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editing tool in both bacteria (Jiang and Marraffini 2015) and eukaryotic cells (Hsu
et al. 2014). We also constructed two other strains, R68232.5, and R6370.1, in which
the non-essential srtA gene in R6 is disrupted by a chloramphenicol-resistant
marker, cat, along with a 0.4 kB sequence derived from streptococcal
bacteriophages φ8232.5 or φ370.1, respectively (Figure 2-6A). Crucially, the first
spacer of the CRISPR array matches perfectly to a region on the 0.4 kB
sequence cloned from both phages (Figure 2-6B). However, CRISPR can only
target φ8232.5 but not φ370.1 as the protospacer on φ370.1 lacks a functional
PAM, which is required for Cas9 targeting (see Chapter 1.2.2).
Next, we transformed R68232.5, and R6370.1 cells with genomic DNA (gDNA)
extracted from crR6 cells. If targeting of the chromosome by CRISPR leads to
cell death, we should expect to recover only R6370.1 transformants. Contrary to
this expectation, we isolated R68232.5 transformants, albeit with approximately 10fold less efficiency than R6370.1 transformants (Figure 2-6C). Transformation of
genomic DNA from crR6M, a strain lacking cas1, cas2 and csn2 yielded similar
result (Figure 2-6C), consistent with the notion that these genes are dispensable
for targeting. Genetic analysis of eight R68232.5 transformants revealed that the
great majority of them had undergone a double recombination event (Figure
2-6D). Since the crR6 gDNA contains the wild-type srtA locus, it can recombine
and replace the φ8232.5 target that would be otherwise recognized by Cas9 and
lead to cell death. This experiment provides the initial proof that the concurrent
introduction of a targeting construct (i.e. a type II CRISPR-Cas system composed
of tracrRNA, crRNA and Cas9 (hereafter referred to as the Cas9 complex) that
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targets a genomic locus) together with an editing template for recombination into
the targeted locus, can lead to targeted genome editing.
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Figure 2-6 CRISPR-Cas as a counter-selection tool: initial proof of principle
in Streptococcus pneumoniae
(A) Using Streptococcus pneumoniae R6 as a parental strain, crR6 was
constructed by replacing the non-essential IS1167 by the CRISPR01 locus of
Streptococcus pyogenes SF370 along with a kanamycin-resistant marker, aphA3. crR6M is a minimal type II CRISPR-Cas system that had cas1, cas2 and csn2
deleted from crR6. Using R6 as a parental strain, R68232.5 and R6370.1 were
constructed by integrating a 0.4 kB region derived from the streptococcal
bacteriophages φ8232.5 and φ370.1 in the srtA gene, respectively. This region
was also fused to a chloramphenicol-resistant marker, cat. (B) The φ8232.5
protospacer matches perfectly to the crRNA derived from spc1 of the CRISPR
locus. The PAM is TGG. (C) Transformation of donor crR6 and crR6M genomic
DNA in recipient cells, R68232.5 and R6370.1. As a control of cell competence a
streptomycin-resistant gene was also transformed. Transformation efficiency was
measured as the number of colony-forming units (CFU) per μg of donor DNA
(mean ± SD of three replicas). (D) PCR analysis of eight R68232.5 transformants
with crR6 genomic DNA. Primers that amplify the srtA locus were used for PCR.
7/8 genotyped colonies replaced the R68232.5 srtA locus (~3.5 kB) by the wild-type
locus (~2.2 kB) from the crR6 genomic DNA. Abbreviations: PAM, protospacer
adjacent motif; Kan, kanamycin; Strp, streptomycin.
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CRISPR-mediated killing also works in E.coli (Figure 2-7A). We constructed a
plasmid, pCas9, which contained tracr and cas9. We also cloned pCRISPR::Ø
and pCRISPR::rpsL, which were plasmids harboring either an empty spacer, or a
spacer that matched the rpsL gene on the genome, respectively. When these two
plasmids were transformed into E.coli cells that already carried pCas9, the
number of pCRISPR::Ø transformants was over three orders of magnitude more
37

than that of pCRISPR::rpsL (Figure 2-7B). In addition, genetic analysis of eight
pCRISPR::rpsL transformants revealed that all had deleted the spacer (Figure
2-7C). These data suggests that CRISPR targeting of host chromosome leads to
cell death, a property that can be exploited as a powerful tool for counterselection.
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Figure 2-7 CRISPR-Cas as a counter-selection tool in E.coli
(A) pCRISPR::Ø and pCRISPR::rpsL are kanamycin-resistant plasmids that
carried either an empty spacer or a spacer that matched the rpsL gene on the
E.coli genome. These plasmids were transformed into an E.coli strain HME63
that already harbored pCas9, which contained tracr and cas9. (B) Transformation
of the pCRISPR::Ø or pCRISPR::rpsL plasmids into HME63 competent cells.
Transformation efficiency was measured as the number of colony-forming units
(CFU) per mL of competent cells (mean ± SD of three replicas). (C) PCR
analysis of eight pCRISPR::rpsL transformants using primers that amplified the
CRISPR array.
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2.3.2 Analysis of targeting requirement by Cas9 complex
To use the Cas9 complex as a counter-selection tool for genome editing, one
must design an editing template carrying mutations that abolish cleavage by it,
thereby preventing cell death. This is easy to achieve when the target to be
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recognized by CRISPR is deleted or replaced by another sequence. When the
goal is to generate gene fusions or single-nucleotide mutations, the prevention of
cleavage by Cas9 is possible only by introducing mutations in the editing
template that alter either the PAM or the protospacer sequences. To determine
the constraints imposed by these sequences, we performed a thorough analysis
of PAM and protospacer mutations that abrogate targeting by Cas9 complex.
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Figure 2-8 Analysis of targeting requirement by Cas9 complex
(A) The crRNA derived from spc1 of the crR6 CRISPR locus targets the φ8232.5
protospacer containing a perfect match and a functional PAM, TGG. (B)
Genomic DNA from R68232.5 was used as a template to obtain a randomized PAM
or protospacer library. This was achieved by PCR with primers containing these
randomized sequences. The PCR products were then transformed into crR6 or
R6

cells

followed

by

chloramphenicol

selection.

More

than

2×105

chloramphenicol-resistant transformants, carrying inactive PAM or protospacer
sequences, were combined for amplification and deep sequencing of the target
region. In (B), single-stranded DNAs were used for illustration but in real
experiments double-stranded PCR products were used.
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Previous studies proposed that S. pyogenes Cas9 requires an NGG PAM
immediately downstream of the protospacer (Deltcheva et al. 2011; Gasiunas et
al. 2012; Jinek et al. 2012). However, because only a very limited number of
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PAM-inactivating mutations have been described thus far (Deltcheva et al. 2011;
Bikard et al. 2012; Gasiunas et al. 2012; Jinek et al. 2012), we conducted a
systematic analysis to find all 5-nucleotide sequences following the protospacer
that

eliminate

Cas9

cleavage

(Figure

2-8).

We

used

randomized

oligonucleotides to generate all possible 1,024 5-nucleotide PAM sequences in a
heterogeneous PCR product that was transformed into crR6 or R6 cells.
Constructs carrying functional PAMs are expected to be recognized and
destroyed by crR6 but not R6 cells. More than 2×105 colonies were pooled to
extract DNA for use as templates for the co-amplification of all targets. PCR
products were deep sequenced and found to contain all 1,024 sequences, with
coverage ranging from 5 to 42,472 reads (see supplementary materials of (Jiang
et al. 2013a)). The functionality of each PAM was estimated by the relative
proportion of its reads in the crR6 sample over the R6 sample. Analysis of the
first three bases of the PAM clearly shows that the NGG pattern is underrepresented in crR6 transformants (Figure 2-9A). Furthermore, the next two
bases have no detectable effect on the NGG PAM (see supplementary materials
of (Jiang et al. 2013a)), demonstrating that the NGGNN sequence is sufficient to
license Cas9 activity. Partial targeting was observed for NAG PAM sequences
(Figure 2-9A). Also the NNGGN pattern partially inactivates CRISPR targeting
(Figure 2-9B, orange and blue sequences), indicating that the NGG motif can
still be recognized by the Cas9 complex with reduced efficiency when shifted by
1 bp. These data shed light on the molecular mechanism of Cas9 target
recognition, and they revealed that NGG (or CCN on the complementary strand)
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sequences were sufficient for targeting. As an editing strategy, mutation of the
two “G”s can abolish targeting, though NGG to NAG or NNGGN mutations
should be avoided. In theory, a given sequence of any di-nucleotide (i.e. the GG
in the PAM) occurs once every 8 bp in a stretch of perfectly random sequences.
This means that almost any position of the genome can be targeted by the Cas9
complex.
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Figure 2-9 PAM analysis
(A) Relative proportion of number of reads after transformation of the random
PAM constructs in crR6 cells (compared to number of reads in R6 transformants).
The relative abundance of each 3-nucleotide PAM sequence is shown. Severely
underrepresented

sequences

(NGG)

are

shown

in

red;

partially

underrepresented one, in orange (NAG). (B) Same as (A) except showing the
relative abundance of the 2nd, 3rd and 4th PAM sequences. Partially
underrepresented sequences are also shown in blue.
46

Another way to disrupt the Cas9-complex-mediated cleavage is to introduce
mutations in the protospacer region of the editing template. It is known that point
mutations within the “seed sequence” (the 8 to 10 protospacer nucleotides
immediately adjacent to the PAM) can abolish cleavage by CRISPR nucleases
(Semenova et al. 2011; Wiedenheft et al. 2011; Jinek et al. 2012). However, the
exact length of this region is not known, and it is unclear whether mutations to
any nucleotide in the seed can disrupt Cas9 target recognition. We followed the
same deep sequencing approach described above to randomize the entire
protospacer sequence involved in base pair contacts with the crRNA and to
determine all sequences that disrupt targeting. Each position of the 20 matching
nucleotides (Deltcheva et al. 2011) in the spc1 target present in R68232.5 cells
(Figure 2-8A) was randomized, and a library containing the resulting sequences
was transformed into crR6 and R6 cells (Figure 2-8B). Consistent with the
presence of a seed sequence, only mutations in the 12 nucleotides immediately
upstream of the PAM abrogated cleavage by Cas9 (Figure 2-10). However,
different mutations displayed markedly different effects. The distal (from the PAM)
positions of the seed (12 to 7) tolerated most mutations and only one particular
base substitution abrogated targeting. In contrast, mutations to any nucleotide in
the proximal positions (6 to 1, except 3) prevented cleavage, although at different
levels for each particular substitution. At position 3, only two substitutions
affected cleavage activity with different strength. We conclude that, although
seed sequence mutations can prevent targeting by the Cas9 complex, there are
restrictions regarding the nucleotide changes that can be made in each position
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of the seed. Moreover, these restrictions can most likely vary for different spacer
sequences.

Figure 2-10 Analysis of the protospacer sequences
Relative proportion of the number of reads after transformation of the random
protospacer constructs in crR6 cells (compared to number of reads in R6
transformants). The relative abundance of each nucleotide for each position of
the first 20 nucleotides of the protospacer sequence is shown. High abundance
indicates lack of cleavage by Cas9 complex, that is, an inactivating mutation. The
gray line shows the level of the wild-type sequence. The dashed line represents
the level above which a mutation significantly disrupts cleavage (see
supplementary materials of (Jiang et al. 2013a)).
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2.3.3 General scheme for the Cas9-complex-mediated counter-selection
for genome editing
Based on the analysis of targeting requirement by the Cas9 complex, we
describe a Cas9-complex-mediated counter-selection scheme for genome editing
(Figure 2-11). First, a targeting construct containing a minimal type II CRISPRCas system (i.e. tracr, cas9 and a spacer that matches the genomic region to be
modified) is designed. An editing template is designed to carry mutations that
abolish recognition and cleavage by the Cas9 complex. Preferably, the mutation
should be deletion or gene replacement that entirely removes the target
sequence recognized by the crRNA. If this is not feasible, a mutation in the PAM
or the seed sequence on the protospacer is generally considered. Based on our
analysis, mutations in the PAM clearly inactivates targeting by the Cas9 complex,
whereas the effect of single-nucleotide mutations in the protospacer is highly
dependent on the sequence context and can be difficult to predict. Therefore we
believe that mutations in the PAM, if possible, should be the preferred editing
strategy. Alternatively, multiple mutations in the seed sequence are likely to
abolish cleavage by the Cas9 complex.
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Figure 2-11 A general scheme for genome editing mediated by the Cas9
complex
A targeting construct encoding the Cas9 complex contains a spacer that matches
a genomic region to be modified. An editing template should contain either
deletion, replacement, or mutations within the PAM or protospacer of the target
sequence. Hence, targeting by the Cas9 complex eliminates cells containing the
wild-type sequence and selects for the newly modified sequence that abolishes
targeting. Abbreviations: R, repeat; S, spacer; PAM, protospacer adjacent motif.
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2.3.4 Genome editing in Streptococcus pneumoniae

Figure 2-12 Methodology for genome editing in S. pneumoniae
S. pneumoniae crR6Rk contains tracr, cas9, a single repeat (white box) and a
kanamycin-resistant marker (aphA-3). Genomic DNA from this strain was used
as a template for PCR with primers designed to introduce a new spacer (green
box designated with N). The left and right PCRs are ligated using Gibson
assembly to make the targeting construct. The targeting construct and an editing
template carrying a desired mutation (red bar), both in the form of dsDNA, were
co-transformed into strain crR6Rc, which is a strain equivalent to crR6Rk but has
the kanamycin-resistant marker replaced by a chloramphenicol-resistant marker
(cat). Selection of kanamycin results in successful editing.
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To develop a rapid and efficient method for targeted genome editing in S.
pneumoniae, we generated crR6Rk and crR6Rc, strains in which spacers can be
easily introduced by PCR (Figure 2-12). We decided to edit the β-galactosidase
(bgaA) gene of S. pneumoniae, whose activity can be easily measured (Zahner
and Hakenbeck 2000). We set out to introduce alanine substitutions of amino
acids in the active site of this enzyme: R481A (R→A) and N563A,E564A
(NE→AA) mutations. To illustrate different editing strategies, we designed
mutations in both the PAM sequence and the protospacer seed. In both cases
we used the same targeting construct with a crRNA complementary to a region of
the β-galactosidase gene that is adjacent to a TGG PAM sequence (CCA in the
complementary strand) (Figure 2-13A). The R→A editing template (Figure
2-13A) created a three-nucleotide mismatch on the protospacer seed sequence
(CGT to GCA, also introducing a BtgZI restriction site). In the NE→AA editing
template (Figure 2-13A) we simultaneously introduced a synonymous mutation
that creates an inactive PAM (TGG to TTG) along with mutations that were 218
nt downstream of the protospacer region (AAT GAA to GCT GCA, also
generating a TseI restriction site). This last editing strategy demonstrated the
possibility of using a remote PAM to make mutations in places where a proper
target might be hard to choose. For instance, although the S. pneumoniae R6
genome (with a 39.7% GC content) contains on average one PAM every 12 bp,
some PAMs are separated by up to 194 bp (Figure 2-14). Finally we designed a
ΔbgaA in-frame deletion template of 6,664 bp. In all three cases, cotransformation of the targeting construct and editing template produced 10-times
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more kanamycin-resistant cells than co-transformation with a control editing
template containing wild-type bgaA sequences (Figure 2-13B). We genotyped
24 transformants (8 for each editing experiment) by PCR, restriction digest and
DNA sequencing and found that all but one incorporated the desired change
(Figure 2-13C, D and E). These data indicate that the editing efficiency in S.
pneumoniae is approximately 90%. The 10% that were not edited were mostly
CRISPR mutants, primarily caused by the error-prone Gibson assembly of two
DNA fragments carrying repeat sequences (data not shown). Finally, we
measured β-galactosidase activity (Zahner and Hakenbeck 2000) to confirm that
all edited cells displayed the expected phenotype (Figure 2-13F).
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Figure 2-13 Genome editing in S. pneumoniae
(A) Nucleotide and amino acid sequences of the wild-type and edited (green
nucleotides; underlined amino acid residues) bgaA. The protospacer, PAM and
restriction sites are shown. (B) Transformation efficiency (counted as CFU/mL) of
cells transformed with targeting constructs in the presence of an editing template
or control. Error bars, mean ± SD for three replicas. (C) PCR analysis for eight
transformants of each editing experiment followed by digestion with BtgZI (R→A)
and TseI (NE→AA). Deletion of bgaA was revealed as a smaller PCR product. (D
and E) Editing was confirmed by DNA sequencing. (F) Miller assay to measure
the β-galactosidase activity of wild-type and edited strains. Error bars, mean ±
SD for three replicas.
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Figure 2-14 Distribution of distances between PAMs
NGG and CCN are considered to be valid PAMs. Data is shown for the S.
pneumoniae R6 genome as well as for a random sequence of the same length
and with the same GC-content (39.7 %). The dotted line represents the average
distance (12 nt) between PAMs in the R6 genome.
Cas9-complex-mediated editing can also be used to generate multiple
mutations for the study of biological pathways. We decided to illustrate this for
the sortase-dependent pathway that anchors surface proteins to the envelope of
Gram-positive bacteria (Marraffini et al. 2006). We introduced a sortase deletion
by co-transformation of a chloramphenicol-resistant targeting construct and a
ΔsrtA editing template (Figure 2-15A). Next we introduced a β-galactosidase
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deletion by co-transformation of a kanamycin-resistant targeting construct that
replaced the previous one and a ΔbgaA editing template. In S. pneumoniae, βgalactosidase is covalently linked to the cell wall by sortase (Zahner and
Hakenbeck 2000). Therefore, deletion of srtA resulted in the release of the
surface protein into the supernatant, whereas the double deletion had no
detectable β-galactosidase activity (Figure 2-15B). Such a sequential selection
can be iterated as many times as required to generate multiple mutations. Finally,
to eliminate the CRISPR-Cas locus, we introduced a plasmid containing the
bgaA target and a spectinomycin resistance gene along with genomic DNA from
the wild-type strain R6. Spectinomycin-resistant transformants that retain the
plasmid eliminated the CRISPR sequences (Figure 2-15C).
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Figure 2-15 Sequential introduction of mutations by CRISPR-mediated
genome editing in S. pneumoniae
(A) A schematic for sequential introduction of mutations by CRISPR-mediated
genome editing. First, R6 is engineered to generate crR6Rk. crR6Rk is cotransformed with a srtA-targeting construct fused to cat for chloramphenicol
selection of edited cells, along with an editing construct containing a ΔsrtA inframe deletion. Strain crR6 ΔsrtA is generated by selection on chloramphenicol.
Subsequently, the ΔsrtA strain is co-transformed with a bgaA-targeting construct
fused to aphA-3 for kanamycin selection of edited cells, along with an editing
construct containing a ΔbgaA in-frame deletion. Finally, the engineered CRISPR
locus can be erased from the chromosome by first co-transforming R6 DNA
containing the wild-type IS1167 locus and a plasmid carrying a bgaA protospacer
(pDB97), and selection on spectinomycin. (B) β-galactosidase activity as
measured by Miller assay. In S. pneumoniae, this enzyme is anchored to the cell
wall by sortase A. Deletion of the srtA gene results in the release of βgalactosidase into the supernatant. ΔbgaA mutants show no activity. (C) PCR
analysis for eight spectinomycin (spec)-resistant transformants to detect the
replacement of the CRISPR locus by wild-type IS1167.
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These two mutations can also be introduced simultaneously. We designed a
targeting construct containing two spacers, one matching srtA and the other
matching bgaA, and co-transformed it with both editing templates at the same
time (Figure 2-16A). Genetic analysis of transformants showed that editing
occurred in 6/8 cases (Figure 2-16B). Notably, the remaining two clones each
contained either a ΔsrtA or a ΔbgaA deletion, suggesting the possibility of
performing combinatorial mutagenesis using this strategy.
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Figure 2-16 Multiplex editing in S. pneumoniae
(A) The ΔsrtA and ΔbgaA in-frame deletion can be performed simultaneously by
co-transforming a targeting construct that contains two spacers, each targeting
srtA and bgaA, into strain crR6Rc followed by kanamycin selection. (B) PCR
analysis of eight transformants to detect deletions in srtA and bgaA loci.
2.3.5 Genome editing in E.coli
We also repurposed the type II CRISPR-Cas system as a counter-selection
tool to facilitate genome editing in E.coli. Two plasmids were constructed: a
pCas9 plasmid carrying the tracrRNA, Cas9 and a chloramphenicol-resistant
marker, and a pCRISPR plasmid carrying the CRISPR array and a kanamycinresistant marker (Figure 2-17A). To be able to measure the efficiency of editing
independently of CRISPR counter-selection, we sought to introduce an A to C
transversion in the rpsL gene (Figure 2-17B) that confers streptomycin
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resistance (Hosaka et al. 2004). We constructed a pCRISPR::rpsL plasmid
harboring a spacer that would guide Cas9 to cleave the wild-type, but not the
mutant rpsL allele (Figure 2-17C). The pCas9 plasmid was first introduced into E.
coli wild-type strain MG1655 and the resulting strain was transformed with either
pCRISPR::rpsL, the targeting construct, or pCRISPR::Ø, which contained a nonmatching spacer serving as a negative control. W542, an editing oligonucleotide
containing the A →C mutation was also co-transformed (Figure 2-17C). As a
result,

we

were

able

to

recover

streptomycin-resistant

colonies

after

transformation of only pCRISPR::rpsL but not pCRISPR::Ø, suggesting that Cas9
cleavage induced recombination of the oligonucleotide (Figure 2-17D). However,
when co-transformed with pCRISPR::rpsL, the frequency of the streptomycinresistant colonies (1.0 ×10-7) was two orders of magnitude lower than that of the
kanamycin-resistant colonies (1.4 ×10-5), which were presumably cells that
escaped cleavage by Cas9, similar to those found in Figure 2-7C. Therefore, in
these conditions, cleavage by the Cas9 complex facilitated the recombination of
the editing template, but with an efficiency that was not enough to select the
edited cells above the background of “escapers”.
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Figure 2-17 CRISPR-mediated genome editing in E.coli
(A) pCas9 plasmid carries tracr, cas9 and a chloramphenicol-resistant marker;
pCRISPR plasmid carries a CRISPR array and a kanamycin-resistant marker. (B)
A K42T mutation (A→C on the nucleotide level) conferring streptomycin
resistance was introduced in rpsL. (C) The targeting construct, pCRISPR::rpsL
contained a spacer that matched the wild-type, but not mutant rpsL. To perform
genome editing, this targeting construct or a control construct, pCRISPR::Ø
(which contains a non-matching spacer) was co-transformed with W542, an
editing oligonucleotide that contained the A→C mutation, into E.coli MG1655 that
already harbored pCas9. (D) Fraction of cells that became streptomycin-resistant
(StrepR) or kanamycin-resistant (KanR) after co-transformation performed in (C).
Dashed line indicates limit of detection of the assay. (E) Fraction of StrepR
colony-forming units (CFUs) calculated from total or KanR CFUs. (F)
Transformation of the pCRISPR::Ø or pCRISPR::rpsL plasmids into HME63
competent cells in the absence or presence of the W542 oligo. Transformation
efficiency was measured as the number of CFU per mL of competent cells. (G)
Editing of the rpsL gene was confirmed by DNA sequencing. In (D), (E) and (F),
error bars represent mean ± SD of three replicas.
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To improve the efficiency of genome editing in E. coli, we combined our
CRISPR-Cas system with the λ-Red recombination technology (see Chapter
2.1.2). The pCas9 plasmid was introduced into the E.coli recombineering strain
HME63 (Costantino and Court 2003), which contains the Exo, Beta and Gam
functions of the λ phage. The resulting strain was co-transformed with the
pCRISPR::rpsL

plasmid

(or

the

pCRISPR::Ø

control)

and

the

W542

oligonucleotide (Figure 2-17C). The recombineering efficiency was 5.3×10-5,
calculated as the fraction of total cells that became streptomycin-resistant when
the control plasmid was used (Figure 2-17E). In contrast, transformation with the
pCRISPR::rpsL plasmid and selection with kanamycin increased the percentage
of edited cells to 65 ± 14 % (Figure 2-17E). Editing efficiency can be also
calculated in another way. When transformation was performed with the targeting
construct alone, we found pCRISPR::rpsL transformants were 1.2×102 CFU/mL,
as opposed to 5.3×102 CFU/mL for transformation performed with both targeting
construct and editing template (Figure 2-17F). This rendered the editing
efficiency 77% ((5.3×102 -1.2×102) / 5.3×102), consistent with the efficiency
calculated from Figure 2-17E. Streptomycin-resistant colonies were confirmed
for editing by DNA sequencing of the rpsL allele (Figure 2-17G).In sum, these
data show that CRISPR-Cas can act as a robust counter-selection tool when
combined with λ-Red recombination. The editing efficiency is drastically boosted
from 0.1% (without CRISPR-Cas, see Chapter 2.1.2) to 65 ± 14 % (with
CRISPR-Cas).
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2.3.6 Genome editing in Staphylococcus aureus
In both S. pneumoniae and E.coli, linear DNA fragments can be used as
editing templates due to either natural competence or the presence of phage
recombineering machineries. However, many other bacteria are not naturally
competent and recombineering typically do not work in them. In these species,
introduction of linear DNA fragments are rapidly degraded by the RecBCD or
homologue complexes and cannot be used as template for genome editing. To
demonstrate that it’s possible to use the same CRISPR-mediated counterselection scheme to facilitate genome editing in these species, I developed a
system in which the editing template was placed on a temperature-sensitive
plasmid. It needs to be mentioned since the following work is still under progress,
the results I showed are qualitative rather than quantitative.
I chose to develop a CRISPR-mediated counter-selection system in
Staphylococcus aureus, the most studied bacterium in our lab yet for which the
genome editing tool had not been optimized. The existing technology relies on
allelic replacement of temperature-sensitive plasmids and subsequent counterselection (Bae and Schneewind 2006; Monk et al. 2012). As depicted in Figure
2-18, the counter-selection marker is a secY antisense RNA cloned under a pTet
promoter inducible by anhydrotetracycline (aTc). Overexpression of the
antisense RNA represses secY, which encodes a membrane protein that makes
up the SecYEG translocase essential for bacterial growth and survival (Manting
and Driessen 2000).

64

Figure 2-18 Allelic replacement in S. aureus
(A) First, a temperature-sensitive plasmid harboring a desired mutation along
with two homology arms are constructed. The plasmid also carries a
chloramphenicol-resistant marker (cat) and a counter-selection marker, an
inducible secY antisense RNA. Upon introduction to S. aureus and selection of
chloramphenicol, the plasmid can be maintained at a permissive temperature (i.e.
30°C). (B) When shifted to a nonpermissive temperature (i.e., 43°C), the plasmid
is forced to integrate into the region of the host chromosome carrying the gene of
interest (goi) through homologous recombination. This low-frequency event can
be selected using chloramphenicol. (C) When applying anhydrotetracylcline (aTc),
overexpression of the secY antisense RNA (a counter-selection marker) forces
plasmid excision, resulting in either gene replacement or reversion at a roughly
1:1 ratio.
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We and others attempted to perform genome editing in S. aureus following
these established protocols. However, we encountered hindrance during the
counter-selection step and were unable obtain edited cells in many cases. In
order to circumvent this problem, I decided to apply the type II CRISPR-Cas as a
counter-selection tool. First, I constructed pWJ40, a plasmid carrying the full type
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II CRISPR-Cas from S. pyogenes and demonstrated heterologous expression in
S. aureus constituted a functional immune system (Goldberg et al. 2014). Next,
cas1, cas2 and csn2 were removed from the plasmid, again creating a minimal
type II system. When programmed to target the S. aureus genome, this minimal
system effectively killed the cells (Bikard et al. 2014) just as in S. pneumoniae
and E.coli. After confirming that Cas9 can be used as a counter-selection tool in
S. aureus, I removed the overexpression element from the original temperaturesensitive vector. In the new scheme, I introduced pWJ326, a plasmid that carried
tracrRNA, Cas9 and a crRNA that targets the chloramphenicol-resistant marker
(cat) in order to achieve counter-selection. As a proof-of-concept (Figure 2-19), I
managed to delete terS from the ΦNM1 prophage genome in two weeks.

67

Figure 2-19 CRISPR-mediated genome editing in S. aureus
(A) First, a temperature-sensitive plasmid harboring the terS deletion along with
two homology arms are constructed. The plasmid also carries a chloramphenicolresistant marker (cat). Upon introduction to S.aureus and selection of
chloramphenicol, the plasmid can be maintained at a permissive temperature (i.e.
28°C). (B) When shifted to a nonpermissive temperature (i.e., 37°C), the plasmid
is forced to integrate into the terS region of the host chromosome through
homologous recombination. This low-frequency event can be selected using
chloramphenicol. (C) In order to counter-select, pWJ326, a temperature-sensitive
plasmid containing tracr, cas9 and a cat-targeting spacer was introduced to
integrant cells, leading to plasmid excision. Gene replacement or reversion
occurred at a roughly 1:1 ratio. Following successful terS deletion, pWJ326 can
be readily lost by growing cells at 37°C.
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Interestingly, since plasmid excision is normally a low-frequency event, it was
expected that counter-selection with pWJ326 should yield only a few colonies. In
contrast, my preliminary results showed that the transformation efficiency of
pWJ326 was very high, suggesting that CRISPR-induced recombination may be
higher in S. aureus than it is in E.coli and S. pneumoniae (Chapter 2.3.7).
Induction of recombination makes CRISPR a superior counter-selection tool in
the case of genome editing, and it undeniably deserves a close investigation in
the future.
2.3.7 Cas9-complex-mediated cleavage actively induces recombination
Continuing from Chapter 2.3.5, the fact that we were able to recover
streptomycin-resistant colonies after transformation of pCRISPR::rpsL but not
pCRISPR::Ø in E.coli suggests that Cas9-complex-mediated cleavage induced
recombination of the editing template (Figure 2-17D). However, since this
recombination efficiency in wild-type E.coli (i.e. MG1655) was too low, we sought
to better quantify the fold-induction of recombination by CRISPR in the
recombineering strain HME63. The experimental set-up is the same as
schematized in Figure 2-17C in which the targeting construct and the editing
template were co-transformed. When we measured the number of edited cells
(StrepR CFU) that simultaneously received the targeting constructs (KanR CFU),
we found that the pCRISPR::rpsL transformants that were resistant to both
antibiotics were isolated at a frequency of 2.0×10-4, while for pCRISPR::Ø the
frequency was 3.0×10-5 under the same condition (Figure 2-20A). This means
Cas9-complex-mediated

cleavage

induced
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recombination

by

6.7-fold

(2.0×10-4/3.0×10-5). A milder induction (2.2-fold) was found in S. pneumoniae
using an erythromycin-resistant marker (Figure 2-20B). Altogether, the Cas9
complex not only provided counter-selection, the cleavage by it induced modest
recombination which aided in genome editing.

Figure 2-20 CRISPR-Cas induces recombination
(A) Fraction of total E.coli cells that became both kanamycin-resistant (KanR) and
streptomycin-resistant (StrepR) after co-transformation of the targeting construct
(pCRISPR::rpsL or the pCRISPR::Ø control) and editing template (W542) shown
in Figure 2-17C . (B) Fraction of total S. pneumoniae cells that became both
kanamycin-resistant

(KanR)

and

erythromycin-resistant

(ErmR)

after

co-

transformation of the targeting construct (CRISPR::erm(stop) or the CRISPR::Ø
control) and an editing template that confers erythromycin resistance. Error bars,
mean ± SD of three replicas.
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2.3.8 Discussion
2.3.8.1 CRISPR may be a universal counter-selection tool
As mentioned in Chapter 2.1, the biggest drawback for existing genome
editing tools such as allelic replacement and λ-Red recombination is limited utility
or complete lack of counter-selection markers. Here we developed a system
consisting of a minimal type II CRISPR-Cas components, i.e. Cas9, tracrRNA
and crRNA derived from S. pyogenes. Cas9 is a nuclease whose specificity can
be programmed by a crRNA. Crucially, we showed that the Cas9 complex can
cleave host chromosome and lead to cell death, hence it can be used as a
counter-selection tool. We expressed this system heterologously in S.
pneumoniae, E.coli and S. aureus without codon optimization, and showed by
programming with different crRNAs, the system can act as a sequence-specific
counter-selection tool and facilitate genome editing. Furthermore, we and others
successfully expanded this tool to many more bacterial species, including
Lactobacillus (Oh and van Pijkeren 2014), Clostridium (Wang et al. 2015; Xu et al.
2015), Streptomyces (Cobb et al. 2015; Huang et al. 2015), Actinomycetes (Tong
et al. 2015), Salmonella (in collaboration with Zhenrun J. Zhang, unpublished
data) as well as bacteriophages (Kiro et al. 2014; Martel and Moineau 2014).
These works suggest that the type II CRISPR-Cas system is likely to serve as a
universal counter-selection tool in a wide variety of bacteria. What if heterologous
expression of the Cas9 complex does not function in some bacteria? As an
immune system, CRISPR-Cas is present in 40% of eubacteria and 90% of
archaea (Grissa et al. 2007). Therefore it is possible to exploit bacteria’s
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endogenous CRISPR-Cas systems for counter-selection. To this end, the more
naturally-abundant type I and type III CRISPR-Cas may be harnessed for this
purpose (Li et al. 2016).
2.3.8.2 The mutation frequency of CRISPR-Cas in the targeting construct
and its effect on counter-selection
In both S. pneumoniae and E. coli, we found that although genome editing is
facilitated by a co-selection of transformant cells and a modest induction of
recombination at the target site by Cas9-complex-mediated cleavage, the
mechanism that contributes the most to editing is the selection against nonedited cells. Therefore the major limitation of the method is the presence of a
background of cells that escape CRISPR-induced cell death and lack the desired
genomic modification. These “escapers” emerged primarily through the deletion
of the targeting spacer, thus inactivating CRISPR-Cas. In E.coli HME63, the
frequency of CRISPR mutation occurred at 2.5×10-4, (Figure 2-7B), as
calculated by taking the ratio of the number of pCRISPR::rpsL transformants
(1.2×102 CFU/mL) and the pCRISPR::Ø transformants (4.8×105 CFU/mL). This
means if editing templates are recombined to the host chromosome at a lower
frequency, CRISPR-Cas no longer effectively counter-selects. For instance, if the
effective recombination frequency (i.e. basal recombination frequency + induction
by CRISPR-Cas) is the same as the mutation frequency, then the theoretical
editing efficiency is 50%; if the effective recombination frequency is ten times
less, the editing efficiency drops to 9%, etc. The recombination frequency in the

73

recombineering strain of E.coli was 5.3×10-5 and the fold-induction by Cas9
cleavage was 6.7-fold (Figure 2-20A), resulting in an effective recombination
frequency of 3.6×10-4. This makes the theoretical editing efficiency 59% (3.6×104

/(3.6×10-4 + 2.5×10-4)), which is consistent with experimental efficiency we

obtained: 65 ± 14 % (Figure 2-17E).
2.3.8.3 Off-target effect
A fundamental aspect of any targeted genome engineering technology is
target specificity. This is extremely important in eukaryotes since recognition and
cleavage of off-target sites will lead to the introduction of undesired mutations by
NHEJ (non-homologous end joining) repair. We think off-target is a much less
pronounced issue in bacteria. First, the genomes are smaller. Our analysis of
targeting requirement (Chapter 2.3.2) revealed that the PAM (NGG) and
sequence of the 12 nucleotides immediately upstream of the PAM were
important for recognition and cleavage by the Cas9 complex. This means that
off-target sequence occurs randomly once every 268 Mb (414 Mb) in theory, and
thus is unlikely to be found in smaller genomes such as the bacterial ones, which
range from 130 Kb to 14 Mb (Koonin 2012).
Second, we demonstrated that cells were killed by CRISPR-Cas when
programmed with crRNAs targeting the host chromosome, hence counterselection. This means if off-target sites exist, it would not be possible to obtain
even the on-target modification, since the Cas9 complex would cleave the offtarget sites and cause cell death. In other words, if certain genomic modifications
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are proved to be difficult to obtain through CRISPR counter-selection, one should
consider the presence of off-target sites as a possible explanation and change
the design of crRNAs accordingly. In our hands, we found that crRNAs matching
off-target sites were rare, and can be usually avoided by using the BLAST tool
provided by NCBI (http://www.ncbi.nlm.nih.gov/). Additionally, we were only able
to isolate CRISPR mutants but not target mutant after applying CRISPR counterselection without the editing template. This means target mutations are indeed
very rare events. This observation is also supported by the fact that the errorprone DNA repair pathway, NHEJ, is absent in most bacteria (Pitcher et al. 2007).
2.4

Dead Cas9 (dCas9) mediates sequence-specific genetic repression

and activation in bacteria
Cas9 has two nuclease domains, RuvC and HNH, each of which cleaves one
strand within the target DNA (Gasiunas et al. 2012; Jinek et al. 2012). Mutation of
the active sites of the two domains, D10A and H840A, abolish cleavage but do
not impair DNA binding. We therefore thought that it may be possible to exploit
the DNA-binding activity of this Cas9 catalytic site mutant, hereafter referred to
as “dead” Cas9 (dCas9), to engineer a programmable transcription regulator. As
a proof-of-concept, we demonstrated in E.coli that tracrRNA and dCas9 when
guided with a proper crRNA (hereafter referred as the dCas9 complex), act as a
transcription repressor by preventing the binding of the RNA polymerase (RNAP)
to promoter sequences or as a transcription terminator by blocking the running
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RNAP (Figure 2-21). In addition, a fusion between the ω subunit of the RNAP
and dCas9 allows for programmable transcription activation (Figure 2-21).

Figure 2-21 A schematic for dCas9-mediated transcription repression
Plasmid pdCas9 encodes a cas9 mutant containing D10A and H840A
substitutions (white holes) that abrogate nuclease activity. This catalytically dead
Cas9 (dCas9), along with tracrRNA and crRNA form a complex. The crRNA
directs binding of the dCas9 complex to promoter or open reading frame regions
to prevent RNAP (RNA polymerase) binding or elongation, respectively.
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2.4.1 dCas9 mediates transcription repression
We converted Cas9 into a programmable DNA-binding protein by introducing
the D10A and H840A mutations in the RuvC and HNH nuclease domains,
respectively (Jinek et al. 2012). This catalytically “dead” version of Cas9, dCas9,
was introduced into the pdCas9 plasmid along with the tracrRNA and a minimal
CRISPR array designed for the easy cloning of new spacers and expression of
crRNA guides (Figure 2-21) (Jiang et al. 2013a). To evaluate how dCas9 binding
to the promoter can affect gene expression in E. coli, we constructed a green
fluorescence protein reporter plasmid (pDB127) carrying the gfp-mut2 gene
(Cormack et al. 1996) under the control of a promoter designed to carry several
NGG PAM sequences on both strands.
Twenty-two different spacers were engineered to express crRNAs guiding
dCas9 to different regions of the gfp-mut2 promoter and open reading frame. A
greater than 100-fold reduction in fluorescence was observed upon targeting of
regions overlapping or adjacent to the -35 and -10 promoter elements and to the
Shine-Dalgarno sequence (Figure 2-22A). Targets on both strands showed
similar repression levels. These experiments suggest that the binding of the
dCas9 complex to any position within the promoter region prevents transcription
initiation, presumably through steric inhibition of RNAP binding. In order to
confirm that repression was due to dCas9 binding to the promoter DNA and not
an effect of the antisense guide crRNA by itself, we repeated experiments in the
absence of dCas9. In all cases tested, the fluorescence levels were identical to a
non-targeting dCas9 control (Figure 2-22B).
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Figure 2-22 dCas9 mediates transcription repression
(A) GFP fluorescence of cells expressing dCas9 guided to different regions of the
gfp-mut2 gene, relative to the fluorescence of cells expressing a non-targeting
dCas9, was plotted as a function of the position of the target sequence within the
gene (+1, transcription start). Squares indicate the PAM position, lines the
extension of complementarity between the crRNA guide and the reporter gene.
Red and blue lines indicate crRNAs sequences identical to top or bottom DNA
strand, respectively. The gfp-mut2 gene (green), its promoter, including the -35
and -10 elements (gray shade), the ribosome binding site (rbs) and the two
probes (P511 and P510) used for Northern blot in (C) are shown. Error bars,
mean ± SD of three replicas. (B) Transcription repression in the absence of
dCas9. GFP fluorescence of cells expressing crRNAs alone (ΔCas9), relative to
the fluorescence of control cells lacking a targeting crRNA (Ø) was measured.
Error bars, mean ± SD of three replicas. (C) Northern blot with probes annealing
either upstream (P511) or downstream (P510) of the T10 and B10 target sites
using RNA extracted from cells expressing T5-, T10-, B10-guided dCas9 or a
control strain without a target (Ø). Detection of 5S RNA serves as a control.
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To determine whether DNA binding of the dCas9 complex could prevent
transcription elongation, we directed it to the open-reading frame of gfp-mut2. A
reduction in fluorescence was observed when both the coding and non-coding
strands were targeted, suggesting that dCas9 binding could block the elongating
RNAP (Figure 2-22A). A range of 2.5- to 5-fold reduction in expression was
observed when the coding strand was targeted (red spacers), while a range of 6to 35-fold reduction was observed when the dCas9 complex was directed to the
non-coding strand (blue spacers). To directly determine the effects of dCas9
binding on transcription, we extracted RNA from strains expressing the T5, T10
or B10 crRNA guides or a non-targeting dCas9 and subjected it to Northern blot
analysis using probes binding before (P511) or after (P510) the B10 and T10
target sites (Figure 2-22C). Consistent with our fluorescence measurement, no
gfp-mut2 transcription was detected when the dCas9 complex was directed to
the promoter region (T5 target) and lower levels of transcription were observed
after the targeting of the T10 region. Interestingly, a smaller transcript was
observed with the P511 probe in cells where the complex binds to the T10 or B10
target. These species corresponded to the expected size of a transcript that
would be interrupted by the dCas9 complex (calculated as ~250 or 300 nt
between the transcription start and the B10 or T10 target sites, respectively).
This result is a direct indication that the dCas9 complex caused transcription
termination. In accordance with the pronounced decrease in fluorescence caused
by B10-bound dCas9 complex, only the truncated gfp transcript, but no full-length
transcript, was detected with the P511 probe. Altogether, these results

80

demonstrate that directing the dCas9 complex to different gene regions can
prevent both the initiation and elongation of transcription. Targeting of the noncoding strand blocks transcription more efficiently than targeting of the coding
strand, suggesting a more efficient displacement of the elongating RNAP by the
complex in this configuration.
2.4.2 dCas9 mediates transcription activation

Figure 2-23 A schematic for dCas9-mediated transcription activation.
Transcription activation in E. coli using dCas9 fused to the ω subunit of RNA
polymerase (RNAP). The dCas9-ω fusion protein is directed to promoter regions,
and the ω subunit recruits the RNAP by interacting with the β’ subunit. A host
with a deletion of rpoZ, encoding ω, is used.
The dCas9 complex can be also converted into a transcription activator.
Previous work demonstrated that a fusion between the λcI protein and the RNAP
omega subunit (ω) can activate transcription by stabilizing the binding of RNAP
to a promoter bearing an upstream λ operator (Dove and Hochschild 1998).
Therefore we made both C- and N-terminal fusions between the ω subunit and
dCas9 (Figure 2-23), generating plasmids pWJ66 and pWJ68, respectively. We
also expressed different crRNAs to program the binding of both chimeric proteins

81

to four different positions in a constitutive synthetic promoter controlling the lacZ
gene (Figure 2-24A) in an E. coli strain lacking the gene encoding the ω subunit
(rpoZ). Using β-galactosidase activity as a reporter, we investigated the effect of
both chimeras on gene expression. When the binding site was too close to the
promoter (e.g. Z1 position), we found binding of the chimeras could still lead to
repression (Figure 2-24B). With binding sites more distant from the promoter, we
observed a modest increase in β-galactosidase activity; in the best case we
observed 2.8-fold activation for the dCas9-ω complex (i.e. when ω is fused to the
C-terminal of dCas9).
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Figure 2-24 dCas9-ω mediates transcription activation
(A) Either N- or C-terminal fusions of the ω subunit to dCas9 were directed to
four positions (Z1-Z4) of the top strand upstream of the -35 element of the lacZ
gene. (B) lacZ gene expression levels in the different strains were measured as β
-galactosidase activity (Miller units). Activation is reported as the relative Miller
units normalized against the units obtained with cells expressing a C-terminal
dCas9-ω fusion but no crRNA guide (Ø). Error bars indicates mean ± SD of three
replicas. Asterisks indicate the P-values associated with each measurement
compared with cells expressing a C-terminal dCas9-ω fusion but no crRNA guide
(Ø). *P≤0.05; **P≤0.005; ***P≤0.001.
We thus decided to further investigate the activation capabilities of dCas9-ω
when targeted to regions increasingly distant from the -35 promoter element as
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well as to both DNA strands (Figure 2-25A). To facilitate measurements we used
a GFP reporter plasmid, pWJ89, with the gfp-mut2 gene under the control of a
weak biobrick promoter (BBa_J23117) that is preceded by a sequence rich in
NGG PAM sequences on both strands. Among ten tested binding sites, two
(specified by W103 and W108 crRNAs, each targeting a different strand) were
found to strongly activate gfp-mut2 (Figure 2-25B). These were located 45 and
56 nt away from the -35 element (80 and 96 nt upstream of the transcription start
site), and provided a 7.2- and 23-fold induction, respectively. A similar level of
induction was observed when fluorescence is measured at different growth
phases (data not shown). These data suggest that the dCas9-ω complex can
induce gene expression when it binds at an optimal distance from the promoter.
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Figure 2-25 dCas9-ω mediates transcription activation (continued)
(A) dCas9-ω was directed to ten positions (W101-W110) of both strands
upstream of the -35 element of the gfp-mut2 gene. (B) GFP fluorescence of cells
expressing dCas9-ω guided to different positions shown in (A), relative to the
fluorescence of cells expressing a non-targeting dCas9-ω, was plotted as a
function of the position of the target sequence within the gfp-mut2 upstream
region (+1, transcription start). Squares indicate the PAM position, lines the
extension of complementarity between the crRNA guide and the reporter gene;
red lines, top strand targets; blue, bottom strand. Error bars, mean ± SD of three
replicas. (C) Transcription activation of gfp-mut2 containing promoters of three
different strengths (J23117, J23116 and J23110) by W103- or W108-guided
dCas9-ω. The relative induction, compared with the fluorescence of cells
expressing a non-targeting dCas9-ω, is shown. Error bars indicate mean ± SD of
three

replicas.

Asterisks

indicate

the

P-values

associated

with

each

measurement compared with the “no spacer” control. *P≤0.05; **P≤0.005;
***P≤0.001.
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To test whether dCas9-ω can induce expression of gfp-mut2 under the control
of stronger promoters, we replaced the weak promoter in pWJ89 (BBa_J23117)
with promoters of intermediate (BBa_J23116) and high (BBa_J23110) strength
(Figure 2-25C), generating plasmids pWJ96 and pWJ97, respectively. We
compared dCas9-ω-mediated activation of gfp expression from the three
constructs using the W103 and W108 crRNA guides. For both binding sites, all
three promoters could be induced by the dCas9-ω complex; however the relative
induction diminished as the promoter became stronger. Altogether, these results
show that dCas9 can be used to activate gene expression, with the possibility of
achieving different levels of activation depending on the strength of the targeted
promoter (the best induction being obtained with weak promoters).
2.4.3 Discussion
Here I described the use of an RNA-guided DNA binding protein, dCas9, to
either repress or activate genes in E. coli. In this method dCas9 can be directed
to any region of the bacterial chromosome that is specified by the base-pair
complementarity between the crRNA guide and the cognate genomic sequence.
Repression was achieved by directing the dCas9 complex to either promoter
or open reading frame regions. While binding of the dCas9 complex to promoters
prevented transcription initiation, binding to the open reading frame prevented
elongation, especially when the non-coding strand is targeted. In general, dCas9
complex mediates stronger repression when directed to the promoter region than
to the open reading frame.
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Compared to sRNA-mediated transcription repression (Chapter 2.2.1), in
which repression occurs at the mRNA level, CRISPR-mediated repression
occurs at the DNA level, by either blocking transcription initiation or elongation.
Being mechanistically different, the CRISPR method can complement the sRNA
method, and possibly allow researchers to explore new avenues of research that
were previously untenable. In addition, since many randomly designed crRNA
guides that target the promoter region can effectively repress gene expression, it
seems CRISPR-mediated repression can be more reliable and predictable than
sRNAs (see Chapter 2.2.1). Future studies should thoroughly compare the
efficacy and predictability of the two methods in parallel.
We also converted the dCas9 complex to a transcription activator by fusing
dCas9 to the ω subunit of RNAP, which was previously shown to provide
effective recruitment of RNAP (Dove and Hochschild 1998). Contrary to dCas9complex-mediated repression, in which directing of the complex by many crRNAs
to a large region surrounding the promoter (-60 ~ +40) led to strong repression
(Figure 2-22A), strong activation was only achieved when guiding the dCas9-ωcomplex to a much narrower region spanning from -100 to -75 (Figure 2-25B).
Among ten tested crRNA guides, only two showed strong activation. This shows
that activation of a gene of interest will be highly contingent upon the availability
of PAM sequences in that defined region. Given the strict position requirement
for gene activation, it may be necessary to harness the power of Cas9 orthologs
that can recognize different PAM sequences. In a recent study, the Cas9 proteins
derived from Streptococcus thermophilus, Neisseria meningitidis and Treponema
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denticola, each recognizing a different PAM, were converted to dCas9. The study
showed that these dCas9 proteins are orthogonal, and can mediate simultaneous
targeted gene regulation in bacterial and human cells (Esvelt et al. 2013).
Another study reported that by applying selection-based directed evolution, the S.
pyogenes Cas9 can be modified to recognize alternative PAM sequences
(Kleinstiver et al. 2015). These natural and engineered Cas9 proteins expand
targetable sequences that are useful for genome editing and gene regulation.
A maximum of a 23-fold induction was achieved when directing a crRNA to
target the bottom strand with a PAM positioned 56 nt upstream of the -35
element (Figure 2-25B), suggesting this distance may be optimal for activation.
Still, the level of activation is lower than the reported 70-fold induction by using
an engineered λ operator and λcI-ω fusion protein (Dove and Hochschild 1998),
though a side-by-side comparison is lacking. We think that activation can be
further optimized by changing the protein linker between dCas9 and ω and/or
testing activation domains other than ω. Importantly, the main advantage of
CRISPR-mediated gene activation is that it circumvents the need to modify the
promoter sequence of the gene of interest, as was required for conventional
transcription activation by a recruitment method such as the λcI-ω fusion.
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CHAPTER 3

TYPE III CRISPR-CAS SYSTEM

Type III CRISPR-Cas systems are defined by the presence of genes encoding
Cas10 and repeat-associated mysterious protein (RAMP) modules Csm or Cmr
for type III-A or III-B sytems, respectively (Makarova et al. 2011), which together
form the Cas10-Csm or Cas10-Cmr complexes (Hale et al. 2009; Zhang et al.
2012; Hatoum-Aslan et al. 2013). Among all CRISPR types, the type III systems
are possibly the most complex. In contrast to type I and type II systems, type III
CRISPR-Cas displays at least two distinct targeting mechanisms. First,
transcription across the target is required for immunity. Second, the system
performs co-transcriptional cleavage of both DNA and RNA targets (see Chapter
1.2.3).
In this chapter, I will describe my published work (Jiang et al. 2016) that
studies the type III-A system of Staphylococcus epidermidis RP62a (Gill et al.
2005). Previous work conducted by Gregory Goldberg and Poulami Samai from
our lab have elucidated key mechanistic questions with regard to cotranscriptional DNA and RNA cleavage. However, while it is well known that DNA
targeting is essential for immunity in all types of CRISPR-Cas, the function of the
RNA-targeting module in type III systems has been elusive. In my research, I
identified a new CRISPR-associated RNase – Csm6. Along with Csm3, a
previously characterized RNase, Csm6 plays an important role in type III-A
CRISPR immunity. In particular, I demonstrated that RNA targeting by one or
both proteins provides a second line of defense – it is essential for cell survival
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when target sequences recognized by CRISPR-Cas reside in late-expressed
phage genes or regions that bear mismatches to the crRNAs.
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3.1
Functionality
epidermidis

of

type

III-A

CRISPR-Cas

of
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Figure 3-1 The type III-A CRISPR-Cas locus of Staphylococcus epidermidis
RP62a
The type III-A CRISPR-Cas locus of Staphylococcus epidermidis RP62a harbors
three spacers and nine cas genes. cas1 and cas2 are present in most CRISPRCas systems and participate in the adaptation phase. cas6 encodes an
endoribonuclease that processes the crRNA precursor (pre-crRNA) into small
crRNA guides. cas10, along with csm2, csm3, csm4 and csm5 encode a protein
complex responsible for crRNA maturation and targeting. The type III-A system
cleaves both DNA and RNA when transcription happens across the target. csm6
is the only gene that has not been characterized in detail.
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The type III-A CRISPR-Cas of Staphylococcus epidermidis RP62a harbors
three spacers and nine cas genes (Figure 3-1) (Gill et al. 2005; Marraffini and
Sontheimer 2008). The first spacer (spc1) matches a region of the nickase (nes)
gene found in a staphylococcal conjugative plasmid, pG0400 (Figure 3-2A)
(Morton et al. 1995). To demonstrate that CRISPR-Cas can act as a defense
system and that spc1 can prevent plasmid conjugation into S. epidermidis RP62a,
the CRISPR array was deleted from the chromosome, generating strain Δcrispr
(Figure 3-2B). As shown in Figure 3-2C and a seminal study by my advisor
(Marraffini and Sontheimer 2008), wild-type cells were refractory to pG0400
transfer. The few transconjugants recovered were subjected to thorough
genotyping and all contained mutation in the CRISPR array or cas genes (Jiang
et al. 2013b). In contrast, conjugation efficiency was at least three orders of
magnitude higher in Δcrispr cells (Figure 3-2C). Complementation of pSpc1, a
plasmid carrying spc1 restored the CRISPR immunity (Figure 3-2C). These data
indicates that spc1 and the cas genes are involved in preventing plasmid
conjugation. To further confirmed that the protospacer sequence on pG0400 was
important for recognition by spc1, the target was introduced with nine silent
mutations, generating plasmid pG0(mut) (Figure

3-2A) (Marraffini and

Sontheimer 2008). Indeed, transfer of pG0(mut) was no longer blocked by wildtype cells, and the conjugation efficiency was as high as that of pG0400 into
Δcrispr cells (Figure 3-2C).
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Figure 3-2 Type III-A CRISPR-Cas has anti-plasmid activity
(A) A staphylococcal conjugative plasmid, pG0400 harbors a protospacer
sequence that matches Spacer 1 (spc1) of the CRISPR array of Staphylococcus
epidermidis RP62a. The protospacer sequence was altered to contain nine
synonymous mutations shown in red, generating plasmid pG0(mut). (B)
Schematics of the wild-type CRISPR-Cas or Δcrispr locus (harboring deletion of
the CRISPR array) of Staphylococcus epidermidis RP62a. (C) Conjugation
experiments were performed by mixing recipient cells carrying different genetic
background (WT: wild-type; Δcrispr: deletion of CRISPR array; Δcrispr + pSpc1:
deletion of CRISPR array complemented with spc1 on a plasmid) and donors
cells carrying pG0400 or pG0(mut). Colony-forming units (CFU) per milliliter (mL)
values (mean ± SD of three replicas) obtained for recipients and transconjugants
are shown. Conjugation efficiency (Conj. Eff.) was calculated as the mean
transconjugants / mean recipients ratio.
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Genetic approaches are required to understand the different function of cas
genes in CRISPR immunity. However, reagents for genetic manipulation such as
availability of antibiotic markers and efficient transformation/transduction
methods had been lacking in S. epidermidis. In addition, we were unable to
identify any bacteriophages, natural immunogens of the CRISPR-Cas system, to
infect our strain. In order to facilitate future studies of the CRISPR immune
response, I cloned the entire type III CRISPR-Cas system onto a plasmid,
generating pWJ30β (Figure 3-3A). I decided to study the plasmid-borne
CRISPR-Cas in Staphylococcus aureus, a close relative of S. epidermidis that is
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much more amenable to genetic manipulation. Importantly, a few phages
capable of infecting S. aureus had been characterized (Bae et al. 2006). The
plasmid-borne CRISPR-Cas system was functional as an immune system and
had both anti-plasmid and anti-phage activity (Figure 3-3B and C).
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Figure 3-3 A plasmid-borne type III-A CRISPR-Cas system is functional in
Staphylococcus aureus
(A) The type III-A CRISPR-Cas system of Staphylococcus epidermidis RP62a is
cloned onto plasmid pC194 (Horinouchi and Weisblum 1982), generating
pWJ30β, which is subsequently introduced to Staphylococcus aureus RN4220.
(B) To test functionality of the plasmid-borne CRISPR-Cas system, conjugation
experiments were performed by mixing recipient cells (RN4220 cells harboring
pWJ30β or parental plasmid pC194) and donor cells carrying pG0400. Colonyforming units (CFU) per milliliter (mL) values (mean ± SD of three replicas)
obtained for recipients and transconjugants are shown. Conjugation efficiency
(Conj. Eff.) was calculated as the mean transconjugants / mean recipients ratio.
(C) Functionality of the plasmid-borne CRISPR-Cas system was subjected to
phage infection assay. First, the CRISPR array of pWJ30β was replaced by
spacers matching the gp14, gp43 genes of lytic phage ΦNM1γ6 (Goldberg et al.
2014), and a non-matching spacer (Δcrispr), generating pWJ245, pWJ191 and
pGG-BsaI-R (Goldberg et al. 2014), respectively. Liquid cultures of RN4220 cells
harboring these individual plasmids were infected with ΦNM1γ6 (at 0hr). Optical
density at 600 nm (OD600) was measured for the following 12 hr to monitor cell
survival. Representative growth curves of at least three independent experiments
are shown.
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The plasmid system I established allowed our lab to investigate the type III
CRISPR-Cas system more easily. First, a biochemical study performed by a
former post-doc, Asma Hatoum-Aslan found that Cas10, Csm2, Csm3, Csm4
and Csm5 can be co-purified with each other in Staphylococcus, suggesting
these proteins form a complex (Hatoum-Aslan et al. 2013). Next, mature crRNAs
of various lengths were found to be associated with the complex (Hatoum-Aslan
et al. 2013). Individual deletion of cas10, csm3 or csm4, but not csm2 or csm5
abolished complex formation and thus crRNA maturation; deletion of csm2 or
csm5 individually compromised crRNA maturation (Hatoum-Aslan et al. 2014).
Moreover, individual deletion of all these genes abrogated anti-plasmid activity,
suggesting complex formation and crRNA maturation were required for immunity
(Hatoum-Aslan et al. 2014). The Cas10-Csm::crRNA ribonucleoprotein complex
(hereafter referred to as Cas10-Csm complex) could be also purified from E.coli,
and was shown to possess DNA- and RNA-targeting activity specified by the
sequence of the crRNA in vitro (Samai et al. 2015). These data indicate that
Cas10, Csm2, Csm3, Csm4 and Csm5 proteins form a complex that is necessary
for crRNA maturation and targeting (Figure 3-1).
Supplementary to the characterization of the Cas10 – Csm5 proteins, it is
established that Cas1 and Cas2 are involved in the adaptation phase, and are
dispensable for crRNA biogenesis and targeting (Heler et al. 2014). Cas6 is an
endoribonuclease that participates in the primary processing of the crRNAs
(Figure 3-1) (Carte et al. 2008). Since these crRNAs then become the substrates
for maturation, deletion of Cas6 results in loss of maturation and thus loss of
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CRISPR immunity (Hatoum-Aslan et al. 2014). The function of csm6 was
unknown. A genetic study from our lab showed that deletion of the gene
abolishes anti-plasmid immunity (Hatoum-Aslan et al. 2014). Our lab also
showed that Csm6 does not co-purify with the Cas10-Csm complex (HatoumAslan et al. 2013) and that deletion of csm6 does not disrupt crRNA biogenesis
(Hatoum-Aslan et al. 2011). Therefore it has been proposed that csm6 may be
involved in the targeting stage of CRISPR immunity.
3.2

Type III CRISPR-Cas immunity requires transcription
The transcription-dependent requirement for type III CRISPR-Cas was first

discovered by Gregory Goldberg in our lab. Using the plasmid-borne version of
the S. epidermidis type III CRISPR-Cas (see Chapter 3.1), Gregory designed
multiple spacers that matched the genome of a dsDNA phage, ΦNM1 (Bae et al.
2006) (Figure 3-4A). To his surprise, half of the spacers he designed did not
protect host cells from phage infection (Figure 3-4B). A close examination of the
orientation of spacers and the phage genome revealed that spacers that confer
immunity were all antisense to the phage transcripts, while the inactive spacers
all represented the sense strand. These experiments suggested that successful
CRISPR immunity may depend on target transcription (Goldberg et al. 2014).
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Figure 3-4 Transcription is required for the type III-A CRISPR-Cas to target
phage
(A) A schematic of the genome of a dsDNA phage, ΦNM1. Twenty spacers that
matched the top strand (T) or the bottom strand (B) of ΦNM1 were designed and
the positions of their targets are shown. Green spacers are antisense to the
phage transcripts, and red spacers have orientations matching the phage sense
strand. (B) Staphylococcus aureus RN4220 cells harboring plasmid-borne
CRISPR-Cas are challenged by ΦNM1. The efficiency of plating was used to
determine immunity against the phage provided by spacers targeting the phage
regions shown in (A). Dotted line indicates the limit of detection of the assay.
Error bars indicates mean ± SD of three replicas. Figure is adapted from
(Goldberg et al. 2014) with modifications.
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One of the key experiments that demonstrated transcription-dependent
targeting is a plasmid-curing assay I developed (Goldberg et al. 2014). In this
assay, host cells harbored two plasmids (Figure 3-5A). pCRISPR-Cas carried
the canonical spc1 and all the cas genes, and pTarget contained a target
sequence cloned after a tetracycline-inducible promoter, Ptet. The two plasmids
were compatible in the absence of the inducer, anhydrotetracycline (aTc);
however, when aTc was added, induction of transcription across the target led to
CRISPR targeting and elimination of the target plasmid (Figure 3-5B). Additional
evidence such as tolerance of lysogenization, phage escaper analysis and
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transcriptome analysis (Goldberg et al. 2014) supported the conclusion that
transcription is required for type III CRISPR-Cas immunity. Moreover,
biochemical work performed by Poulami Samai in the lab showed that the
purified Cas10-Csm complex cleaves double-stranded DNA targets only when
transcription occurs across the target, further corroborating the transcriptiondependent targeting model in vitro (Samai et al. 2015).
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Figure 3-5 Transcription is required for the type III-A CRISPR-Cas to target
plasmids
(A) The plasmid-curing assay used Staphylococcus aureus RN4220 harboring
two plasmids. pCRISPR-Cas carried the conical spc1 and all cas genes of
Staphylococcus epidermidis RP62a. pTarget (pWJ153) carried a target sequence
inserted

after

a

tetracycline-inducible

promoter

(Ptet).

Addition

of

anhydrotetracycline (aTc) induces transcription across the target sequence by
derepressing the Tet repressor protein (TetR). (B) Agarose gel of linearized
plasmid DNA purified from aTc-treated (+aTc) and untreated (-aTc) liquid
cultures at the indicated time points.
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3.3

Type III CRISPR-Cas targets both DNA and RNA
The identity of the target nucleic acid for type III CRISPR-Cas systems was

controversial at a time. In vivo genetic studies done by our lab showed the type
III-A system of S. epidermidis targets DNA (Marraffini and Sontheimer 2008;
Goldberg et al. 2014; Hatoum-Aslan et al. 2014). However, various other groups
showed that type III-B systems of Pyrococcus furiosus (Hale et al. 2009),
Sulfolobus solfataricus (Zhang et al. 2012) and Streptococcus thermphilus
(Zebec et al. 2014) all target RNA in vitro. Therefore, it was thought that the III-A
and III-B subtypes were functionally different, as the nucleic acids recognized
and cleaved by the systems are DNA and RNA, respectively. Two subsequent
reports found that the III-A systems of Streptococcus thermphilus (Tamulaitis et
al. 2014) and Thermus thermophilus (Staals et al. 2014) also target RNA in vitro,
further fueling the controversy. However, the aforementioned work conducted by
Poulami settled the discussion by demonstrating that the type III-A complex of S.
epidermidis can cleave both DNA and RNA targets, in vitro and in vivo (Samai et
al. 2015). This finding is reinforced by two subsequent studies, both confirming
the dual DNA- and RNA-targeting activity of the III-B systems (Elmore et al. 2016;
Estrella et al. 2016). Poulami’s work also identified active sites within the
staphylococcal Cas10-Csm complex responsible for DNA and RNA targeting: the
D586, D587 residues of Cas10 (Figure 3-6) and D32 residue of Csm3 (Figure
3-7), respectively. Furthermore, mutations that abrogate DNA cleavage did not
affect RNA cleavage and vice versa, strongly suggesting that DNA- and RNA-
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targeting functions of the Cas10-Csm complex are independent of each other
(Samai et al. 2015).
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Figure 3-6 Co-transcriptional DNA cleavage by purified Cas10-Csm
complex
(A) Schematic of the co-transcriptional DNA cleavage assay. First, an elongation
complex (EC) is assembled in the following order: template strand, RNA primer,
RNA polymerase (RNAP) and non-template strand. Next the purified Cas10-Csm
complex containing a matching crRNA (derived from spc1) and ribonucleoside triphosphates (rNTPs) are added to the EC to reconstitute the co-transcriptional
DNA cleavage in vitro. (B, C) Denaturing PAGE and autoradiography of the
products of two co-transcriptional dsDNA cleavage assays differing in the
location of the radioactive label: (B) non-template strand; (C) template strand. (D)
Same as (B) but using a mutant complex containing Cas10D586, D587. Panels (B-D)
are adapted from (Samai et al. 2015) with modifications.
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Figure 3-7 RNA cleavage by purified Cas10-Csm complex
(A) Schematic of the RNA cleavage assay. A 5’ radiolabeled ssRNA substrate is
mixed with purified Cas10-Csm complex containing a matching crRNA (derived
from spc1). (B) Reaction products of the RNA cleavage assay are collected at 0,
1, 2, 3, 4, 5, 7.5, 10, 15, 20, and 30 min, separated by denaturing PAGE and
visualized by phosphorimaging. (C) Same as (B) but using a mutant complex
containing Csm3D32A, and the reaction times are 0, 5, 10, 20, 30, 60, 120, 180
and 240 min. Panels (B) and (C) are adapted from (Samai et al. 2015) with
modifications.
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3.4

Discovery of Csm6 as a novel RNase associated with the type III-A

CRISPR-Cas system
csm6 is the least characterized among the cas genes. A previous study by our
lab showed that deletion of the csm6 abolishes anti-plasmid activity, suggesting a
potential role in DNA cleavage (Hatoum-Aslan et al. 2014). Contradicting to this
hypothesis, the Csm6 protein does not co-purify with the Cas10-Csm complex,
which is sufficient to cleave target DNA in vitro (Samai et al. 2015). A recent
bioinformatics analysis of the Higher Eukaryotes and Prokaryotes Nucleotidebinding (HEPN) family reveals that Csm6 is a member of this group and may
function as a metal-independent RNase (Anantharaman et al. 2013). To test this
possibility, I expressed Csm6 in E. coli and purified it to homogeneity (Figure
3-8A). The putative active site double mutant R364A, H369A (Anantharaman et
al. 2013) was also purified (Figure 3-8A). Incubation of the purified proteins with
ssRNAs radiolabeled at either end resulted in degradation of the substrate by the
wild-type Csm6, but not Csm6R364A, H369A or “dead” Csm6 (dCsm6) (Figure 3-8B).
The reaction did not require any metal cation (Mg, Mn and EDTA were tested
and obtained the same cleavage; data not shown). I obtained similar results with
the individual active site mutants (Figure 3-8A), using substrates of different
sequences and lengths (Figure 3-8C). These results confirmed that Csm6 is a
metal-independent, sequence-independent RNase.
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Figure 3-8 RNase activity of Csm6
(A) Csm6 purification. SDS-PAGE of S. epidermidis Csm6 and its putative active
site mutants, Csm6R364A and Csm6H369A as well as the double mutant, Csm6R364A,
H369A

were purified from E.coli. (B) Purified wild-type Csm6 (WT) and Csm6R364A,

H369A

, or “dead” Csm6 (dCsm6) were incubated with a ssRNA substrate (R55)

radiolabeled at either end. The reaction proceeded for 1 hr and aliquots were
taken at 0, 5, 15, 30, 45 and 60 min for PAGE and phosphorimager visualization.
(C) Purified Csm6, Csm6R364A and Csm6H369A were incubated with two different 5’
radiolabeled ssRNA substrates of 24 and 55 nucleotides in length (R24 and R55,
respectively). The reaction proceeded for 1 hr and products were subjected to
PAGE and visualized by phosphorimaging. “Ø” indicates a control reaction
without enzyme added. Abbreviations: kDA, kilodalton; nt, nucleotide.
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Since previous work proposed that Csm6 participates in DNA targeting
(Hatoum-Aslan et al. 2014), I tested this idea directly using the plasmid-curing
assay I previously developed (Figure 3-5). When transcription was induced
across the target, the pTarget plasmid was equally degraded by both wild-type
CRISPR-Cas and a Δcsm6 system (Figure 3-9A), suggesting DNA degradation
does not require csm6. To corroborate this finding, I determined that csm6 is not
required for targeting of chromosomal DNA (Figure 3-9B). Finally, I tested the
activity of Csm6 for ssDNA and dsDNA substrates in vitro, but failed to obtain
any cleavage products (Figure 3-9C). These results demonstrate that Csm6 is
not involved in DNA targeting.

112

Figure 3-9 Csm6 is not involved in DNA targeting
(A) Plasmid-curing assay schematized in Figure 3-5A is using plasmids
harboring a wild-type CRISPR-Cas (WT), a Δcsm6 or a non-targeting CRISPRCas system (Δcrispr). Plasmid DNA was extracted from cells before and after 10
hr of treatment with the inducer, aTc, linearized and subjected to agarose gel
electrophoresis. (B) Chromosomal targeting assay. A target sequence (a region
of the gp43 gene from phage ΦNM1) under the control of a tetracycline-inducible
promoter, Ptet, was inserted to the chromosome (geh locus) of S. aureus RN4220.
The target was placed in both orientations with respect to the origin of replication
(direct and inverted insertions). Orange arrows represent crRNAs. Competent
cells containing these targets were transformed with different pCRISPR-Cas
plasmids carrying wild-type CRISPR-Cas (WT), Δcsm6 or Δcrispr (non-targeting
control), and plated in the presence of the aTc inducer. Co-transcriptional
cleavage of the target DNA prevents colony formation, presumably through the
introduction of lethal chromosomal lesions. Transformation efficiency was
measured as the number of colony-forming units (CFU) per μg of plasmid DNA
(mean ± SD of three replicas). The dotted line indicates the limit of detection of
the assay. (C) DNase activity assay for wild-type Csm6. The purified protein was
incubated either with a 5’ radiolabeled ssDNA oligonucleotide (PS362) or a
dsDNA substrate obtained by annealing PS362 and PS363. The reaction
proceeded for 2 hr and aliquots were taken at 0, 15, 30, 45, 60, 90 and 120 min
for

PAGE

and

phosphorimager

visualization.

Abbreviations:

aTc,

anhydrotetracycline; kB, kilobase; chr, chromosome; ssDNA, single-stranded
DNA; dsDNA, double-stranded DNA.
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Together with previous reports, the results above show that S. epidermidis
type III-A CRISPR-Cas system encodes two RNases: a sequence-specific,
crRNA-guided endoribonuclease, Csm3, and a crRNA-independent ribonuclease,
Csm6. While it is well established that DNA targeting is required for CRISPR
immunity, the function of RNases has not been fully explored. One report showed
that the heterologous expression of the Cas10-Csm complex in E.coli could
provide immunity against RNA phage MS2 (Tamulaitis et al. 2014). However,
since RNA phages are rare and a great majority of phages are dsDNA in nature
(Koonin et al. 2015), the function of RNases merited further investigation.
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3.5

A challenge for transcription-dependent targeting
What is the function of the RNases encoded by the type III CRISPR-Cas

systems? To answer this question, it’s worth revisiting the biology of phage lytic
cycles. As introduced in Chapter 1.1 and recapitulated in Figure 3-10, gene
expression of many lytic phages is precisely programmed over time. For instance,
genes that are involved in DNA replication and transcriptional regulation are
transcribed immediately upon infection. Selective expression of the early genes
allows phages to replicate at an optimal pace. Genes that encode various phage
parts are transcribed near and/or after replication is complete, which then
package the replicated DNA and assemble into hundreds of live phage progenies.
Two other important late genes encode lysin and holin, which lyse cell walls and
therefore are toxic to the host. Upon host cell lysis, the phage progeny is
released and they go on to infect neighboring susceptible cells.
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Figure 3-10 Phage lytic cycle
① In general, when a lytic phage infects a cell, it injects its DNA (in this case in a
form of dsDNA) which is quickly circularized. ② Transcription starts. The
expression of phage genes are temporally regulated. For instance, genes that

are involved in DNA replication are transcribed early. ③ This allows for phage
replication. ④ Late genes encode various phage parts, which package the

replicated DNA and assemble into hundreds of live progenies. ⑤ Two other late
genes encode lysin and holin. ⑥ These enzymes lyse host bacteria and liberate

infectious phage progeny.

The fact that phage genes are temporally regulated creates a challenge for
the transcriptional requirement of the type III CRISPR-Cas system. When
CRISPR spacers target early genes, which are immediately transcribed upon
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infection, CRISPR can mount an efficient attack while the phage is still at low
copy number (Figure 3-11A). However, when CRISPR spacers target late genes,
the infection cycle can proceed unchecked until the target is transcribed. At this
point, the phage may have already finished replication and host cells may be
loaded with phage DNA and transcripts (Figure 3-11B). This is a challenge
because first, CRISPR-Cas may be overwhelmed by the number of target nucleic
acids inside the cell. Secondly, if CRISPR-Cas is only capable of targeting DNA,
phage transcripts cannot be restricted and will continue to produce toxic lytic
enzymes.
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Figure 3-11 Models for co-transcriptional type III CRISPR-Cas immunity
when targeting early- and late-expressed phage genes
(A) When the target (red segment) is located in an early-expressed phage gene,
type III CRISPR-Cas can act soon upon phage DNA injection and clear infection.
(B) When the target is located in a late-expressed phage gene, CRISPR-Cas can
only mount an attack after phage replication. At this stage, host bacteria are full
of phage DNA and transcripts. Lytic enzymes such as holin and lysin are poised
to lyse the cell and liberate phage progenies.
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Based on these properties of the phage lytic cycle, I hypothesize that (i) when
type III CRISPR-Cas systems target a late-expressed phage gene, the
transcriptional requirement for targeting can lead to accumulation of phage DNA
inside host cells and (ii) in this situation, RNA targeting is required to eliminate
phage transcripts that would otherwise compromise cell viability.
3.6

Transcriptional requirement of type III-A CRISPR-Cas targeting leads

to accumulation of phage DNA
To investigate the fate of phage DNA upon infection, I constructed two type
III-A CRISPR-Cas systems: one with a spacer matching an early-expressed
phage gene, gp14 (encoding a protein involved in phage DNA replication) and
the other with a spacer matching a late-expressed gene, gp43 (encoding a phage
capsid subunit) (Figure 3-12A). Previous transcriptome analysis of S. aureus
cells infected with lytic phage ΦNM1γ6 in the absence of CRISPR immunity
confirmed that gp14 is an early gene transcribed between 6 minutes and 15
minutes after infection while gp43 is a late gene transcribed between 15 minutes
and 30 minutes after infection (Goldberg et al. 2014). I also used a CRISPR
system containing a non-matching spacer as a negative control (Δcrispr). In
addition to these three different type III spacers, I constructed a type II CRISPRCas system of Streptococcus pyogenes (Chapter 2) with a spacer matching gp43
as a positive control, since it is known that type II CRISPR immunity does not
require transcription (Gasiunas et al. 2012; Jinek et al. 2012). Next, I infected S.
aureus cells carrying the four different CRISPR-Cas systems with lytic phage,
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ΦNM1γ6. To determine the abundance of phage DNA inside host bacteria, I
extracted total DNA at various time points post infection and subjected them to
qPCR with primers specific to the phage (Figure 3-12B). For quantification, the
relative abundance of the phage DNA at 15 minutes post-infection in cells
harboring the type II system was set as the reference point (i.e. a value of 1). As
a result of CRISPR immunity, phage DNA was rapidly cleared by the type II
system and its accumulation was minimal (Figure 3-12B), consistent with a
previous report showing that phage DNA is immediately degraded upon injection
by the type II CRISPR-Cas (Garneau et al. 2010). By contrast, in cells harboring
a non-matching CRISPR-Cas system (Δcrispr), the abundance of phage DNA
increased dramatically with time (Figure 3-12B), reflecting the progression of
viral replication during the infectious cycle. Phage DNA clearance by type III
CRISPR-Cas immunity strongly depended on the region targeted. When the
early-expressed gene gp14 was targeted, the phage DNA was barely detectable
(Figure 3-12B). In contrast, when the late-expressed gene gp43 was targeted,
substantial phage DNA accumulated (Figure 3-12B). For instance, the relative
abundance at 0.75 hr was 64x (134 divided by 2.1) more than that of the gp14targeting cells at the same time point. Phage DNA reached a very high level for
the first 1.5 hr before it started a slow decline, in contrast to near-instant
clearance in the gp14-targeting cells. A complete clearance was only achieved
when cells at 9 hr post-infection were diluted and refreshed in new culture broth
and grown for an additional 9 hr (Figure 3-12B R9 point).
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Figure 3-12 Co-transcriptional type III CRISPR-Cas targeting leads to
accumulation of phage DNA
(A) A schematic of the genome of lytic phage, ΦNM1γ6. The position of two
spacers that target gp14 and gp43 is shown. Opposed arrows indicate the
primers used for qPCR experiments in (B) and Figure 3-13A. (B) qPCR
performed on the ΦNM1γ6 gp43 gene using total DNA collected from S. aureus
RN4220 cells carrying different CRISPR-Cas systems at different times postinfection. Values for the rho gene were used for normalization. The normalized
value for the measurement at 15 min in cells harboring a type II system was set
to 1 to obtain the relative abundance of the phage DNA for the rest of the data
points (mean ± SD of four replicas). The R9 time point indicates that cells were
refreshed with new culture broth at 9 hr post-infection and were grown for an
additional 9 hr before collection of DNA for qPCR.
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The qPCR was performed with primers that amplify the gp43 target. A similar
result was obtained when I performed qPCR using primers that amplify the gp14
target (Figure 3-13A), suggesting that DNA abundance at the target as well as at
a distant locus is equally affected by CRISPR targeting. Phage DNA
accumulation was also corroborated by Southern blot analysis (Figure 3-13B, C).
Whereas phage DNA in cells carrying a type II CRISPR-Cas system was
minimally detected, it accumulated over the first 90 min of infection cycle in cells
carrying a type III system targeting the late gp43 gene, with levels similar to
those determined by qPCR (Figure 3-12B). Interestingly, no cleavage products
(expected at 2.2 kB and 1.7 kB) were detected. This indicates that cleaved DNA
may be rapidly degraded by the CRISPR-Cas systems or host nucleases under
these experimental conditions.
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Figure 3-13 Corroboration of phage DNA accumulation in vivo
(A) qPCR performed on the ΦNM1γ6 gp14 gene (Figure 3-12A) using total DNA
collected from S. aureus RN4220 cells carrying different CRISPR-Cas systems at
different times post-infection. Values for the rho gene were used for
normalization. The normalized value for the measurement at 15 min in cells
harboring the gp14-targeting spacer was set to 1 to obtain the relative
abundance of the phage DNA for the rest of the data points (mean ± SD of four
replicas). (B) Schematic showing the location of the EcoRI and PsiI restriction
sites used to detect phage DNA via Southern blot in (C). The position of the gp43
target is located 2.2-kB from the EcoRI site and 1.7-kB from the PsiI site. The
green line indicates the location of the dsDNA probe used in this assay. (C)
Southern blot on total DNA extracted from cells treated with ΦNM1γ6 at different
times after infection and digested with EcoRI and PsiI. The intensity, relative to
cells harboring the type II CRISPR-Cas system, of the 3.9-kb phage fragment is
reported.
124

Together these data revealed that the requirement of target transcription for
type III CRISPR-Cas DNA cleavage results in the accumulation of phage DNA
when a region that is expressed late in the infectious cycle is targeted. To
support this finding in vitro, an co-transcriptional DNA cleavage assay
(schematized in Figure 3-6) with different complex:target molar ratios were
performed, and target DNA cleavage was detected at a 10:1, but not 1:1, ratio
(Figure 3-14). This means an excess of target DNA can prevent efficient
cleavage by the Cas10-Csm complex, suggesting that the accumulation of phage
DNA found in cells targeting a late gene can be due to the excess of target DNA
and inefficient CRISPR targeting.
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Figure 3-14 Co-transcriptional DNA cleavage using different complex:target
ratios
Co-transcriptional DNA cleavage of the Cas10-Csm complex and dsDNA target
at different complex:target ratio. 5 nM of elongation complex (EC) containing a
radiolabeled dsDNA target, RNA primer and RNA polymerase were incubated
with 5 or 50 nM of purified Cas10-Csm complex harboring a matching crRNA
(derived from spc1). Ribonucleoside tri-phosphates (rNTPs) were added to
initiate transcription and the products of the reactions (30 min after addition of
rNTPs) were subject to PAGE and phosphorimager visualization.
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3.7

The biological function of RNases in type III CRISPR immunity

In spite of this significant difference in phage DNA accumulation and cleavage
of the target DNA (Figure 3-12B), both gp14- and gp43-targeting spacers
protected host bacteria from lytic infection (Figure 3-3C). This raises the
question as to how lytic phages in great abundance can be in harmony with host
cells for an extended period of time. It should be pointed out that the phage DNA
per se does not kill cells. However, host cells are in peril if lytic enzymes encoded
by the DNA are made in sufficient amount. I therefore hypothesized that the
RNases of the type III CRISPR-Cas may act as a second line of defense; they
degrade phage transcripts and prevent translation of toxic proteins when DNA
targeting is inefficient.
As previously mentioned, type III-A CRISPR-Cas systems encode two
RNases: a sequence-specific, crRNA-guided endoribonuclease, Csm3, and
another, crRNA-independent ribonuclease, Csm6. Active sites of the two proteins
were also validated in vitro (Figure 3-7B and Figure 3-8B and C). To test if
these RNases function in vivo and play a role in immunity, I generated mutant
CRISPR-Cas systems containing catalytically dead Csm3 (dCsm3), catalytically
dead Csm6 (dCsm6), or both (dCsm3/dCsm6), respectively. Along with cells
harboring a wild-type (WT) or a non-matching spacer (Δcrispr), I performed a
phage infection assay. Total RNAs were extracted at 15, 45 and 90 minutes postinfection and were subjected to RT-qPCR. When CRISPR targeted the earlyexpressed gp14, I did not detect any substantial accumulation of phage
transcripts in the wild-type, dcsm6, dcsm3 or dcsm3/dcsm6 cells (Figure 3-15A).
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In contrast, phage transcripts increased dramatically in the absence of immunity
(Δcrispr) as expected (Figure 3-15A). When I conducted the same experiment
but targeting the late-transcribed gp43 gene, I observed minor differences
between target transcripts abundance in wild-type, dcsm3 and dcsm6 strains
(Figure 3-15B). However, I observed a 50-fold (351 divided by 7) increase in
viral transcripts in the dcsm3/dcsm6 double mutant, which accumulated similar
level of phage mRNA as Δcrispr cells 45 minutes after infection (Figure 3-15B). I
also performed RNA deep sequencing (RNA-seq) in infected cells with the
different genetic backgrounds. The results confirmed the RT-qPCR data,
showing that gp14 phage transcripts did not accumulate during the immune
response of the different CRISPR-Cas systems (Figure 3-15C), but that there
was a substantial increase in gp43 transcript levels (similar to the Δcrispr control)
in the dcsm3/dcsm6 double mutant at 45 minutes post-infection (Figure 3-15D).
Together, these results indicate that the RNase activity of either Csm3 or Csm6
is required to prevent the accumulation of phage transcripts when the type III-A
CRISPR-Cas system targets late-, but not early-, expressed phage genes.
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Figure 3-15 Csm3 and Csm6 are required for the degradation of phage
transcripts
(A) RT-qPCR performed on the ΦNM1γ6 gp14 transcript using total RNA
collected from S. aureus RN4220 cells carrying different type III-A CRISPR-Cas
systems targeting the gp14 gene at different times post-infection. Values for the
rho gene were used for normalization. The normalized value for the
measurement at 15 min in wild-type cells was set to 1 to obtain the relative
abundance of the gp14 transcript for the rest of the data points (mean ± SD of
four replicas). (B) Same as (A), but using CRISPR-Cas systems targeting the
ΦNM1γ6 gp43 gene and measuring relative abundance of the gp43 transcript. (C)
RNA-seq reads (reads per 500 bases of transcript per million mapped reads,
RPM) for transcripts in the vicinity of the gp14 target at 15 and 45 min postinfection of cells harboring different type III-A CRISPR-Cas systems. Vertical
purple line indicates target position. (D) Same as (C), but showing transcription
levels in the gp43 target region. Vertical orange line indicates target position.
Since it is known that λ-like phages such as ΦNM1γ6 produce long transcripts
through antitermination mechanisms (Krebs 2010), it is possible to investigate
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the effect of the RNase activity of Csm3 and Csm6 on phage transcripts further
away from the target site defined by the crRNA guide (Figure 3-16A). RNA-seq
of phage transcripts in wild-type, dcsm3, dcsm6 or dcsm3/dcsm6 cells revealed
that degradation of the phage transcripts extended for at least 1 kB at each side
of the target site (Figure 3-16B, gp42 and gp44). In particular, a very low level of
phage transcripts were found in dcsm3 cells, indistinguishable to that of wild-type
cells. On the other hand, transcript levels in dcsm6 cells were higher.
Interestingly, this pattern extended 5 kB further downstream, but not upstream
from the target site (Figure 3-16B). These data suggest that Csm6, and not
Csm3, is responsible for much of the transcript degradation outside of the target
region. Since Csm6 is not part of the Cas10-Csm complex (Hatoum-Aslan et al.
2013), the mechanism by which the RNase activity of Csm6 is first localized to
the target transcript remains to be elucidated.
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Figure 3-16 Csm6, and not Csm3, degrades phage transcripts in the vicinity
of the region targeted by the Cas10-Csm complex
(A) Schematic of the genomic region of ΦNM1γ6 in the vicinity of the gp43 target
(up to 5 kB upstream and downstream). Vertical colored bars indicate the 100-nt
window of the RNA-seq data shown in (B). Opposed arrows indicate the primers
used for RT-qPCR experiments in (C). (B) Total RNA collected from S. aureus
RN4220 cells carrying different type III-A CRISPR-Cas systems targeting the
gp43 gene at 45 min post-infection were subjected to RNA-seq. RNA-seq reads
(reads per 500 bases of transcript per million mapped reads, RPM) for transcripts
in the regions indicated in (A) were shown. (C) RT-qPCRs using primers shown
in (A). RT-qPCRs were performed on the ΦNM1γ6 gp37, gp42, gp44 and gp52
transcripts using total RNA collected from S. aureus RN4220 cells carrying wildtype, dcsm3/dcsm6 or Δcrispr type III-A CRISPR-Cas systems targeting the gp43
gene at 45 min post-infection. Values for the rho gene were used for
normalization. The normalized value for the measurement in wild-type cells was
set to 1 to obtain the relative abundance of the transcripts in other genetic
backgrounds (mean ± SD of four replicas).
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In light of the results above, I wanted to investigate whether the degradation
of late-expressed phage transcripts mediated by Csm3 and Csm6 can truly act
as a second line of defense, i.e., required for CRISPR-Cas immunity during the
targeting of late genes. To this end, I infected S. aureus cells harboring wild-type
and RNase-null type III CRISPR-Cas systems and monitored their growth. When
CRISPR targeted gp14, the mutants dcsm3, dcsm6 and dcsm3/dcsm6 were as
effective as the wild-type CRISPR-Cas to confer immunity (Figure 3-17A), a
result that demonstrates the sufficiency of DNA cleavage for viral clearance. In
contrast, when gp43 was targeted the dcsm3/dcsm6 double mutant failed to
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provide immunity (Figure 3-17B), similarly to a no-targeting control (Δcrispr). A
similar result was obtained when I measured the effect of type III-A CRISPR-Cas
immunity on the propagation of the phage by determining the average burst size,
i.e. the number of viral particles (counted as plaque forming units, PFU) released
per infected cells (Figure 3-17C and D). Both experiments indicate that the
RNase activity of either Csm3 or Csm6 is required for immunity when targeting a
late-, but not early-, expressed gene. To confirm this temporal pattern I tested
immunity mediated by dcsm3/dcsm6 mutant systems targeting two other earlytranscribed (gp5 and gp19) and two other late-transcribed (gp50 and gp59)
genes (Figure 3-17E). Upon infection, targeting of gp5, gp14 and gp19 produced
efficient immunity, whereas targeting of gp43, gp50 and gp59 resulted in the
death of bacteria expressing inactive Csm3 and Csm6 RNases (Figure 3-17F).
These data demonstrate that the RNase activities of Csm3 and Csm6 are
required for type III-A CRISPR-Cas immunity when the targets specified by the
crRNA guide reside within late-expressed genes.
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Figure 3-17 Degradation of phage transcripts by Csm3 and Csm6 enables
type III CRISPR-Cas immunity targeting late-expressed genes
(A) S. aureus RN4220 cells carrying different type III-A CRISPR-Cas systems
targeting the gp14 gene were grown in liquid media and infected with phage
ΦNM1γ6 phage (at 0 hr) with a multiplicity of infection of five viruses per bacteria
(MOI = 5). Optical density at 600 nm (OD600) was measured for the following 12
hr to monitor cell survival. Representative growth curves of at least three
independent assays are shown. (B) Same as (A), but with the CRISPR-Cas
systems programmed to target gp43. (C) The different infections performed in (A)
were plated to enumerate plaque forming units (PFU) and calculate the average
burst size. Mean ± SD of three replicas are reported. (D) Same as (C), but with
the CRISPR-Cas systems programmed to target gp43. (E) A schematic of the
genome of ΦNM1γ6. The position of spacers that target early genes, gp5, gp14
and gp19, and late genes, gp43, gp50 and gp59 were shown. (F) Survival of cells
(determined by measuring growth at OD600) carrying dcsm3/dcsm6 type III-A
CRISPR-Cas systems targeting the different ΦNM1γ6 genes shown in (E).
Representative growth curves of at least three independent assays are shown.
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Why is the RNase activity required when late phage genes are targeted? I
showed earlier that when CRISPR targeted a late-expressed phage gene, phage
DNA accumulated inside host bacteria and persisted for a long time (Figure
3-12B). The experiments performed with the RNase-null systems (Figure 3-15B
and Figure 3-17B) strongly indicate that degradation of phage transcripts by
Csm3 and Csm6 limits further viral gene expression and the continuation of the
lytic infectious cycle, thus allowing for a “peaceful” co-existence of the phage
DNA and host bacteria for an extended period of time. To validate the essentiality
of the RNases and demonstrate that the lingering phage DNA is capable of
continuing the lytic cycle in the absence of the RNase activity, I designed an
experiment to eliminate RNase activity 10 hours post-infection, a time when
phage DNA is still present in host bacteria, and checked for host cell viability.
First, I infected cells harboring dcsm3/Δcsm6 CRISPR-Cas systems (Δcsm3 is
not feasible since deletion of the gene results in loss of formation of the Cas10Csm complex) targeting gp14 or gp43 and carrying a pCsm6 plasmid, which
provides aTc-dependent expression of Csm6 (Figure 3-18A). As expected from
my previous results, in the absence of the inducer the cells targeting gp43, but
not those targeting gp14, succumbed to phage infection (Figure 3-18B). In the
presence of aTc, both populations survived (Figure 3-18B). The cells from these
two populations were washed with fresh broth to eliminate aTc, and thus Csm6
expression, 10 hours after infection. Cells were diluted in fresh broth with or
without aTc and their growth was monitored (Figure 3-18C). While the growth of
gp14-targeting cells was not affected by removal of Csm6, gp43-targeting cells
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were lysed by phage. This finding corroborates that Csm6 has been keeping the
accumulated phage DNA “in check” and keep host bacteria alive. Once the
RNase activity is abrogated, the accumulated phage DNA can continue the lytic
cycle in spite of DNA cleavage (by Cas10 within the complex), leading to the lysis
of host bacteria.
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Figure 3-18 Degradation of phage transcripts by Csm6 enables type III
CRISPR-Cas immunity against late-expressed genes
(A) S. aureus RN4220 cells harboring Δcsm6/dcsm3 type III-A CRISPR-Cas
systems targeting gp14 or gp43 were complemented with a pCsm6 plasmid,
which carried the csm6 gene under the control of a tetracycline-inducible
promoter (Ptet). (B) These cells were infected with ΦNM1γ6 (MOI = 5) in the
presence or absence of the inducer, aTc (0.008 mg/ml), i.e., induction of Csm6
expression. Bacterial growth was monitored by measuring OD600 for 10 hr. (C)
The cells grown in the presence of aTc shown in (B) were collected after 10 hr,
washed to remove residual phages in the supernatant as well as the inducer in
order to eliminate further expression of Csm6. Washed cells were diluted (1:333)
in fresh media without phage nor aTc. As a control washed cells were also
diluted (1:333) in fresh media with aTc (0.008 mg/ml). Bacterial growth was
monitored by measuring OD600 for 12 hr.
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3.8

Requirement of Csm6 in providing immunity against phages with

target mutations
So far, my data showed that CRISPR targeting of a late-expressed gene led
to the accumulation of target DNA. In this scenario the RNase activities of Csm3
or Csm6 were required to clear the phage transcripts and slow down the phage
lytic cycle until all DNA targets were destroyed. A similar situation could present
during infection with phages harboring target mismatches. In both type I and type
II CRISPR-Cas immunity mutations in the target region lead to the escape of
mutant phages due to reduced crRNA-guided DNA cleavage. Type III CRISPRCas systems, however, seem much more tolerant of such mutations and are able
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to provide immunity even in the presence of several mismatches within the
crRNA:target interaction (Manica et al. 2013; Goldberg et al. 2014). I speculated
that, if target mutations result in inefficient DNA cleavage also during type III
CRISPR-Cas immunity, the reported tolerance to mutations could be the result of
phage transcript cleavage by the Csm3 and/or Csm6 RNase activity, as it is
known that RNA-RNA binding can be promiscuous. To test this I introduced 3, 4
and 5 mismatches into the spacer sequence targeting the gp43 gene of ΦNM1γ6
(Figure 3-19A). I infected hosts carrying these mutations and looked for the
CRISPR immune response. Consistent with previous reports, type III CRISPRCas immunity protected hosts even in the presence of 3 and 4 mismatches (but
not 5) between the crRNA guide and its target (Figure 3-19B). I first tested if
Csm6 was important for immunity in the presence of mismatches by performing
infections in a Δcsm6 host (Figure 3-19C). Consistent with Figure 3-17B, csm6
was not required to provide immunity when the phage carried a target with
perfect homology. However, Δcsm6 cells were not as protected in the presence
of 3 mismatches and immunity was completely abrogated with 4 mismatches in
the crRNA:target interaction. Protection in the presence of 4 mismatches
required the RNase activity of Csm6 but not that of Csm3 (Figure 3-19E).
The RNase activity of Csm3 or Csm6 was required for full immunity when
DNA clearance was slow and inefficient, as was the case when CRISPR-Cas
targeted late-expressed phage genes. To see if the presence of mismatches
between crRNA:target can also lead to slow DNA clearance, I performed qPCR
of the gp43 target to compare phage DNA accumulation during the course of
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infection of wild-type hosts carrying a perfectly matching or 4-mismatch spacer
(Figure 3-20A). I observed that indeed the presence of mismatches led to the
accumulation of target phage DNA. This was corroborated by a plasmid-curing
assay similar to the one presented in Figure 3-5A (Figure 3-20B, C and D).
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Figure 3-19 Csm6 is required to provide immunity against viruses with
target mutations
(A) Introduction of mutations (in red) in the spacer matching the gp43 gene of
phage ΦNM1γ6 that generate three, four, or five mismatches in the crRNA:target
region. (B) S. aureus RN4220 cells that harbored a wild-type III-A CRISPR-Cas
system targeting the gp43 gene in the presence of different crRNA:target
mismatches were grown in liquid media and infected with ΦNM1γ6 (at 0 hr) with
a multiplicity of infection of five viruses per bacteria (MOI = 5). Optical density at
600 nm (OD600) was measured for the following 12 hr to monitor cell survival.
Representative growth curves of at least three independent assays are shown.
(C) Same as (B), but with cells harboring a CRISPR-Cas locus without csm6. (D)
S. aureus RN4220 cells that carried different type III-A CRISPR-Cas systems
matching the gp43 gene were grown in liquid media and infected with phage
ΦNM1γ6 (at 0 hr) with a multiplicity of infection of five viruses per bacteria (MOI =
5). Optical density at 600 nm (OD600) was measured for the following 12 hr to
monitor cell survival. Representative growth curves of at least three independent
assays are shown. (E) Same as (D), but with cells expressing a crRNA with 4
mismatches. Abbreviation: mm, mismatch.
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Figure 3-20 Mismatches in crRNA:target leads to accumulation of target
DNA
(A) S. aureus RN4220 cells that harbored a wild-type CRISPR-Cas system
expressing crRNAs with no mismatch (0 mm) or 4 mismatches (4 mm) to the
target were infected with phage ΦNM1γ6. qPCR was performed on the ΦNM1γ6
gp43 gene using total DNA collected from cells at different times post-infection.
Values for the rho gene were used for normalization. The normalized value for
the measurement at 45 min in 0 mm cells was set to 1 to obtain the relative
abundance of the phage DNA for the rest of the data points (mean ± SD of four
replicas). (*) P<0.05; (**) P<0.01. (B) Plasmid-curing assay similar to Figure
3-5A was performed. pCRISPR-Cas carried a gp43-targeting spacer containing 0
or 4 mismatches. pTarget (pWJ267) carried a gp43 target sequence inserted
after a tetracycline-inducible promoter (Ptet). (C) Agarose gel of linearized
plasmid DNA purified from cells at 0, 10, 30 and 60 min after aTc induction.
Δcrispr cells were used as a non-targeting control. (D) Agarose gel of linearized
plasmid DNA purified from cells either before or after 10 hr of treatment with aTc.
Abbreviation: mm, mismatch.
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Target mismatches are not only present within a viral population but are very
common between related phages. For example, our lab previously engineered a
spacer matching the gp32 gene present in phage ΦNM1γ6 (Goldberg et al. 2014)
but simultaneously containing 4 mismatches to the same gene in the related
phage ΦNM4γ4 (Bae et al. 2006; Heler et al. 2015) (Figure 3-21A). Consistent
with my results, type III-A CRISPR-Cas immunity against ΦNM1γ6 mediated by
this spacer does not require the RNase activity of Csm6 (Figure 3-21A and B).
In contrast, whereas the wild-type CRISPR-Cas system tolerated the 4
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mismatches and protected cells from ΦNM4γ4 infection, the dcsm6 mutant cells
were susceptible to viral attack (Figure 3-21A and B). Together with Figure 3-19
and Figure 3-20, my results show that Csm6 RNase activity is required to
maintain immunity even in the presence of target mutations that decrease the
efficiency of DNA targeting, a distinct property of type III systems.

Figure 3-21 Csm6 is required to provide immunity against viruses with
target mutations (continued)
(A) The gp32-targeting spacer matches phage ΦNM1γ6 genome perfectly but
presents four mismatches in the phage ΦNM4γ4 genome. (B) S. aureus RN4220
cells that harbored a wild-type, dcsm6 or Δcrispr type III-A CRISPR-Cas system
targeting the gp32 gene were grown in liquid media and infected with ΦNM1γ6
(at 0 hr) with a multiplicity of infection of five viruses per bacteria (MOI = 5).
Optical density at 600nm (OD600) was measured for the following 12 hr to monitor
cell survival. Representative growth curves of at least three independent assays
are shown. (C) Same as (B), but following infection with ΦNM4γ4.
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3.9

Discussion
Type III-A CRISPR-Cas systems encode a Cas10-Csm complex that is

responsible for crRNA biogenesis and targeting. Previous work showed that the
complex can cleave both the genome and the transcripts of invaders (Peng et al.
2015; Samai et al. 2015), and that the DNA- and RNA-targeting activity resides in
Cas10 and Csm3 within the complex, respectively. Here I identified a new
CRISPR-associated RNase, Csm6, that is not associated with the Cas10-Csm
complex. I demonstrated that Csm6 has RNase activity both in vitro and in vivo,
and it plays an important role in CRISPR immunity.
Whereas DNA cleavage is fundamental for CRISPR immunity against
invaders such as phages, a role for the RNase activity of these systems has not
been determined. Previous works showed that the type III CRISPR-Cas immunity
requires transcription of the target (Goldberg et al. 2014). This provides a clue,
as the transcriptional requirement creates a challenge for the type III CRISPRCas system when it targets viral genes that are expressed late in the infection
cycle. Since CRISPR immunity cannot mount attacks until the phages have
finished replication in this scenario, the immune system can be overwhelmed by
the abundance of DNA targets present at this point, and cell viability can be
compromised. Indeed, my data showed phage DNA accumulates substantially
when CRISPR targets a late- but not early-expressed gene during infection.
Under this condition, I showed that the two RNases encoded by the type III-A
CRISPR-Cas, Csm3 and Csm6 provide a second line of defense. While mutation
of the active site of either protein alone is not sufficient to break immunity, cells
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harboring double mutation succumb to phage infection. In contrast, when an
early-transcribed gene is targeted, DNA cleavage occurs shortly after genome
injection. In this case the endonuclease activity of the Cas10-Csm complex is
sufficient to clear the virus; the infectious cycle does not proceed further and I
showed that degradation of phage transcripts by the two RNases is not
necessary to prevent phage propagation.
Temporal regulation of phage gene expression is universal. I believe that the
ability of transcript degradation by type III-A CRISPR-Cas systems would be
important to provide immunity against most classes of dsDNA viruses when the
crRNA guide targets genes that are expressed late in the infectious cycle. Target
selection occurs during the “adaptation” phase of CRISPR-Cas immunity, when
new spacer sequences from an invading phage are incorporated into the
CRISPR array (Heler et al. 2014). Although little is known about the acquisition of
spacers by type III CRISPR-Cas systems, type I and II systems incorporate
spacers matching all regions of the viral genome (Datsenko et al. 2012; PaezEspino et al. 2013; Heler et al. 2015), without any noticeable bias towards early
or late genes. If such bias is also absent during spacer acquisition by type III
CRISPR-Cas systems, the RNase activity would be necessary to confer
immunity to all bacteria that incorporate a spacer specifying a late-expressed
gene. At the moment we do not know the genomic position at which type III-A
targets are expressed “too late” for viral clearance by the Cas10-Csm DNA
cleavage activity; i.e., the targeting region at which the Csm3 or Csm6 RNase
activities are required to rescue the host. I speculate that the onset of phage
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replication might mark a turning point at which these RNase activities become
essential.
My study showed that either Csm3 or Csm6 RNase activity is required for
immunity when the target of the Cas10-Csm complex is located in a lateexpressed gene. Mutations in the active sites of either of these genes are not
sufficient to disrupt immunity. However, in the presence of target mismatches
that lead to the accumulation of phage DNA, Csm6, but not Csm3, RNase activity
is required for immunity. How can this be explained? Whereas the RNase activity
of Csm3 is strictly defined by crRNAs, I showed that Csm6 is a crRNAindependent nuclease that can degrade transcript at least 1 kB away from the
target site. Thus, it is conceivable that mismatches between the crRNA and
target may disrupt activity of Csm3 but not Csm6, a hypothesis that should be
tested by future experiments.
Mismatch tolerance is an important aspect that distinguishes the type III from
the type I and II CRISPR immune systems. Whereas type I and II CRISPR
immunity is very sensitive to mutations in the target sequence (especially in the
“seed” region of the target) (Wiedenheft et al. 2011; Gasiunas et al. 2012; Jinek
et al. 2012; Westra et al. 2012), type III immunity is unusually tolerant of such
mutations (Manica et al. 2013; Goldberg et al. 2014), allowing the targeting of
“escape” or related viruses. In all three systems, target mutations prevent
efficient DNA cleavage. Here I demonstrated that in type III systems, transcript
degradation by Csm6 results in robust immunity, presumably by stalling the
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progression of the phage lytic cycle and allowing for more time for phage DNA
clearance.
Whereas Csm3 is part of the Cas10-Csm complex and cleaves sequences
that are specified by the crRNA guide (Staals et al. 2014; Tamulaitis et al. 2014;
Samai et al. 2015), Csm6 is not part of the complex and has sequenceindependent activity. As mentioned above, how Csm6 achieves specificity for
phage transcripts is not known. In vitro, this RNase performs multiple cleavages
in RNA substrates of different lengths and sequences, in principle lacking such
specificity. On the other hand, the Cas10-Csm complex recognizes its RNA
targets using crRNA guides, thus displaying a sequence specificity that will result
in the cleavage of phage transcripts by Csm3 when the crRNA derives from a
phage-matching spacer. Therefore one plausible mechanism to restrict Csm6
activity to the Cas10-Csm target would be the existence of a transient biophysical
interaction between them during the targeting stage. This intriguing hypothesis
should be examined in the future.
Another intriguing aspect of Csm6 is its requirement to prevent plasmid
conjugation (Hatoum-Aslan et al. 2014). Since I found that Csm6 is not involved
in DNA degradation, I speculate that it may assist the Cas10-Csm complex in the
clearance of the plasmid DNA by degrading plasmid transcripts, some of them
possibly important for plasmid replication and maintenance. Additional work
focused on Csm6 should address question.
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Figure 3-22 A model for co-transcriptional cleavage of target DNA and its
transcript during type III-A CRISPR-Cas immunity
(A) Type III-A CRISPR-Cas cleaves both DNA (by Cas10) and RNA (by Csm3
and Csm6). Cleavage activity requires target transcription. (B) The role of RNA
cleavage in type III-A CRISPR immunity. Type III RNases are dispensable when
CRISPR targets early-expressed phage genes. However, they are required when
CRISPR targets late-expressed phage genes or when crRNA:target region
contains mismatches. See text also. Abbreviations: crRNA, CRISPR RNA; RNAP,
RNA polymerase.
In summary, my results allow the formulation of a model for the molecular
mechanisms underlying type III-A CRISPR-Cas immunity (Figure 3-22). The type
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III-A Cas10-Csm complex performs co-transcriptional cleavage of the target DNA
and its transcripts. Within this complex, Cas10 contains the DNase activity and
Csm3 is an RNase. Csm6 is another type III-A RNase that degrades target
transcripts. This molecular mechanism of immunity allows for the rapid attack of
the viral genome when early-expressed targets are specified by the crRNA guide,
which leads to fast and efficient degradation of the invader’s genetic material and
the clearance of the infection without the need of RNase activity. In contrast, the
targeting of late-expressed genes allows viral replication and transcription before
DNA cleavage can occur. The accumulated genomes are not cleared efficiently
by the endonuclease activity of the Cas10-Csm complex, and the degradation of
phage transcripts by Csm3 or Csm6 is required to prevent the completion of the
infectious cycle and the lysis of the host cell. Similarly, the presence of
crRNA:target mismatches within the phage population prevents efficient DNA
cleavage that also leads to the accumulation of phage genomes in the cell. In this
scenario, the Csm6 RNase is required for transcript degradation and survival.
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CHAPTER 4 PERSPECTIVES
CRISPR-Cas is a sequence-specific adaptive immune system that defends
prokaryotic cells against infectious viruses. This immune system also acts as a
barrier to horizontal gene transfer of plasmids and other mobile genetic elements,
which is a major route through which bacteria exchange beneficial genes such as
those that encode antibiotic resistance. From a basic science point of view,
studying CRISPR-Cas can allow scientists to better understand evolution, such
as the arms race between bacteria and phages, and perhaps discover novel
methods to prevent the spread of antibiotic resistance. CRISPR-Cas may even
impact on human health. It is well known that the bacteria living on and inside us,
known as the human microbiota, play an indispensable role in maintaining
normal physiological function and providing many benefits for human beings.
Since CRISPR-Cas is widely present in prokaryotes and protect them from viral
predation, this immune system may play a role in shaping the bacterial
population and diversity in this microenvironment.
CRISPR-Cas encodes a suite of fascinating molecular machineries such as
Cas9 that can cleave DNA with incredible precision. The protein has not only
been developed for genetic manipulation in prokaryotic cells, but also in
eukaryotic cells (Cong et al. 2013; Mali et al. 2013). Compared to conventional
targeted genome editing tools such as zinc finger nucleases (ZFNs) (Carroll 2011)
and transcription activator-like effector nucleases (TALENs) (Joung and Sander
2013), one of the biggest advantages of the CRISPR-Cas is that sequencespecificity is determined by small crRNAs or sgRNAs (see Chapter 2.3). Not only
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are the design and generation of the targeting reagents made much easier, it
also opens up opportunities to design multiple sgRNAs in order to interrogate
gene function on a genome-wide scale. Indeed, this is an obvious future direction
seen by many scientists, as a few independent groups demonstrated that by
harnessing the cellular NHEJ pathways, Cas9 with a library of sgRNAs can be
used to generate knockout libraries of human cells. This approach was
successfully applied to identify genes responsible for drug resistance (Shalem et
al. 2014; Wang et al. 2014), genes important for bacterial toxicity (Zhou et al.
2014), and genes conferring resistance to bacterial toxins (Koike-Yusa et al.
2014). In addition to genome-wide screening, Cas9 has seen scores of
applications in basic biology, synthetic biology, gene therapy, cancer
therapeutics, drug development and beyond (Hsu et al. 2014; Jiang and
Marraffini 2015).
We and others also showed that the two nuclease domains of Cas9 can be
inactivated to make the protein a sequence-specific DNA-binding protein (Bikard
et al. 2013; Qi et al. 2013). This catalytically dead Cas9, dCas9, can mediate
transcription repression and activation. As mentioned in Chapter 2.4.3, there are
similarities and differences between dCas9- and sRNA-mediated gene regulation,
and future endeavors should be made to compare and contrast the two methods
in order to discover rules governing the efficacy of repression. The activation of
gene expression by dCas9 when fused to ω was moderate. Future experiments
should consider using different activator domains and varying the linker distance
between the activator and dCas9 to enhance the level of activation. Since dCas9
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is a sequence-specific DNA-binding protein, this general property can be
principally exploited to direct any protein of interest to desired locations in the
genome for many purposes. Indeed, dCas9 was fused to machineries involved in
epigenetic modification to modulate gene expression (Mendenhall et al. 2013;
Hilton et al. 2015), or enhanced green fluorescent protein (eGFP) to visualize the
spatiotemporal dynamics of DNA sequences in living cells (Chen et al. 2013;
Anton et al. 2014).
CRISPR-Cas has three types and three stages (Figure 1-4). Current
technological development primarily focuses on the targeting stage of the type II
systems, and this frontier is being extended at a breathtaking speed. What is not
yet developed? Adaptation is the first stage of the immune system in which cells
use Cas machineries to integrate foreign DNA or RNA fragments into the host
chromosome. Given that integrases have been successfully developed as tools
for site-specific recombination historically, it is highly plausible that the CRISPR
adaptation machineries can be engineered for technological uses as well.
Secondly, works performed by us and others revealed that the type III CRISPRCas systems cleave both DNA and RNA, suggesting that these systems may be
exploited to manipulate RNA molecules.
The type III CRISPR-Cas encodes elaborate molecular scissors that cleave
both DNA and RNA. My work identified Csm6, a new CRISPR-associated
ribonuclease and elucidated at least one biological function of the RNA cleavage
– when the activity of DNA cleavage is weakened (i.e. when targeting lateexpressed phage genes or regions bearing mismatches), type III RNases
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degrade phage transcripts and prevent the production of toxic enzymes, thus
acting as a second line of defense in addition to the DNA-cleaving module. As
mentioned in Chapter 3.9 , there are many questions remained to be explored.
Csm6 is not associated with the Cas10-Csm complex, what is the mechanism
through which the protein gets recruited to the target transcript, and what is the
processivity of it? When the crRNA and the target contain mismatches, the
RNase activity of Csm6 but not Csm3 is required for immunity against phage
infection. Given that the activity of Csm3 is strictly defined by crRNAs while that
of Csm6 can be extended to at least 1 kB away from the target site, could this
mean that mismatches between the crRNA and target disrupt activity of Csm3
but not Csm6? Csm6 is not involved in DNA degradation, and yet it is required to
prevent plasmid conjugation. Could this be attributed to its RNase activity
towards plasmid transcripts essential for replication and maintenance?
Understanding these fundamental problems can strengthen the current model in
which the type III RNases function as a second line of defense.
Forty years ago, the discovery of restriction enzymes unleashed a revolution
in modern molecular biology. Today, CRISPR-Cas is driving numerous
innovative applications from basic biology to biotechnology and medicine.
Despite being forty years apart, both restriction enzymes and CRISPR-Cas
systems share remarkably similar pathways. They both originated from basic
studies of bacterial immune systems that cleave viral DNA, and have
unequivocally revolutionized biological sciences by facilitating manipulation of
DNA sequences. Restriction enzymes and CRISPR-Cas systems are testaments
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to the practical value of studying the microbial world, which harbors a reservoir of
amazing molecular machineries yet to be discovered.
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CHAPTER 5 MATERIALS AND METHODS
5.1

Bacterial strains and growth conditions
Cultivation of E.coli strains DH5α, MG1655, HME63 (derived from MG1655,

Δ(argF-lac) U169 λ cI857 Δcro-bioA galK tyr 145 UAG mutS<>amp) (Costantino
and Court 2003) and their derivatives was done in LB medium (BD) or Terrific
Broth medium (Fisher Scientific) at 37 °C. Whenever applicable, media were
supplemented with ampicillin (100 µg/ml), chloramphenicol (25 µg/ml) or
streptomycin (50 μg/ml) to ensure plasmid maintenance or selection of rpsL
mutant cells.
Cultivation of S. aureus strain RN4220 (Nair et al. 2011) and derivatives was
done in TSB medium (BD) at 37 °C unless otherwise indicated. Whenever
applicable, media were supplemented with chloramphenicol (10 µg/ml) or
erythromycin (10 µg/ml) to ensure plasmid maintenance. When appropriate,
anhydrotetracycline (aTc) was used at a concentration of 0.25 µg/ml (unless
otherwise indicated) to initiate transcription from the Ptet promoter.
Cultivation of S. epidermidis strain RP62a (Gill et al. 2005) and derivatives
was done in BHI medium (BD) at 37 °C. Whenever applicable, media were
supplemented with 10 µg/ml chloramphenicol or 5µg/ml mupirocin to ensure
plasmid maintenance.
Liquid culture of S. pneumoniae strain R6 (Hoskins et al. 2001) and
derivatives were grown in THYE medium (30 g/l Todd-Hewitt agar, 5 g/l yeast
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extract). Plating was done on tryptic soy agar (TSA) medium (BD) supplemented
with 5% defibrinated sheep blood. When appropriate, media were supplemented
with kanamycin (400 μg/ml), chloramphenicol (5 μg/ml), erythromycin (1 μg/ml),
streptomycin (100 μg/ml) or spectinomycin (100 μg/ml) for selection.
5.2

Bacterial strain construction
Construction of E.coli JEN202 was described in (Bikard et al. 2013).
Construction of S. pneumoniae strains crR6, R68232.5 and R6370.1 were

described in (Bikard et al. 2012). crR6M, crR6Rk, crR6Rc, JEN38 and JEN62
were described in (Jiang et al. 2013a).
Construction of S. epidermidis Δcrispr, known as LAM104, was described in
(Marraffini and Sontheimer 2008).
5.3

Plasmid Cloning

5.3.1 Cloning in E.coli
Cloning used E.coli DH5α electrocompetent cells. To clone WT Csm6 for
purification, PCR was performed using pWJ30β (Hatoum-Aslan et al. 2013) as
template and primers PS11 and PS12. The PCR product was digested with
restriction enzymes NdeI and XhoI and ligated to the vector pET23a-His6 (Cterminal) digested with the same enzymes, making plasmid pPS10. The Csm6
mutants R364A (plasmid pPS42), H369A (plasmid pPS43) and R364A-H369A
(plasmid pPS44) were constructed using the plasmid pPS10 as a backbone with
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three sets of primers PS245/PS246, PS243/PS244 and PS247/PS248,
respectively.
Construction of plasmids pCas9, pCRISPR::Ø and pCRISPR::rpsL were
described in (Jiang et al. 2013a). pdCas9, pDB127, pWJ66, pWJ68, pWJ89,
pWJ96 and pWJ97 were described in (Bikard et al. 2013).
5.3.2 Cloning in S. pneumoniae
Construction of plasmid pDB97 was described in (Jiang et al. 2013a).
5.3.3 Cloning in S. aureus
Cloning used S. aureus RN4220 electrocompetent cells. For type III-A
pCRISPR-Cas plasmids, new spacers were cloned by ligation of annealed
oligonucleotide pairs and BsaI-digested parent vector, pGG-BsaI-R (Goldberg et
al. 2014). The sequences of the spacers cloned are provided in Table 1. To
construct Δcsm6 plasmids, PCR was performed using WT plasmid as template
and primers L342/L343. PCR product was restriction digested with PspOMI and
EagI (NEB), followed by ligation by T4 DNA Ligase (NEB). To construct dcsm6
plasmids, PCR was performed using WT plasmid as template and primers
W852/PS248 and primers PS247/W614. The two PCR products were then
ligated using Gibson assembly. To construct dcsm3 plasmids, PCR was
performed using WT plasmid as template and primers W852/PS466 and primers
PS465/W614. The two PCR products were then ligated using Gibson assembly.
To construct pCsm6 overexpression plasmid, one PCR was performed using
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pWJ153 (Goldberg et al. 2014) as template and primers W1129/W1113. Another
PCR was performed using pWJ30β as template and primers W1127/W1128. The
two PCR products were then ligated using Gibson assembly.
Construction plasmid pG0(mut) was described in (Marraffini and Sontheimer
2008). Plasmid pSpc1was known as pCRISPR in (Marraffini and Sontheimer
2008). pWJ30β was described as pcrispr in (Hatoum-Aslan et al. 2013). pWJ40
was described in (Goldberg et al. 2014). pTarget (pWJ153) was described in
(Goldberg et al. 2014); pTarget (pWJ267) was constructed by PCR using
pWJ153 as a template and primers W1105/W1106.
5.4

Plasmid DNA preparation
Plasmid DNA was purified from 2 to 6 ml of E. coli DH5α or S. aureus RN4220

overnight cultures. For preparation from S. aureus cultures, cells were pelleted,
re-suspended in 100 µl TSM buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.5 M
sucrose) then treated with 5 µl lysostaphin (2 mg ml−1) at 37 °C for 1 h before
treatment with plasmid miniprep reagents from Qiagen. Purification used Qiagen
or EconoSpin columns.
5.5

Conjugation
Conjugation was carried out by filter mating as described elsewhere (Morton

et al. 1995). Briefly, donor (S. aureus RN4220 carrying pG0400 or pG0(mut)) and
recipient cells were cultured overnight with appropriate antibiotics. The following
day, equal amount (109 CFU) of donors and recipients were mixed in 5ml of fresh
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BHI medium and vacuum-filtered through 0.45 mM filters (Millipore). Filters were
incubated on BHI agar plates at 37 °C for 18 hours and grown bacteria were
resuspended in 3 ml of fresh BHI. Serial dilutions were then plated on BHI agar
containing the appropriate antibiotics for the enumeration of recipients and
transconjugants.
5.6

Preparation of electrocompetent S. aureus cells
S. aureus RN4220 or derivative strains were grown overnight in TSB medium,

diluted 1:100 in fresh medium without antibiotics, then allowed to grow to an
OD600 reading of 0.8–1.0. At this point, cells were pelleted at 4 °C, and two or
three washes were performed using chilled, sterile dH2O. Cells were ultimately
re-suspended in 1/100th (of the original culture) volume of chilled, sterile 10%
glyercol and 50 µl aliquots were distributed for storage at -80 °C.
5.7

Preparation of competent E.coli cells
Chemically competent and electrocompetent cells were made according to

(Renzette 2011).
5.8

E. coli λ-Red recombination
E.coli strain HME63 was used for all λ-Red recombination experiments.

Recombineering cells were prepared and handled according to a previously
published protocol (Sharan et al. 2009). Briefly, a 2 ml overnight culture (LB
medium) inoculated from a single colony obtained from a plate was grown at
162

30 °C. The overnight culture was diluted 100-fold and grown at 30 °C with
shaking (200 r.p.m.) until the OD600 was 0.4–0.5 (~3 h). For λ-Red induction, the
culture was transferred to a 42 °C water bath to shake at 200 r.p.m. for 15 min.
Immediately after induction, the culture was swirled in an ice-water slurry and
chilled on ice for 5–10 min. Cells were then washed and aliquoted according to
the protocol. For electro-transformation, 50 μl of cells were mixed with 1 nmol of
salt-free oligos (IDT) or 100–150 ng of plasmid DNA (prepared by QIAprep Spin
Miniprep Kit, Qiagen). Cells were electroporated using 1 mm Gene Pulser
cuvette (Bio-rad) at 1.8 kV and were immediately re-suspended in 1 ml of room
temperature LB medium. Cells were recovered at 30 °C for 1–2 h before being
plated on LB agar with appropriate antibiotic resistance and incubated at 32 °C
overnight.
5.9

S. aureus transformation
Electrocompetent S. aureus RN4220 or derivative strains were thawed, mixed

with appropriate amount (~100 ng) of dialysed plasmid DNA and incubated at
room temperature for 5 min. Electroporation was performed using a GenePulser
Xcell (BioRad) with the following parameters: 2900 V, 25 mF, 100V, 2mm. After
electroporation, cells were immediately re-suspended in 200 µl – 1 ml of TSB and
recovered at 37 °C for 2 h with shaking. Serial dilutions were then prepared
before plating with appropriate antibiotics. Serial dilutions were then plated on
tryptic soy agar containing appropriate antibiotics for transformants-counting.
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Transformation efficiency was expressed either as colony-forming unit
(CFU)/µg of DNA or CFU/ml of recovered cells.
5.10

S. pneumoniae transformation

Competent cells were prepared as described previously (Bikard et al. 2012).
Briefly, an overnight THYE culture was diluted to OD600 of 0.05 in M1 medium
(THYE with 0.2% BSA, 1 mM CaCl2, pH 7.1) and grown until OD600 of 0.15. Cells
were pelleted and re-suspended in 1/10th (of the original volume) in M2 medium
(THYE with 0.2% BSA, 1 mM CaCl2, 10% glycerol, pH 7.9), and frozen at −80°C
for later use. For all genome editing transformations, cells were gently thawed on
ice, and re-suspended in 10 volumes of M3 medium (THYE with 0.2% BSA,
1 mM CaCl2, 100 ng/ml of competence-stimulating peptide CSP1 (Havarstein et
al. 1995), pH 7.9). Editing constructs were added to cells at a final concentration
of 0.7 ng/μl to 2.5 μg/μl, followed by incubation for 20 min at 37 °C before the
addition of 2 μl of targeting constructs (similar concentration as the editing
templates) and then incubated 40 min at 37 °C. Serial dilutions were then plated
on agar containing appropriate antibiotics for transformants counting.
5.11

Preparation of S. pneumoniae genomic DNA

For transformation purposes, S. pneumoniae genomic DNA was extracted
using the Wizard Genomic DNA Purification Kit, following instructions provided
by the manufacturer (Promega). For genotyping purposes, 700 μl of overnight S.
pneumoniae cultures were pelleted, re-suspended in 60 μl of lysozyme solution
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(2 mg/ml) and incubated 30 min at 37 °C. The genomic DNA was extracted using
QIAprep Spin Miniprep Kit (Qiagen).
5.12

Analysis of targeting requirement (PAM and seed sequences) by

Cas9 complex in S. pneumoniae
The five nucleotides following the canonical spc1 target were randomized
through amplification of R68232.5 genomic DNA with primers W377/L426. This
PCR product was then assembled with the cat gene and the srtA upstream
region that were amplified from the same template with primers L422/W376. 80
ng of the assembled DNA was used to transform strains R6 and crR6. Samples
for the randomized targets were prepared using the following primers: B280B290/L426 to randomize bases 1–10 of the target and B269-B278/L426 to
randomize bases 10–20. Primers L422/B268 and L422/B279 were used to
amplify the cat gene and srtA upstream region to be assembled with the first and
last ten PCR products, respectively. The assembled constructs were pooled and
30 ng was used to transform R6 and crR6. After transformation, cells were plated
on chloramphenicol selection. For each sample more than 2 × 105 cells were
pooled together in 1 ml of THYE and genomic DNA was extracted with the
Promega Wizard kit. Primers B250/B251 were used to amplify the target region.
PCR products were tagged and run on one Illumina MiSeq paired-end lane using
300 cycles.

165

5.13

Generation of targeting constructs and editing templates for genome

editing in S. pneumoniae
Targeting constructs used for genome editing were made by Gibson assembly
(Gibson et al. 2009) of Left PCRs and Right PCRs (Table 2). Editing constructs
were made by SOEing PCR (Horton et al. 1993) fusing PCR products A (PCR A),
PCR products B (PCR B) and PCR products C (PCR C) when applicable (Table
2). The CRISPR::Ø and CRISPR::ermAM(stop) targeting constructs were
generated by PCR amplification of JEN62 and crR6 genomic DNA respectively,
with oligos L409 and L481.
5.14

β-galactosidase (Miller) assay

β-galactosidase (Miller) assays were performed as previously described
(Zahner and Hakenbeck 2000).
5.15

Fluorescence

measurements

for

dCas9-mediated

transcription

repression and activation
Fluorescence was measured in a Tecan microplate reader. In all experiments,
background fluorescence, or auto-fluorescence, was measured using a control
strain lacking the GFP reporter. Auto-fluorescence was subtracted from the
fluorescence readings and relative fluorescence was normalized to cells
expressing a non-targeting crRNA (encoded by the BsaI sequences designed for
spacer cloning). All transcription repression studies were performed in E.coli
MG1655 cells.
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Transcription activation of the lacZ gene (encoding β-galactosidase) was
studied in E. coli KS1ΔZ, a strain carrying the lacZ gene under the control of a
weak promoter that can be induced by a cI-ω fusion (Dove and Hochschild 1998).
KS1ΔZ also carried a deletion of rpoZ, the gene encoding the ω subunit of RNAP.
Green fluorescence protein (GFP) assays were performed in an E. coli MG1655
mutant, JEN202 (Bikard et al. 2013), in which rpoZ was replaced by a
spectinomycin resistance gene.
All spacers used for dCas9-mediated transcription repression and activation
are provided in Table 3.
5.16

Northern blot analysis

RNA was extracted from overnight cultures using TRIzol (Invitrogen) following
the manufacturer’s protocol. For each sample, 10 mg of RNA were separated on
a 5% polyacrylamide gel. The RNA was electro-transferred to a charged
membrane and hybridized either to a probe upstream (P511) or downstream
(P510) of the T10 and B10 target sites. A probe annealing to the 5S rRNA (B507)
was used as a control.
5.17

Plasmid-curing assay

S. aureus RN4220 cells harboring both the wild-type CRISPR-Cas plasmid or
its variant and the target plasmid (pWJ153 or pWJ267 contained the spc1 or
gp43

targets,

respectively)

were

cultured

in

TSB

supplemented

with

chloramphenicol (10 µg/ml). ATc was added to a final concentration of 0.25 µg/ml
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during log phase (at OD600 of 0.6-0.8). Plasmid DNA was prepared at designated
time points, linearized with the common single cutter BamHI and subjected to
agarose gel electrophoresis.
5.18

Purification of Csm6

The pPS10, pPS42, pPS43 and pPS44 plasmids were transformed into E. coli
BL21 (DE3) Rosetta 2 cells (Merck Millipore). Cultures (1 liter) were grown at
37 °C in Terrific Broth medium (Fisher Scientific) containing 100 μg/ml ampicilin
and 34 μg/ml chloramphenicol until the OD600 reached 0.6. The cultures were
adjusted to 0.3 mM isopropyl-1-thio-β-d-galactopyranoside and incubation was
continued for 16 h at 16 °C with constant shaking. The cells were harvested by
centrifugation and the pellets stored at −80 °C. All subsequent steps were
performed at 4 °C. Thawed bacteria were resuspended in 35 ml of buffer A (50
mM Tris–HCl, pH 7.5, 500 mM NaCl, 200 mM Li2SO4, 20% sucrose, 15 mM
Imidazole) containing one complete EDTA free protease inhibitor tablet (Roche).
Triton X-100 and lysozyme were added to final concentrations of 0.1 % and 0.1
mg/ml, respectively. After 1 hour, the lysate was sonicated to reduce viscosity.
Insoluble material was removed by centrifugation for 1 hour at 15,000 rpm in a
Beckman JA-3050 rotor. The soluble extract was mixed for 1 hour with 5 ml of
Ni2+ -Nitrilotriacetic acid-agarose resin (Thermo) that had been pre-equilibrated
with buffer A. The resin was recovered by centrifugation, then first washed with
50 ml of buffer A, followed by washing with 50 ml of IMAC buffer (50 mM Tris-HCl
pH 7.5, 250 mM NaCl, 10% glycerol) containing 50 mM imidazole. The resin was

168

subsequently resuspended in 10 ml of IMAC buffer containing 100 mM imidazole,
and then poured into a column. The column was then eluted step-wise with 10 ml
aliquots of IMAC buffer (50 mM Tris-HCl pH 7.5, 250 mM NaCl, 10% glycerol)
containing 200, and 500 mM imidazole. The 500 mM imidazole elutes containing
the protein was pooled together and dialyzed against 50 mM Tris-HCl pH 7.5, 50
mM NaCl, 10% glycerol. Subsequently Csm6 was purified using a 5 ml HiTrap Q
Sepharose Fast Flow (GE Life Sciences), eluting with a linear gradient of 50 mM
- 2 M NaCl. The peak fraction from the Q sepharose column was further purified
by hydrophobic interaction chromatography using butyl sepharose 4 FF (GE
Healthcare Life Sciences), eluting with stepwise lowering of ammonium sulphate
concentration from 1 M to 50 mM. The final purification step was performed using
size exclusion chromatography with Superdex 200 10/300 GL (GE Healthcare)
column, using buffer B (50 mM Tris-HCl pH 7.5, 5% glycerol, 150 mM NaCl, 1
mM TCEP).
5.19

Csm6 RNA cleavage assay

RNA cleavage reactions were performed at 37°C with 1 µM of 5’-radiolabeled
(R55 and R24) and 3’-radiolabeled ssRNA (R55) substrates and 10 µM of wild
type or mutant Csm6. The reaction was carried out in reaction buffer containing
50 mM Tris-HCl [pH7.5], 30 mM NaCl, 2 mM DTT and 1% glycerol. Reaction
mixtures were withdrawn at specified time intervals and subsequently quenched
with 90% formamide and 50 mM EDTA. Reaction products were separated by
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denaturing PAGE and the gel was visualized by phosphorimaging. The 5’radiolabeled decade RNA ladder (Life Technologies) was used as a size marker.
5.20

Csm6 DNA cleavage assay

DNA cleavage reactions were performed at 37°C for up to 2 hours with 1 µM
of 5’-radiolabeled ssDNA (PS362) and dsDNA (PS362/PS363) substrates and 10
µM of wild type Csm6. The reaction was carried out in reaction buffer containing
50 mM Tris-HCl [pH7.5], 10 mM MgCl2, 30 mM NaCl, 2 mM DTT and 1% glycerol.
Reaction mixtures were withdrawn at specified time intervals and subsequently
quenched with 90% formamide and 50 mM EDTA. Reaction products were
separated by denaturing PAGE and the gel was visualized by phosphorimaging.
The 5’-radiolabeled 10 bp DNA ladder (Promega) was used as a size marker.
5.21

Co-transcriptional DNA cleavage assay

Elongation complexes (ECs) were reconstituted essentially as described in
(Samai et al. 2015). Typically, 2 μl 1 pmol/μl of template strand (TS) and 1 μl of 4
pmol/μl RNA oligos were mixed in 1 × transcription buffer and incubated at 65°C
for 5 min, followed by gradual cooling to room temperature. After addition of 1.5
μl E. coli RNAP core enzyme (NEB), the reaction was incubated at 25°C for 25–
30 min and at 37°C for 1 min. Then, 4 μl 1.25 pmol/μl nontemplate strand (NTS)
(pretreated by heating to 65°C for 5 min, then on ice for 2 min, and finally at 37°C
for 2 min) was added and incubated for 10–15 min at 37°C. The final
concentration of TS was 0.10 pmol/μl after adding supplement buffer to obtain
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transcription conditions. Assembled ECs were kept on ice until use. In a
transcription coupled DNA cleavage assay, 5 nM of EC was used and, Cas10Csm complex was added to a final concentration of 5 nM and 50 nM.
Transcription was initiated with the addition of 2.5 mM of RNTPs. All the
reactions were performed at 37°C. For all the DNA cleavage time course
experiments, RNTPs were added to the elongation complex (EC), prior to the
addition of Cas10-Csm complex. After addition of Cas10-Csm, the samples were
collected at 30 min, and quenched by mixing with Proteinase K (NEB) and 20
mM EDTA. The DNA/RNA samples were then extracted using phenolchloroformisoamyl alcohol (25:24:1), ethanol precipitated and resuspended into loading
buffer (90% formamide). The DNA products were heater at 95°C for 5 min before
loading onto the gel. Cleavage products were resolved on a 12% denaturing
polyacrylamide gels containing 7 M urea and visualized by phosphorimaging
(Typhoon, GE Life Sciences).
5.22

Phage infections and plate reader growth curves

S. aureus RN4220 cells were infected with phages ΦNM1γ6 or ΦNM4γ4
during early log phase (at OD600 of 0.3-0.4). Plate reader growth curves were
measured as previously described (Goldberg et al. 2014)

with slight

modifications. Briefly, overnight cultures were launched from single colonies and
diluted 1:250 in TSB broth supplemented with 5mM CaCl2 and appropriate
antibiotics. After 1 h of growth, phage was added at a multiplicity of infection
(MOI) of 5. Measurements were taken every 10 minutes.
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5.23

Measurement of average burst size

S. aureus RN4220 cells with appropriate CRISPR-Cas plasmids were grown
in TSB supplemented with 5mM CaCl2 and appropriate antibiotics to an OD600 of
0.3-0.5. Cells were infected by ΦNM1γ6 at MOI = 0.1 for 5 min. Cells were
immediately washed in TSB twice at 4 °C and re-suspended in equal initial
volume. An aliquot of cells were spotted on heart infusion (BD) soft agar plates
with a sensitive lawn (i.e. RN4220). The rest of the cells were incubated at 37 °C
for another 75 min before an aliquot of cells were spotted on a sensitive lawn.
Agar plates were incubated at 37 °C for 16-20 hours before plaques were
enumerated. Average burst size was calculated as the ratio of plaques formed at
80 min to plaques formed at 5 min for each strain of interest.
5.24

Extraction of total RNA in S. aureus

10-25 ml of S. aureus culture were pelleted and immediately frozen at -20 °C.
Pellets were gently thawed at 4 °C and washed with 1 ml ice-cold TE pH 6.8.
Pellets were re-suspended in 100 µl of ice-cold TE pH 6.8 and mixed with 750 µl
of ice-cold TRIzol®. The mix was transferred into a 2 ml microtubes pre-filled with
0.25 cm3 of 0.1 mm glass beads on ice. Cells were disrupted using
MiniBeadbeater-1 (BioSpec Products) at an intensity setting of 42 for 30 seconds
twice at 4 °C. 200 µl of chloroform was added to the disrupted mix was and the
rest of RNA extraction protocol was followed according to TRIzol®.
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5.25

Extraction of total DNA in S. aureus

10-25 ml of S. aureus culture were pelleted and immediately frozen at -20 °C.
Pellets were gently thawed at 4 °C and washed with 1 ml ice-cold TE pH 8.0.
Pellets were re-suspended in 400 µl of ice-cold TE pH 8.0 and mixed with 500 µl
of ice-cold Phenol/Chloroform/Isoamyl alcohol (25:24:1) (Fisher Scientific). The
mix was transferred into a 2 ml microtubes pre-filled with 0.25 cm3 of 0.1 mm
glass beads on ice. Cells were disrupted using Mini-Beadbeater-1 (BioSpec
Products) at an intensity setting of 42 for 30 seconds twice at 4 °C. The disrupted
mix was centrifuged at 16,000 rcf for 10 minutes at room temperature. The
aqueous phase was collected and mixed with 500 µl of chloroform and
centrifuged as above. The aqueous phase was collected again and mixed with 1
ml of isopropanol. Precipitated DNA was washed with 1 ml of 75% ethanol, air
dried and dissolved in 50-300 µl of water.
5.26

qPCR

S. aureus RN4220 were infected by ΦNM1γ6 (MOI=5) during early log phase
(at OD600 of 0.3-0.4). qPCR was performed using Fast SYBR® Green Master Mix
(Life technologies) and 7900HT Fast Real-Time PCR System (Applied
Biosystems). For RNA samples, total RNA was treated with DNase I (SigmaAldrich). 1 µg of DNase I treated RNA samples were subjected to reverse
transcription using M-MuLV Reverse Transcriptase (NEB) and 100 ng of random
hexamer (Invitrogen) according to the NEB protocol. The resulting cDNA was
diluted 5 times as stocks. 500 nM of primers were used and 0.2 µl of the cDNA
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stock was used as template for a 10 µl reaction according to the Fast SYBR®
Green Master Mix protocol. For DNA samples, 25 ng of total DNA were used as
template. The house-keeping rho gene was used as endogenous control for
normalization (Theis et al. 2007). Primers used for amplification are shown in
Table 5.
5.27

RNA sequencing

Total RNA was treated with DNase I (Sigma-Aldrich) and subjected to TruSeq
Stranded mRNA Library Prep Kit (Illumina) without rRNA depletion and Illumina
NextSeq. Reads were aligned to reference genomes using Bowtie and sorted
using Samtools. Using a custom script, sorted reads were accessed via Pysam,
normalized as reads per million values, and plotted as the average over
consecutive windows of 500 base pairs using matplotlib tools for IPython.
5.28

Southern blot

20 µg of total DNA prepared from infected cells were digested with restriction
enzymes EcoRI and PsiI for 5 hours and resolved on a 1% argarose gel. DNA
fragments were transferred from the gel via capillary action to a Hybond
membrane (GE Healthcare) using alkaline transfer (Sambrook 1989). Probes for
the upstream and downstream fragments were produced via PCR of ΦNM1γ6
DNA using primers W863/W864 and W865/W866, respectively, and α-32P-dATP
in addition to regular dNTPs. Hybridization was performed at 65°C overnight in
Church buffer (Sambrook 1989).
174

Table 1 Spacers used in Chapter 3
Target
gp5
gp14
gp19
gp32
gp43
gp43 (3 mm)
gp43 (4 mm)
gp43 (5 mm)
gp43 (type II)
gp50
gp59
nes

5-nt upstream
TTTCG
TTCTA
TTCTA
CAACT
TTCTA
TTCTA
TTCTA
TTCTA
TTCTA
TTCTA
AGAGA

Spacer sequence (5'-3')
CCATTCATCTAATTTCAAGGCTATGTTTGATGTAG
CTACGTCCGTAATGCTAGGATTTGCAAATTTCTTA
CACCCATATCATCTAGTACAAGTAAATCAATATCA
GTAAACCTTTGATTGCTCTTAGCTCGAGTTATGTGC
ATTCGTCATCTTCAAGTAATGCCTCTAAATCAATA
TTTCGTCTTCTTCATGTAATGCCTCTAAATCAATA
TTTCGTCTTCATCATGTAATGCCTCTAAATCAATA
TTTGGTCTTCATCATGTAATGCCTCTAAATCAATA
ACTTCACACAAGATAACATTATTGATTTAG
GTCCAATATTTTCTGCGATTTCATCTAGTGCTTCA
ATCGCGTTAAACGCCAATCTTGTTCGTGTCGTTTG
ACGTATGCCGAAGTATATAAATCATCAGTACAAAG
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5-nt downstream
AGGCA
-

Edition
bgaA R>A
bgaA NE>AA
ΔbgaA
ΔsrtA
ermB Stop
ΔsrtA ΔbgaA

Template DNA
crR6Rk
crR6Rk
crR6Rk
crR6Rc
crR6Rk
JEN51 (for Left PCR) and
JEN52 (for Right PCR)

Targeting Constructs

Left PCR
W256/W391
W256/W391
W256/W391
W256/B218
W256/W356
W256/W465

Right PCR
W392/L403
W392/L403
W392/L403
B217/L403
W357/L403
W466/W403

Spacer sequence
GCTCACTAGCAGGGTTGTGGGTTGTACGGA
GCTCACTAGCAGGGTTGTGGGTTGTACGGA
GCTCACTAGCAGGGTTGTGGGTTGTACGGA
TCCTAGCAGGATTTCTGATATTACTGTCAC
TTTAAAAGAAACCGATACCGTTTACGAAAT
same as the ones used for ΔsrtA and ΔbgaA

PAM
TGG
TGG
TGG
TGG
TGG
TGG

Name of
resulting
Template DNA
PCR A
PCR B
PCR C
SOEing PCR strains
R6
W403/W397 W398/W404 N/A
W403/W404 JEN56
R6
W403/W431 W432/W433 W434/W404 W403/W404 JEN60
R6
B255/B256 B257/B258 N/A
B255/B258
JEN52
R6
B230/W463 W464/B229 N/A
B230/B229
JEN51
JEN38
L422/W370 W371/L426 N/A
L422/L426
JEN43
same as the ones used for ΔsrtA and ΔbgaA
JEN64

Editing Templates
Primers used to
verify edited
genotype
W403/W404
W403/W404
W393/W405
W422/W426
L457/L458
same as the ones
used for ΔsrtA and
ΔbgaA

Table 2 Targeting constructs and editing templates used for genome

editing in S. pneumonaie
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Table 3 Spacers used for dCas9-mediated transcription repression and
activation
Name
T0
T1
T3
T4
T5
T6
T7
T8
T9
T10
T11
B0
B1
B2
B3
B4
B5
B7
B8
B9
B10
B11
Z1
Z2
Z3
Z4
W101
W102
W103
W104
W105
W106
W107
W108
W109
W110

Spacer sequence (5'-3')
CTACGGAACTCTTGTGCGTAAGGAAAAGTA
CTGAGCAATCACCTATGAACTGTCGACTCG
TGTCGACTCGAGGCCTTGACAGGTACCTCA
CCTTGACAGGTACCTCATGGATACCTATAA
CAGGTACCTCATGGATACCTATAATGGTTC
ACCTATAATGGTTCCGGAATTCCTTTAAAG
CCTTTAAAGAGGAGAAATCTAGATGAGTAA
CTAGATGAGTAAAGGAGAAGAACTTTTCAC
TGGAGTTGTCCCAATTCTTGTTGAATTAGA
TCAAGAGTGCCATGCCCGAAGGTTATGTAC
GATACCCTTGTTAATAGAATCGAGTTAAAA
TCTTCAGAAATGAGCTTTTGCTCCTCTGCT
CCTTTACTCATCTAGATTTCTCCTCTTTAA
TAGGTGATTGCTCAGGACATTTCTGTTAGA
CTCGAGTCGACAGTTCATAGGTGATTGCTC
ACCTGTCAAGGCCTCGAGTCGACAGTTCAT
CCATTATAGGTATCCATGAGGTACCTGTCA
TCCTCTTTAAAGGAATTCCGGAACCATTAT
CATCTAGATTTCTCCTCTTTAAAGGAATTC
ATTAACATCACCATCTAATTCAACAAGAAT
CTTGAAAAAGTCATGCTGTTTCATATGATC
CAATACCTTTTAACTCGATTCTATTAACAA
ACAACACGCACGGTGTTACATTAGGCACCC
GATCTTCGACAACACGCACGGTGTTACATT
GGCTGCAGGTCGGATCTTCGACAACACGCA
ATTCTGTCGAAGATCAGCTTGGCTGCAGGT
GATCTTCCACAACACGCACGGTGTTACATT
GGCTGCAGGCCGGATCTTCCACAACACGCA
CCTCTATGGATTATCACCTTGGCTGCAGGC
GTCGACTCGAGCCTCTATGGATTATCACCT
TCACCTATGAACTGTCGACTCGAGCCTCTA
GGTATGCCTAATGTAACACCGTGCGTGTTG
AATGTAACACCGTGCGTGTTGTGGAAGATC
GCGTGTTGTGGAAGATCCGGCCTGCAGCCA
CCGGCCTGCAGCCAAGGTGATAATCCATAG
AATCCATAGAGGCTCGAGTCGACAGTTCAT
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Target
pDB127
pDB127
pDB127
pDB127
pDB127
pDB127
pDB127
pDB127
pDB127
pDB127
pDB127
pDB127
pDB127
pDB127
pDB127
pDB127
pDB127
pDB127
pDB127
pDB127
pDB127
pDB127
KS1ΔZ lacZ promoter
KS1ΔZ lacZ promoter
KS1ΔZ lacZ promoter
KS1ΔZ lacZ promoter
pWJ89
pWJ89
pWJ89
pWJ89
pWJ89
pWJ89
pWJ89
pWJ89
pWJ89
pWJ89

Table 4 DNA oligonucleotides used in Chapter 2
Name
B217
B218
B229
B230
B250
B251
B255
B256
B257
B258
B269
B270
B271
B272
B273
B274
B275
B276
B277
B278
B279
B280
B281
B282
B283
B284
B285
B286
B287
B288
B289
B290
B296
B297
B298
B299
B300
B301
B302
B303
B304
B305
B306
B307
B308
B309
B310
B311
B312

Sequence (5'-3')
TCAGGCTTTCAAACAGATACAAGGGCGACCCGCTTTGTGATCTAGGCACCAATAACTGCC
GTGACAGTAATATCAGAAATCCTGCTAGGAGTTTTGGGACCATTCAAAACAGC
GGGTTTCAAGTCTTTGTAGCAAGAG
GCCAATGAACGGGAACCCTTGGTC
NNNNGACGAGGCAATGGCTGAAATC
NNNNTTATTTGGCTCATATTTGCTG
CTTTACACCAATCGCTGCAACAGAC
CAAAATTTCTAGTCTTCTTTGCCTTTCCCCATAAAACCCTCCTTA
AGGGTTTTATGGGGAAAGGCAAAGAAGACTAGAAATTTTGATACC
CTTACGGTGCATAAAGTCAATTTCC
TGGCTCGATTTCAGCCATTGC
CTTTGACGAGGCAATGGCTGAAATCGAGCCAANAAAGCGCAAG
CTTTGACGAGGCAATGGCTGAAATCGAGCCAAANAAGCGCAAG
CTTTGACGAGGCAATGGCTGAAATCGAGCCAAAANAGCGCAAG
CTTTGACGAGGCAATGGCTGAAATCGAGCCAAAAANGCGCAAG
CTTTGACGAGGCAATGGCTGAAATCGAGCCAAAAAANCGCAAG
CTTTGACGAGGCAATGGCTGAAATCGAGCCAAAAAAGNGCAAG
CTTTGACGAGGCAATGGCTGAAATCGAGCCAAAAAAGCNCAAGAAG
CTTTGACGAGGCAATGGCTGAAATCGAGCCAAAAAAGCGNAAGAAG
CTTTGACGAGGCAATGGCTGAAATCGAGCCAAAAAAGCGCNAGAAG
GCGCTTTTTTGGCTCGATTTCAG
CAATGGCTGAAATCGAGCCAAAAAAGCGCANGAAGAAATC
CAATGGCTGAAATCGAGCCAAAAAAGCGCAANAAGAAATC
CAATGGCTGAAATCGAGCCAAAAAAGCGCAAGNAGAAATC
CAATGGCTGAAATCGAGCCAAAAAAGCGCAAGANGAAATC
CAATGGCTGAAATCGAGCCAAAAAAGCGCAAGAANAAATC
CAATGGCTGAAATCGAGCCAAAAAAGCGCAAGAAGNAATCAACC
CAATGGCTGAAATCGAGCCAAAAAAGCGCAAGAAGANATCAACC
CAATGGCTGAAATCGAGCCAAAAAAGCGCAAGAAGAANTCAACC
CAATGGCTGAAATCGAGCCAAAAAAGCGCAAGAAGAAANCAACC
CAATGGCTGAAATCGAGCCAAAAAAGCGCAAGAAGAAATNAACCAGC
CAATGGCTGAAATCGAGCCAAAAAAGCGCAAGAAGAAATCNACCAGC
GATCCTCCATCCGTACAACCCACAACCCTGG
AATTCCAGGGTTGTGGGTTGTACGGATGGAG
CATGGATCCTATTTCTTAATAACTAAAAATATGG
CATGAATTCAACTCAACAAGTCTCAGTGTGCTG
AAACATTTTTTCTCCATTTAGGAAAAAGGATGCTG
AAAACAGCATCCTTTTTCCTAAATGGAGAAAAAAT
AAACCTTAAATCAGTCACAAATAGCAGCAAAATTG
AAAACAATTTTGCTGCTATTTGTGACTGATTTAAG
AAACTTTTCATCATACGACCAATCTGCTTTATTTG
AAAACAAATAAAGCAGATTGGTCGTATGATGAAAA
AAACTCGTCCAGAAGTTATCGTAAAAGAAATCGAG
AAAACTCGATTTCTTTTACGATAACTTCTGGACGA
AAACAATCTCTCCAAGGTTTCCTTAAAAATCTCTG
AAAACAGAGATTTTTAAGGAAACCTTGGAGAGATT
AAACGCCATCGTCAGGAAGAAGCTATGCTTGAGTG
AAAACACTCAAGCATAGCTTCTTCCTGACGATGGC
AAACATCTCTATACTTATTGAAATTTCTTTGTATG
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B313
B314
B315
B316
B317
B318
B319
B320
B321
B337
B338
B339
B340
B352
B353
B368
B369
B370
B371
B441
B442
B446
B448
B507
H001
H002
H003
H004
L402
L403
L403
L409
L422
L426
L430
L444
L445
L446
L447
L448
L457
L458
L459
L461
L481
L488
P510
P511
W256
W286

AAAACATACAAAGAAATTTCAATAAGTATAGAGAT
AAACTAGCTGTGATAGTCCGCAAAACCAGCCTTCG
AAAACGAAGGCTGGTTTTGCGGACTATCACAGCTA
AAACATCGGAAGGTCGAGCAAGTAATTATCTTTTG
AAAACAAAAGATAATTACTTGCTCGACCTTCCGAT
AAACAAGATGGTATCGCAAAGTAAGTGACAATAAG
AAAACTTATTGTCACTTACTTTGCGATACCATCTT
GAGACCTTTGAGCTTCCGAGACTGGTCTCAGTTTTGGGACCATTCAAAACAG
TGAGACCAGTCTCGGAAGCTCAAAGGTCTCGTTTTAGAGCTATGCTGTTTTG
GACGCTATTTGTGCCGATAGCTAAGCCTATTGAGTATTTC
GAAATACTCAATAGGCTTAGCTATCGGCACAAATAGCGTC
GGAAACTTTGTGGAACAATGGCATCGACATCATAATCACT
AGTGATTATGATGTCGATGCCATTGTTCCACAAAGTTTCC
AAACTACTTTACGCAGCGCGGAGTTCGGTTTTTTG
AAAACAAAAAACCGAACTCCGCGCTGCGTAAAGTA
TTTGGATCCTTATTTGTATAGTTCATCCATGCC
TCGAGGCCTTGACAGGTACCTCATGGATACCTATAATGGTTCCGG
AATTCCGGAACCATTATAGGTATCCATGAGGTACCTGTCAAGGCC
ACAGAATTCCTTTAAAGAGGAGAAATCTAGATGAGTAAAGGAGAAGAACTTTTC
TCCTGAACAGTTACGCGTGCAGCTGCGTCACCTCCTAGCTGACTCAAATC
TGAGTCAGCTAGGAGGTGACGCAGCTGCACGCGTAACTGTTCAGGACGCTG
CTATTGCTGAAGGTCGTCGTGCTGCAGATAAGAAATACTCAATAGGCTTAG
CCTATTGAGTATTTCTTATCTGCAGCACGACGACCTTCAGCAATAGCGG
TCGGCGCTACGGCGTTTCACTTCTGAGTTCGG
GGGCACTTTTTCACTCATTTTAGCTTCCTTAGCTCCTGAAAATC
GGTGCCAGCCAATGATTTTTTTAAGGCAGTTATTGG
GCTAAGGAAGCTAAAATGAGTGAAAAAGTGCCCGCC
ACTGCCTTAAAAAAATCATTGGCTGGCACCAAGCAG
TTTCCCTTGAACTAGTCGAAGG
AGTCATCCCAGCAACAAATGG
AGTCATCCCAGCAACAAATGG
CGTGGTAAATCGGATAACGTTCCAAGTGAAG
TGCTCTTCTTCACAAACAAGGG
AAGCCAAAGTTTGGCACCACC
GTAGCTTATTCAGTCCTAGTGG
CGTTTGTTGAACTAATGGGTGCAAATTACGAATCTTCTCCTGACG
CGTCAGGAGAAGATTCGTAATTTGCACCCATTAGTTCAACAAACG
GATATTATGGAGCCTATTTTTGTGGGTTTTTAGGCATAAAACTATATG
CATATAGTTTTATGCCTAAAAACCCACAAAAATAGGCTCCATAATATC
ATTATTTCTTAATAACTAAAAATATGG
CGTGTACAATTGCTAGCGTACGGC
GCACCGGTGATCACTAGTCCTAGG
CCTAGGACTAGTGATCACCGGTGCAAATATGAGCCAAATAAATATAT
GCCGTACGCTAGCAATTGTACACGTTTGTTGAACTAATGGGTGC
TTCAAATTTTCCCATTTGATTCTCC
CCATATTTTTAGTTATTAAGAAATAATACCAGCCATCAGTCACCTCC
AAACTTGACTTCAGCACGTGTCTTGTAGTTCC
CAACAAGAATTGGGACAACTCCAGTGAAAAGTTC
AGACGATTCAATAGACAATAAGG
GTTTTGGGACCATTCAAAACAGCATAGCTCTAAAACCTCGTAGAC

179

W287
W288
W326
W327
W341
W354
W355
W356
W357
W365
W366
W370
W371
W376
W377
W391
W392
W393
W397
W398
W403
W404
W405
W431
W432
W433
W434
W463
W464
W465
W466
W542
W550
W551
W552
W553
W573
W574

GCTATGCTGTTTTGAATGGTCCCAAAACCATTATTTTAACACACGAGGTG
GCTATGCTGTTTTGAATGGTCCCAAAACGCACCCATTAGTTCAACAAACG
AATTCTTTTCTTCATCATCGGTC
AAGAAAGAATGAAGATTGTTCATG
GGTACTAATCAAAATAGTGAGGAGG
GTTTTTCAAAATCTGCGGTTGCG
AAAAATTGAAAAAATGGTGGAAACAC
ATTTCGTAAACGGTATCGGTTTCTTTTAAAGTTTTGGGACCATTCAAAACAGC
TTTAAAAGAAACCGATACCGTTTACGAAATGTTTTAGAGCTATGCTGTTTTGA
AAACGGTATCGGTTTCTTTTAAATTCAATTGTTTTGGGACCATTCAAAACAGC
AATTGAATTTAAAAGAAACCGATACCGTTTGTTTTAGAGCTATGCTGTTTTGA
GTTCCTTAAACCAAAACGGTATCGGTTTCTTTTAAATTC
GAAACCGATACCGTTTTGGTTTAAGGAACAGGTAAAGGGCATTTAAC
CGATTTCAGCCATTGCCTCGTC
GCCTTTGACGAGGCAATGGCTGAAATCGNNNNNAAAAAGCGCAAGAAGAAATCAAC
TCCGTACAACCCACAACCCTGCTAGTGAGCGTTTTGGGACCATTCAAAACAGC
GCTCACTAGCAGGGTTGTGGGTTGTACGGAGTTTTAGAGCTATGCTGTTTTGA
TTGTTGCCACTCTTCCTTCTTTC
CAGGGTTGTGGGTTGTTGCGATGGAGTTAACTCCCATCTCC
GGGAGTTAACTCCATCGCAACAACCCACAACCCTGCTAGTG
GTGGTATCTATCGTGATGTGAC
TTACCGAAACGGAATTTATCTGC
AAAGCTAGAGTTCCGCAATTGG
GTGGGTTGTACGGATTGAGTTAACTCCCATCTCCTTC
GATGGGAGTTAACTCAATCCGTACAACCCACAACCCTG
GCTTCACCTATTGCAGCACCAATTGACCACATGAAGATAG
GTGGTCAATTGGTGCTGCAATAGGTGAAGCTAATGGTGATG
CTGATTTGTATTAATTTTGAGACATTATGCTTCACCTTC
GCATAATGTCTCAAAATTAATACAAATCAGTGAAATCATG
GTTTTGGGACCATTCAAAACAGCATAGCTCTAAAACGTGACAGTAATATCAG
GTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACGCTCACTAGCAGGGTTG
ATACTTTACGCAGCGCGGAGTTCGGTTTTGTAGGAGTGGTAGTATATACACGAGTACAT
CTGTATTACTGCATTTATTAAGAGTATTAACGACGACCTTCAGCAATAG
TTGCTGAAGGTCGTCGTTAATACTCTTAATAAATGCAGTAATACAGGG
CAGGTTCAGTCTGCCAACAATTTGTTCAATAATAGTTTTAATGACCTCCG
CGGAGGTCATTAAAACTATTATTGAACAAATTGTTGGCAGACTGAACCTG
TCATGCCCAGTCATTTCTTCACCTGTGGAGCTTTTTAAGTCCTGTTGATACCGGGAAGCC
TCAGGCTTTCAAACAGATACAAGGGCGACCCGCTTTGTGATCTAGGCACCAATAACTGCC
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Table 5 DNA oligonucleotides used in Chapter 3
Name
L342
L343
PS11
PS12
PS243
PS244
PS245
PS246
PS247
PS248
PS362
PS363
PS465
PS466
W614
W852
W863
W864
W865
W866
W893
W894
W897
W898
W901
W902
W905
W906
W909
W910
W915
W916
W1085
W1086
W1105
W1106
W1113
W1127
W1128
W1129

Sequence (5'-3')
aaaGGGCCCAAATAATATTTTCATTATAGCACCTC
aaaCGGCCGGAAAAAAATAAGGAATTTAAAGAGC
CGCCATATGAAAATATTATTTAGTCCAATAGG
CGCCTCGAGTAATAGCTCTTTAAATTCC
GGTTTAAGAAATTCCATAGCCGCTAATTTAGATAC
GTATCTAAATTAGCGGCTATGGAATTTCTTAAACC
CGATATAAATGGTTTAGCAAATTCCATAGCCC
GGGCTATGGAATTTGCTAAACCATTTATATCG
GATATAAATGGTTTAGCAAATTCCATAGCCGCTAATTTAGATAC
GTATCTAAATTAGCGGCTATGGAATTTGCTAAACCATTTATATC
GTATAGGCACAGCGGGAATAAGGCTATCACTGATGTGCTCGAGTAACTTAACAGC
GCTGTTAAGTTACTCGAGCACATCAGTGATAGCCTTATTCCCGCTGTGCCTATAC
GAATCTAGTATGATTGGAGCAATTGcTTCTCCTGTAGTTAGAGATTTGCAAACC
GGTTTGCAAATCTCTAACTACAGGAGAAgCAATTGCTCCAATCATACTAGATTC
GGTTATACTAAAAGTCGTTTGTTGG
CCAACAAACGACTTTTAGTATAACC
TATGTGGCCGAAAAAACCAAGC
TTGGATATCCATAGTTTTTACACC
ATGACATCAGAAGCGGTTGACG
TGGTTTAACAGTGCGTCTAATCC
TCCATTCGGTAAATCAATTGCAC
TGTTTTTGAGATAAACGCATTTGC
GAAGAATCAGATGGAGATAATGG
AAGACGCTTGTTATATTCTTCTTG
TGCAGTTAAACGCTACAACAGG
CTTCATACTCCTTGAAATCGTTC
TTATAGTAAGAAAACAGCAGAGTC
AAACGCTCTTCTTGTATCTGTTC
TGAATGCATTCAGCGGATCATC
GATTGTCCAACTTGTTCAGACC
GTCAATGACCATAACGCAGAAG
CAATCGGTGTTACTAAATCCATG
GATTAGACATTCACCTTCAATAAC
TTGCGCTTGTCCTGTGATTTTC
CATCTTCAAGTAATGCCTCTAAATCAATAATGTTATCGATCTCCTAGGTCATTTGATATG
GATTTAGAGGCATTACTTGAAGATGACGAATTAGAAGCATATTTATCAGAGCTCGTGCTA
TATGAGATAATGCCGACTGTACTTTTTACAGTCGGTATCAGAGCTCGTGCTATAATT
GCTCTCTATCATTGATAGAGTGAGTTAAACAATGAGGTGCTATAA TG
GTAAAAAGTACAGTCGGCATTATCTCATATTTATCATAATAGCTCTTTAAATTCC
TCACTCTATCAATGATAGAGAGC
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Purpose
Cloning ofΔcsm6
Cloning ofΔcsm6
Cloning of Csm6
Cloning of Csm6
Cloning of Csm6 (R364A)
Cloning of Csm6 (R364A)
Cloning of Csm6 (H3694A)
Cloning of Csm6 (H3694A)
Cloning of Csm6(R364A, H369A)
Cloning of Csm6(R364A, H369A)
DNA cleavage assay
DNA cleavage assay
Cloning of Csm3(D32A)
Cloning of Csm3(D32A)
Cloning
Cloning
Probe for southern blot
Probe for southern blot
Probe for southern blot
Probe for southern blot
gp43 qPCR
gp43 qPCR
gp42 qPCR
gp42 qPCR
gp44 qPCR
gp44 qPCR
gp37 qPCR
gp37 qPCR
gp52 qPCR
gp52 qPCR
rho qPCR as endogenous control
rho qPCR as endogenous control
gp14 qPCR
gp14 qPCR
Construction of pWJ267
Construction of pWJ267
Cloning of pCsm6
Cloning of pCsm6
Cloning of pCsm6
Cloning of pCsm6

Table 6 RNA oligonucleotides used in Chapter 3
Name Sequence (5'-3')
R24
CGUGUCGCCCUUAUUCCGAUAGUG
R55
GCUGUUAAGUUACUCGAGCACAUCAGUGAUAGCCUUAUUCCCGCUGUGCCUAUAC
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